


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 8
August 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**CUMULATIVE SUPPLEMENT 8
August 2018**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to:
 FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME <u>(FORMER ABBREVIATED NAME)</u>	NEW APPLICANT NAME <u>(NEW ABBREVIATED NAME)</u>
IDT AUSTRALIA LTD (IDT AUSTRALIA LTD)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
KREMERS URBAN PHARMACEUTICALS INC (KREMERS URBAN PHARMS)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT HOLDINGS INC)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX PHARMS INC)	LANNETT CO INC (LANNETT CO INC)

SAGENT AGILA LLIC
(SAGENT AGILA)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT AGILA LLC
(SAGENT AGILA LLC)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT STRIDES LLC
(SAGENT STRIDESC)

MYLAN ASI LLC
(MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (AbbVie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (AbbVie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001

LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS	19294	19359	19529		
LISTED SINGLE SOURCE	2758 (14.3%)	2763 (14.3%)	2703 (13.8%)		
MULTISOURCE	16536 (85.7%)	16596 (85.7%)	16826 (86.2%)		
THERAPEUTICALLY EQUIVALENT	16431 (85.2%)	16501 (85.2%)	16735 (85.7%)		
NOT THERAPEUTICALLY EQUIVALENT	105 (0.5%)	95 (0.5%)	91 (0.5%)		
EXCEPTIONS ¹	73 (0.4%)	72 (0.4%)	72 (0.4%)		
NEW MOLECULAR ENTITIES APPROVED	25	6	26		
NUMBER OF APPLICANTS	1075	1084	1091		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the

collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL
ABACAVIR SULFATE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/ML	A077950	001	Mar 14, 2018	Feb NEWA
----	----------------------	-----------------	---------	-----	--------------	----------

ABIRATERONE ACETATE

TABLET;ORAL
YONSA
+! SUN PHARMA GLOBAL 125MG
ZYTIGA
+ JANSSEN BIOTECH 250MG
+! 500MG

N210308	001	May 22, 2018	May NEWA
N202379	001	Apr 28, 2011	Feb CHRS
N202379	002	Apr 14, 2017	Feb CHRS

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE

AB	! AMNEAL PHARM	EQ 200MG BASE	A075047	001	Dec 30, 1999	Jun CHRS
AB	!	EQ 400MG BASE	A075047	002	Dec 30, 1999	Jun CHRS
	SECTRAL					
	+ @ PROMIUS PHARMA	EQ 200MG BASE	N018917	001	Dec 28, 1984	Jun DISC
	+ @	EQ 400MG BASE	N018917	003	Dec 28, 1984	Jun DISC

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN

AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jun CDFR
	FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015	Jun CDFR
AP	SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Jun CDFR
	OFIRMEV					
AP	+! MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun CDFR

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
APADAZ
+ KEMPHARM 325MG;EQ 6.12MG BASE

N208653	001	Feb 23, 2018	Feb NEWA
---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
BUTALBITAL AND ACETAMINOPHEN
MAYNE PHARMA INC 300MG;50MG

A207313	001	Dec 27, 2017	Mar CAHN
---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
AA NUVO PHARM INC 300MG;50MG;40MG

A207118	001	Oct 28, 2016	Apr CTEC
---------	-----	--------------	----------

AA	TEDOR PHARMA INC	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr CTEC
----	------------------	-----------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
>A> @ ACI HEALTHCARE LTD 120MG/5ML;12MG/5ML
>D> @ ALLIED 120MG/5ML;12MG/5ML
AA LANNETT CO INC 120MG/5ML;12MG/5ML

A086366	001		Aug CAHN
---------	-----	--	----------

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

A086366	001		Aug CAHN
---------	-----	--	----------

>D>	@ ANDA REPOSITORY	300MG;15MG	A089673	002	Feb 10, 1988	Aug CAHN
>D>	@	300MG;30MG	A089673	003	Feb 10, 1988	Aug CAHN
>D>	@	300MG;60MG	A089673	001	Feb 10, 1988	Aug CAHN
	@ FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992	Jan CAHN
	@	300MG;60MG	A081249	001	Jul 16, 1992	Jan CAHN
>A>	@ FRONTIDA BIOPHARM	300MG;15MG	A089673	002	Feb 10, 1988	Aug CAHN
>A>	@	300MG;30MG	A089673	003	Feb 10, 1988	Aug CAHN
>A>	@	300MG;60MG	A089673	001	Feb 10, 1988	Aug CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A> AA	GENUS LIFESCIENCES	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Aug CAHN
>D> AA	VINTAGE PHARMS	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Aug CAHN
TABLET;ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	EPIC PHARMA LLC	325MG;5MG	A203863	001	Mar 30, 2018	Mar NEWA
AA		325MG;7.5MG	A203863	002	Mar 30, 2018	Mar NEWA
AA		325MG;10MG	A203863	003	Mar 30, 2018	Mar NEWA
AA	PAR PHARM	325MG;5MG	A202935	002	Jun 15, 2016	Jul CAHN
AA		325MG;7.5MG	A202935	003	Jun 15, 2016	Jul CAHN
AA		325MG;10MG	A202935	004	Jun 15, 2016	Jul CAHN
AA	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Mar NEWA
AA		300MG;7.5MG	A207808	002	Mar 30, 2018	Mar NEWA
AA		300MG;10MG	A207808	003	Mar 30, 2018	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

@ SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Jan DISC
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN @ VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	Jan DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ABHAI LLC	325MG;2.5MG	A210644	001	Feb 09, 2018	Jan NEWA
AA		325MG;5MG	A210644	002	Feb 09, 2018	Jan NEWA
AA		325MG;7.5MG	A210644	003	Feb 09, 2018	Jan NEWA
AA		325MG;10MG	A210644	004	Feb 09, 2018	Jan NEWA
AA	ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Jun NEWA
AA		325MG;7.5MG	A209385	002	Jul 02, 2018	Jun NEWA
AA		325MG;10MG	A209385	003	Jul 02, 2018	Jun NEWA
AA	EPIC PHARMA LLC	325MG;5MG	A203864	001	Jul 02, 2018	Jun NEWA
AA		325MG;7.5MG	A203864	002	Jul 02, 2018	Jun NEWA
AA		325MG;10MG	A203864	003	Jul 02, 2018	Jun NEWA
AA	WES PHARMA INC	325MG;5MG	A207510	001	Mar 21, 2018	Mar NEWA
AA		325MG;7.5MG	A207510	002	Mar 21, 2018	Mar NEWA
AA		325MG;10MG	A207510	003	Mar 21, 2018	Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	+! ICU MEDICAL INC	250MG/100ML	N017656	001		Mar CRLD
SOLUTION/DROPS;OTIC						
ACETIC ACID						
AT	LANNETT CO INC	2%	A040607	001	Feb 24, 2005	May CAHN
AT	RISING PHARMS	2%	A207280	001	Mar 09, 2018	Feb NEWA

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT	TARO PHARM INDs LTD	2%;1%	A088759	001	Mar 04, 1985	May CAHN
----	---------------------	-------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP	ZYDUS PHARMS USA INC	6GM/30ML (200MG/ML)	A208166	001	Jul 20, 2018	Jul NEWA
----	----------------------	---------------------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997	Mar CMFD
OINTMENT;TOPICAL						
ACYCLOVIR						
AB	ALEMBIC PHARMS LTD	5%	A209000	001	Apr 06, 2018	Mar NEWA
TABLET;ORAL						
ACYCLOVIR						
@ MYLAN PHARMS INC		400MG	A075211	001	Sep 28, 1998	Jun DISC
@		800MG	A075211	002	Sep 28, 1998	Jun DISC
AB	YILING PHARM LTD	400MG	A210401	001	Mar 07, 2018	Feb NEWA
AB		800MG	A210401	002	Mar 07, 2018	Feb NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

@ FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Jun DISC
@ HIKMA PHARMS	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Jun DISC
@	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Jun DISC
>A> ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Aug NEWA
@	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	Jun DISC
>A>	EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Aug NEWA
@	EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	Jun DISC

ADAPALENE

SOLUTION; TOPICAL

ADAPALENE

AB CALL INC	0.1%	A203981	001	Sep 23, 2016	Jul CMFD
@	0.1%	A203981	001	Sep 23, 2016	Jun DISC
AB	0.1%	A204593	001	Jan 05, 2016	Jul CMFD
@	0.1%	A204593	001	Jan 05, 2016	Jun DISC

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB PERRIGO ISRAEL	0.1%;2.5%	A205033	001	Jan 23, 2018	Jan NEWA
AB TARO	0.1%;2.5%	A206959	001	Jan 24, 2018	Jan NEWA
AB TOLMAR	0.1%;2.5%	A206164	001	May 23, 2018	May NEWA

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

AB APOTEX INC	10MG	A205459	001	Jul 06, 2018	Jun NEWA
---------------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

+ @ ASTELLAS	3MG/ML	N019937	002	Oct 30, 1989	May DISC
AP ! AKORN	3MG/ML	A078076	001	Oct 31, 2008	May CHRS
AP FRESENIUS KABI USA	3MG/ML	A205568	001	Apr 16, 2018	Apr NEWA
AP GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb NEWA

SOLUTION; INTRAVENOUS

ADENOSCAN

+ @ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Jun CDFR
+ @	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Jun CDFR
AP AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014	Jun CDFR
AP	90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014	Jun CDFR
AP AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Jun CDFR
AP	90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Jun CDFR
AP EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Jun CDFR
AP	90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Jun CDFR
AP FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Jun CDFR
AP	90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Jun CDFR
AP HOSPIRA INC	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Jun CDFR
AP	90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Jun CDFR
AP MYLAN ASI	60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014	Jun CDFR
AP	90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014	Jun CDFR
AP ! TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Jun CDFR
AP !	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Jun CDFR

ALBUTEROL SULFATE

SOLUTION; INHALATION

PROVENTIL

+ @ SCHERING	EQ 0.083% BASE	N019243	002	Jan 14, 1987	Jun CRLD
+ @	EQ 0.5% BASE	N019243	001	Jan 14, 1987	Jun CRLD

SYRUP; ORAL

ALBUTEROL SULFATE

AA LANNETT CO INC	EQ 2MG BASE/5ML	A078105	001	Dec 27, 2006	May CAHN
TABLET; ORAL					
AA AMNEAL PHARMS CO	EQ 2MG BASE	A208804	001	May 21, 2018	May NEWA
	EQ 4MG BASE	A208804	002	May 21, 2018	May NEWA

TABLET;ORALALBUTEROL SULFATE

>D> AB	APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Aug CAHN
AB		EQ 2MG BASE	A207046	001	Jun 29, 2018	Jun NEWA
>D> AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Aug CAHN
AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Jun NEWA
>A> AB	RISING PHARMS	EQ 2MG BASE	A207046	001	Jun 29, 2018	Aug CAHN
>A> AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Aug CAHN
@ YAOPHARMA CO LTD		EQ 2MG BASE	A072151	001	Dec 05, 1989	Jan CAHN
@		EQ 4MG BASE	A072152	001	Dec 05, 1989	Jan CAHN

TABLET, EXTENDED RELEASE;ORALALBUTEROL SULFATE

! MYLAN	EQ 8MG BASE	A078092	001	Jan 29, 2007	May CTEC
VOSPIRE ER		A076130	003	Sep 26, 2002	May DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION;INHALATIONALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Jan CAHN
TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007	Aug DISC
@	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007	Aug DISC

ALCOHOLSOLUTION;INTRA-ARTERIALABLYSINOL

+ BELCHER PHARMS LLC	99% (1ML)	N207987	001	Jun 21, 2018	Jun NEWA
+!	99% (5ML)	N207987	002	Jun 21, 2018	Jun NEWA

ALENDRONATE SODIUMTABLET;ORALALENDRONATE SODIUM

>D> AB	DR REDDYS LABS LTD	EQ 5MG BASE	A079049	003	Aug 04, 2008	Aug CAHN
>D> AB		EQ 10MG BASE	A079049	004	Aug 04, 2008	Aug CAHN
>D> AB		EQ 35MG BASE	A079049	001	Aug 04, 2008	Aug CAHN
>D> AB		EQ 70MG BASE	A079049	002	Aug 04, 2008	Aug CAHN
AB	HANGZHOU BINJIANG	EQ 5MG BASE	A090258	001	Sep 24, 2009	Jan CAHN
AB		EQ 10MG BASE	A090258	002	Sep 24, 2009	Jan CAHN
AB		EQ 35MG BASE	A090258	003	Sep 24, 2009	Jan CAHN
AB		EQ 70MG BASE	A090258	004	Sep 24, 2009	Jan CAHN
@ MYLAN		EQ 35MG BASE	A076584	003	Aug 04, 2008	Apr DISC
@		EQ 70MG BASE	A076584	004	Aug 04, 2008	Apr DISC
>A> AB	NEOPHARMA	EQ 5MG BASE	A079049	003	Aug 04, 2008	Aug CAHN
>A> AB		EQ 10MG BASE	A079049	004	Aug 04, 2008	Aug CAHN
>A> AB		EQ 35MG BASE	A079049	001	Aug 04, 2008	Aug CAHN
>A> AB		EQ 70MG BASE	A079049	002	Aug 04, 2008	Aug CAHN

ALISKIREN HEMIFUMARATECAPSULE, PELLET;ORALTEKTURNA

+ @ NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017	Jun DISC
------------------	----------------	---------	-----	--------------	----------

ALLOPURINOLTABLET;ORALALLOPURINOL

@ FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985	Jan CAHN
----------------	-------	---------	-----	--------------	----------

ALOSETRON HYDROCHLORIDETABLET;ORALALOSETRON HYDROCHLORIDE

AB	PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Feb NEWA
AB		EQ 1MG BASE	A206113	002	Feb 23, 2018	Feb NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN KSOLUTION;INTRAVENOUSINFUVITE ADULT

+! SANDOZ INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG /ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000	Jun CDFR
+!	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;	N021559	001	Jun 16, 2003	Jun CDFR

SOLUTION; INTRAVENOUS
INFUVITE ADULT

1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.
2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 30MCG/ML

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

>A> AB	BRECKENRIDGE PHARM	0.25MG	A207507	001	Jul 09, 2018	Aug CAHN
>A> AB		0.5MG	A207507	002	Jul 09, 2018	Aug CAHN
>A> AB		1MG	A207507	003	Jul 09, 2018	Aug CAHN
>A> AB		2MG	A207507	004	Jul 09, 2018	Aug CAHN
>D> AB	CENTAUR PHARMS PVT	0.25MG	A207507	001	Jul 09, 2018	Aug CAHN
AB		0.25MG	A207507	001	Jul 09, 2018	Jun NEWA
>D> AB		0.5MG	A207507	002	Jul 09, 2018	Aug CAHN
AB		0.5MG	A207507	002	Jul 09, 2018	Jun NEWA
>D> AB		1MG	A207507	003	Jul 09, 2018	Aug CAHN
AB		1MG	A207507	003	Jul 09, 2018	Jun NEWA
>D> AB		2MG	A207507	004	Jul 09, 2018	Aug CAHN
AB		2MG	A207507	004	Jul 09, 2018	Jun NEWA
AB	OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008	Jul CAHN
AB		0.5MG	A078491	002	Sep 25, 2008	Jul CAHN
AB		1MG	A078491	003	Sep 25, 2008	Jul CAHN
AB		2MG	A078491	004	Dec 12, 2008	Jul CAHN

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
+ @ PHARMACIA AND UPJOHN 0.005MG/VIAL

N020379 003 Jun 27, 1996 Jun DISC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE
@ LANNETT CO INC 100MG
TABLET; ORAL
AMANTADINE HYDROCHLORIDE
AB JUBILANT GENERICS 100MG
TABLET, EXTENDED RELEASE; ORAL
OSMOLEX ER
+ OSMOTICA PHARM EQ 129MG BASE
+ EQ 193MG BASE
+! EQ 258MG BASE

A209221	001	Jun 15, 2017	Jun DISC
A210403	001	Feb 07, 2018	Jan NEWA
N209410	001	Feb 16, 2018	Feb NEWA
N209410	002	Feb 16, 2018	Feb NEWA
N209410	003	Feb 16, 2018	Feb NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
@ YAOPHARMA CO LTD EQ 5MG ANHYDROUS; 50MG

A073357 001 Nov 27, 1991 Jan CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS
KABIVEN IN PLASTIC CONTAINER
+ FRESENIUS KABI USA 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/1 N200656 004 Aug 25, 2014 Jul CDFR
00ML; 174MG/100ML; 239MG/100ML
; 147MG/100ML; 3.9GM/100ML (1026ML)
+ 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/1 N200656 005 Aug 25, 2014 Jul CDFR
00ML; 174MG/100ML; 239MG/100ML; 147MG
/100ML; 3.9GM/100ML (1540ML)
+ 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/1 N200656 006 Aug 25, 2014 Jul CDFR
00ML; 174MG/100ML; 239MG/100ML; 147MG
/100ML; 3.9GM/100ML (2053ML)
+! 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/1 N200656 007 Aug 25, 2014 Jul CDFR
00ML; 174MG/100ML; 239MG/100ML; 147MG
/100ML; 3.9GM/100ML (2566ML)

PERIKABIVEN IN PLASTIC CONTAINER

+ FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/1 N200656 001 Aug 25, 2014 Jul CDFR 00ML; 124MG/100ML; 170MG/100ML; 105MG /100ML; 3.5GM/100ML (1440ML)
+ 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/1 N200656 002 Aug 25, 2014 Jul CDFR 00ML; 124MG/100ML;	

EMULSION; INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+ 170MG/100ML; 105MG/100ML; 3.5GM/100ML
 L (1920ML)
 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/1 N200656 003 Aug 25, 2014 Jul CDFR
 00ML; 124MG/100ML; 170MG/100ML
 ; 105MG/100ML; 3.5GM/100ML (2400ML)

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 8.5% W/ ELECTROLYTES

@ ICU MEDICAL INC 8.5%; 102MG/100ML; 45MG/100ML; 522MG/ N019437 005 Apr 03, 1986 May DISC
 100ML; 410MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 487MG/100ML; 28MG/ N017673 009 Oct 25, 2002 May NEWA
 100ML; 425MG/100ML

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 492MG/100ML; 60MG/ N019437 008 Oct 25, 2002 May NEWA
 100ML; 425MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

@ ICU MEDICAL INC 8.5%; 102MG/100ML; 522MG/100ML; 410MG N017673 005 May DISC
 /100ML

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

+ CLOVER PHARMS 500MG N015197 001 Jul CTEC
 AMINOCAPROIC
 @ AKORN 500MG A075602 001 May 24, 2001 Jul DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ AKORN 50MG/ML A076232 001 Jul 05, 2006 Jun DISC
 NEXTERONE
 + @ BAXTER HLTHCARE 50MG/ML N022325 001 Dec 24, 2008 Jun DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SUN PHARM INDs INC	10MG	A089399	002	Jul 14, 1987	Jan CMFD
AB		25MG	A089399	001	Jul 14, 1987	Jan CMFD
AB		50MG	A089399	003	Jul 14, 1987	Jan CMFD
AB		75MG	A089399	004	Jul 14, 1987	Jan CMFD
AB		100MG	A089399	005	Jul 14, 1987	Jan CMFD
AB		150MG	A089399	006	Jul 14, 1987	Jan CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@ FOSUN PHARMA	10MG; 2MG	A071062	001	Nov 27, 1987	Jan CAHN
@	10MG; 4MG	A071862	001	Dec 21, 1987	Jan CAHN
@	25MG; 2MG	A071063	001	Nov 27, 1987	Jan CAHN
@	25MG; 4MG	A071064	001	Nov 27, 1987	Jan CAHN
@	50MG; 4MG	A071863	001	Dec 21, 1987	Jan CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	OXFORD PHARMS	EQ 2.5MG BASE	A078414	001	Apr 07, 2010	Jul CAHN
AB		EQ 5MG BASE	A078414	002	Apr 07, 2010	Jul CAHN
AB		EQ 10MG BASE	A078414	003	Apr 07, 2010	Jul CAHN
AB	SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018	Apr NEWA
AB		EQ 5MG BASE	A206524	002	May 04, 2018	Apr NEWA
AB		EQ 10MG BASE	A206524	003	May 04, 2018	Apr NEWA
@ YAO PHARMA CO LTD		EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN

TABLET;ORAL

AMLODIPINE BESYLATE

@ EQ 10MG BASE

A076859 003 Sep 10, 2007 Jan CAHN

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+ KITOV PHARMS LTD	EQ 2.5MG BASE;200MG	N210045 001 May 31, 2018	May NEWA
+ @	EQ 5MG BASE;200MG	N210045 002 May 31, 2018	May NEWA
+!	EQ 10MG BASE;200MG	N210045 003 May 31, 2018	May NEWA

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>A> AB	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600 001 Aug 30, 2018	Aug NEWA
>A> AB		EQ 5MG BASE;40MG	A209600 003 Aug 30, 2018	Aug NEWA
>A> AB		EQ 10MG BASE;20MG	A209600 002 Aug 30, 2018	Aug NEWA
>A> AB		EQ 10MG BASE;40MG	A209600 004 Aug 30, 2018	Aug NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	SOFIE	18.8mCi-188mCi/5ML (3.75- 37.5mCi/ML)	A204667 001 Apr 22, 2015	Feb CAHN
	@ UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933 001 Jun 27, 2014	Jun DISC

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

@ SUN PHARM INDs INC EQ 12% BASE

N020508 001 Aug 29, 1996 Feb CAHN

LOTION;TOPICAL

LAC-HYDRIN

+ @ SUN PHARM INDs INC EQ 12% BASE

N019155 001 Apr 24, 1985 Feb CAHN

AMOXAPINE

TABLET;ORAL

AMOXAPINE

WATSON LABS

25MG

A072691 002 Aug 28, 1992

Mar CMS1

50MG

A072691 003 Aug 28, 1992

Mar CMS1

100MG

A072691 004 Aug 28, 1992

Mar CMS1

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	! RISING PHARMS	500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/A,30MG	A206006 001 Oct 07, 2016	Jun CHRS
	@ TEVA PHARMS USA	500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/A,30MG	A200218 001 Aug 30, 2013	Jun DISC
	PREVPAC			
+ @	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757 001 Dec 02, 1997	Jun DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

+! SHIRE DEV LLC

12.5MG;12.5MG;12.5MG;12.5MG

N022063 004 Jun 20, 2017

May CHRS

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>D> AP	AUROBINDO PHARMA	EQ 125MG BASE/VIAL	A065499 001 Aug 17, 2010	Aug DISC
>A>	@	EQ 125MG BASE/VIAL	A065499 001 Aug 17, 2010	Aug DISC
	@ ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797 001 Jul 12, 1993	Mar DISC

ANASTROZOLE

TABLET;ORAL

ARIMIDEX

AB	+! ANI PHARMS INC	1MG	N020541 001 Dec 27, 1995	Jan CAHN
----	-------------------	-----	--------------------------	----------

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS
GIAPREZA

+!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun CDFR
+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun CDFR
+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun CAHN
>D>	+!	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Aug DISC
>A>	+ @	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Aug DISC
+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun CAHN
	SOLUTION; IV (INFUSION) GIAPREZA					
+!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jan CAIN
+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jan CAIN

ANIDULAFUNGIN

POWDER; INTRAVENOUS
ERAXIS

+!	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006	Jun CDFR
+!		100MG/VIAL	N021632	002	Nov 14, 2006	Jun CDFR

APALUTAMIDE

TABLET; ORAL
ERLEADA

+!	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb NEWA
----	-----------------	------	---------	-----	--------------	----------

APREPITANT

CAPSULE; ORAL
APREPITANT

AB	GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan CAHN
AB		80MG	A207777	002	Oct 12, 2017	Jan CAHN
AB		125MG	A207777	003	Oct 12, 2017	Jan CAHN
>A>	EMULSION; INTRAVENOUS					
>A>	CINVANTI					
>A>	+! HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017	Aug CDFR
>D>	EMULSION; IV (INFUSION)					
>D>	CINVANTI					
>D>	+! HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017	Aug CDFR

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan NEWA
>A>	INJECTABLE; INTRAVENOUS					
>A>	ARGATROBAN IN 0.9% SODIUM CHLORIDE					
>A>	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Aug CDFR
>A>	ARGATROBAN IN SODIUM CHLORIDE					
>A>	+! EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Aug CDFR
>A> AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	Aug CDFR
>A> AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Aug CDFR
>D>	INJECTABLE; IV (INFUSION)					
>D>	ARGATROBAN IN 0.9% SODIUM CHLORIDE					
>D>	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Aug CDFR
>D>	ARGATROBAN IN SODIUM CHLORIDE					
>D>	+! EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Aug CDFR
>D> AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	Aug CDFR
>D> AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Aug CDFR
	SOLUTION; INTRAVENOUS					
	ARGATROBAN IN DEXTROSE					
	@ SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	Jul CDFR

ARIPIPRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL
ARIPIPRAZOLE

AB	SCIEGEN PHARMS INC	10MG	A207240	001	Apr 18, 2018	Apr NEWA
AB		15MG	A207240	002	Apr 18, 2018	Apr NEWA
>A> AB	ZYDUS PHARMS USA INC	10MG	A090165	001	Aug 28, 2018	Aug NEWA
>A> AB		15MG	A090165	002	Aug 28, 2018	Aug NEWA
>A>		20MG	A090165	003	Aug 28, 2018	Aug NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ARIPIPRAZOLE

>A> 30MG A090165 004 Aug 28, 2018 Aug NEWA

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT
+ ALKERMES INC 675MG/2.4ML N209830 001 Jun 29, 2018 Jun NEWA

ARMODAFINIL

TABLET;ORAL
ARMODAFINIL

AB	AUROBINDO PHARMA LTD	50MG	A206069 001 Mar 06, 2018 Feb NEWA
AB		150MG	A206069 002 Mar 06, 2018 Feb NEWA
AB		250MG	A206069 003 Mar 06, 2018 Feb NEWA

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
>A> ARSENIC TRIOXIDE
>A> FRESENIUS KABI USA 1MG/ML A208231 001 Aug 31, 2018 Aug NEWA
TRISENOX
+ @ CEPHALON 1MG/ML N021248 001 Sep 25, 2000 Jul DISC

ASCORBIC ACID

SOLUTION;INTRAVENOUS
ASCOR
+! MCGUFF 25,000MG/50ML (500MG/ML) N209112 001 Oct 02, 2017 Jul CDFR

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

>A> INJECTABLE;INTRAVENOUS
>A> INFUVITE PEDIATRIC
>A> +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL N021265 001 Feb 21, 2001 Aug CDFR

>A> INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)
>A> +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL N021646 001 Jan 29, 2004 Aug CDFR

>D> INJECTABLE;IV (INFUSION)
>D> INFUVITE PEDIATRIC
>D> +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL N021265 001 Feb 21, 2001 Aug CDFR

>D> INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)
>D> +! SANDOZ INC 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL N021646 001 Jan 29, 2004 Aug CDFR

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

>A> FOR SOLUTION;INTRAVENOUS
>A> M.V.I. PEDIATRIC
>A> +! HOSPIRA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL N018920 001 Sep 21, 2000 Aug CDFR

>D> FOR SOLUTION;IV (INFUSION)
>D> M.V.I. PEDIATRIC
>D> +! HOSPIRA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL N018920 001 Sep 21, 2000 Aug CDFR

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

>A>	INJECTABLE; INTRAVENOUS						
>A>	M.V.I. ADULT						
>A>	+! HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIA L; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIA L; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6M G/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/V IAL	N 021625	001	Jan 30, 2004	Aug	CDFR
>A>	M.V.I. ADULT (PHARMACY BULK PACKAGE)						
>A>	+! HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 1 5MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG /5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG /5ML; 10MG/5ML; 0.15MG/5ML	N 021643	001	Feb 18, 2004	Aug	CDFR
>D>	INJECTABLE; IV (INFUSION)						
>D>	M.V.I. ADULT						
>D>	+! HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIA L; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIA L; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6M G/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/V IAL	N 021625	001	Jan 30, 2004	Aug	CDFR
>D>	M.V.I. ADULT (PHARMACY BULK PACKAGE)						
>D>	+! HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 1 5MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG /5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG /5ML; 10MG/5ML; 0.15MG/5ML	N 021643	001	Feb 18, 2004	Aug	CDFR

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL						
PLENUV						
+! SALIX PHARMS INC	7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9 GM	N 209381	001	May 04, 2018	May	NEWA

ASENAPINE MALEATE

TABLET; SUBLINGUAL						
ASENAPINE MALEATE						
AB SIGMAPHARM LABS LLC	EQ 5MG BASE	A 206107	001	Jul 17, 2018	Jul	NEWA
AB	EQ 10MG BASE	A 206107	002	Jul 17, 2018	Jul	NEWA
SAPHRIS						
AB + FOREST LABS LLC	EQ 5MG BASE	N 022117	001	Aug 13, 2009	Jul	CFTG
AB +!	EQ 10MG BASE	N 022117	002	Aug 13, 2009	Jul	CFTG

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL						
BUTALBITAL, ASPIRIN AND CAFFEINE						
@ FOSUN PHARMA	325MG; 50MG; 40MG	A 086398	002	Apr 06, 1984	Jan	CAHN

>D> ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

>D> CAPSULE; ORAL						
>D> SYNALGOS-DC						
>D> +! SUN PHARM INDUSTRIES	356.4MG; 30MG; 16MG	N 011483	004	Sep 06, 1983	Aug	DISC
>A> + @	356.4MG; 30MG; 16MG	N 011483	004	Sep 06, 1983	Aug	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL						
ORPHENGESIC						
@ GALT PHARMS	385MG; 30MG; 25MG	A 075141	001	May 29, 1998	Feb	CAHN
ORPHENGESIC FORTE						
@ GALT PHARMS	770MG; 60MG; 50MG	A 075141	002	May 29, 1998	Feb	CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL						
ASPIRIN AND DIPYRIDAMOLE						
AB ANI PHARMS INC	25MG; 200MG	A 206964	001	Jan 18, 2017	May	CAHN
>A> AB SUN PHARMA GLOBAL	25MG; 200MG	A 208572	001	Aug 21, 2018	Aug	NEWA

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

+ @ ARALEZ PHARMS	81MG;40MG
+ @	325MG;40MG
+ @ GENUS LIFESCIENCES	81MG;40MG
+ @	325MG;40MG

N205103	001	Sep 14, 2016	Apr DISC
N205103	002	Sep 14, 2016	Apr DISC
N205103	001	Sep 14, 2016	Jul CAHN
N205103	002	Sep 14, 2016	Jul CAHN

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	AUROBINDO PHARMA LTD	EQ 100MG BASE	A204806	001	Jun 25, 2018	Jun NEWA
AB		EQ 150MG BASE	A204806	002	Jun 25, 2018	Jun NEWA
AB		EQ 200MG BASE	A204806	003	Jun 25, 2018	Jun NEWA
AB		EQ 300MG BASE	A204806	004	Jun 25, 2018	Jun NEWA
AB	Cipla LTD	EQ 100MG BASE	A200626	001	Aug 09, 2018	Jul NEWA
AB		EQ 150MG BASE	A200626	002	Aug 09, 2018	Jul NEWA
AB		EQ 200MG BASE	A200626	003	Aug 09, 2018	Jul NEWA
AB		EQ 300MG BASE	A200626	004	Aug 09, 2018	Jul NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Jun CTEC

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072302	002	May 31, 1990	Jul CMS1
----	---------------	-----------	---------	-----	--------------	----------

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb NEWA
AB		18MG	A090609	002	Feb 23, 2018	Feb NEWA
AB		25MG	A090609	003	Feb 23, 2018	Feb NEWA
AB		40MG	A090609	004	Feb 23, 2018	Feb NEWA
AB		60MG	A090609	005	Feb 23, 2018	Feb NEWA
AB		80MG	A090609	006	Feb 23, 2018	Feb NEWA
AB		100MG	A090609	007	Feb 23, 2018	Feb NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018	Mar NEWA
AB		EQ 20MG BASE	A207687	002	Mar 30, 2018	Mar NEWA
AB		EQ 40MG BASE	A207687	003	Mar 30, 2018	Mar NEWA
AB		EQ 80MG BASE	A207687	004	Mar 30, 2018	Mar NEWA
AB	GRAVITI PHARMS	EQ 10MG BASE	A209912	001	Jun 18, 2018	Jun NEWA
AB		EQ 20MG BASE	A209912	002	Jun 18, 2018	Jun NEWA
AB		EQ 40MG BASE	A209912	003	Jun 18, 2018	Jun NEWA
AB		EQ 80MG BASE	A209912	004	Jun 18, 2018	Jun NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

>A> AB	@ APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Jun DISC
	LUPIN LTD	750MG/5ML	A209105	001	Sep 11, 2018	Aug NEWA

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPINE (AUTOINJECTOR)

@ RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018	Jul NEWA
-----------------	---	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+ @ HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jun DISC
-------------	----------------------	---------	-----	--------------	----------

SOLUTION;IV (INFUSION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+! FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Jan NEWA
-----------------------	---------------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Jul CMFD
----------------	----	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

@	1%	N208151	001	Dec 01, 2016	Apr DISC
	1%	N208151	001	Dec 01, 2016	Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>A> AA	@ FOSUN PHARMA	0.025MG;2.5MG	A086173	001	Jan CAHN	
	UPSHER-SMITH LABS	0.025MG;2.5MG	A210571	001	Aug 31, 2018	Aug NEWA
	LONOX					
	@ FOSUN PHARMA	0.025MG;2.5MG	A085311	002	Jan CAHN	

AVATROMBOPAG MALEATE

TABLET;ORAL

DOPELET

+! AKARX INC EQ 20MG BASE

N210238 001 May 21, 2018 May NEWA

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+! ALLERGAN SALES LLC EQ 0.5GM BASE;2GM/VIAL

N206494 001 Feb 25, 2015 Jan CAHN

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	ACCORD HLTHCARE	100MG/VIAL	A207475	001	Jul 02, 2018	Jun NEWA
AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	May CDFR
AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	May CDFR
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	May CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	May CDFR
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	May CDFR
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	May CDFR
	VIDAZA					
AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	May CDFR
	POWDER;IV (INFUSION), SUBCUTANEOUS					
	AZACITIDINE					
AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	Apr NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	AMNEAL PHARMS LLC	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018	Jul NEWA
AB		EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018	Jul NEWA
AB	EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018	Mar NEWA
AB		EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018	Mar NEWA
AB	ZYDUS WORLDWIDE	EQ 100MG BASE/5ML	A211147	001	Jul 31, 2018	Jul NEWA
AB		EQ 200MG BASE/5ML	A211147	002	Jul 31, 2018	Jul NEWA

FOR SUSPENSION, EXTENDED RELEASE;ORAL
ZMAX

+ @ PF PRISM CV EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005 Jun DISC

TABLET;ORAL

AZITHROMYCIN

@ APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Mar DISC
@	EQ 500MG BASE	A065509	001	Jul 13, 2011	Mar DISC
@	EQ 600MG BASE	A065508	001	Jul 13, 2011	Mar DISC
AB AUROBINDO PHARMA LTD	EQ 250MG BASE	A207370	001	Jul 05, 2018	Jul NEWA
AB	EQ 500MG BASE	A207398	001	Jul 05, 2018	Jul NEWA

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

@ MYLAN ASI 50,000 UNITS/VIAL
@ PHARMACIA AND UPJOHN 10,000 UNITS/VIALA090211 001 May 11, 2010 Jan DISC
A060733 001 Jul DISCBACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	MYLAN LABS LTD	0.5MG/ML	A209592	001	Mar 21, 2018	Mar NEWA
AP		1MG/ML	A209594	001	Mar 06, 2018	Feb NEWA
AP		2MG/ML	A209592	002	Mar 21, 2018	Mar NEWA

**INJECTABLE; INTRATHECAL
GABLOFEN**

AP +! PIRAMAL CRITICAL 1MG/ML N022462 004 Jun 22, 2012 Feb CFTG

BARICITINIB

TABLET; ORAL

OLUMTANT

+! ELI LILLY AND CO 2MG N207924 001 May 31, 2018 May NEWA

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

+! BRACCO 98% (334GM/BOT) N208036 001 Jan 11, 2016 Apr CPOT

E-Z-PAQUE

+! BRACCO 96% (169GM/BOT) N208036 002 Apr 07, 2017 Apr CPOT

PASTE; ORAL

VARIBAR PUDDING

BRACCO

40%

40% (92GM/230ML) N208844 001 Oct 14, 2016 Jun CPOT

SUSPENSION; ORAL

LIQUID E-Z-PAQUE

+! BRACCO 60% (213GM/BOT) N208143 003 Mar 01, 2017 Apr CPOT

READI-CAT 2

+! BRACCO 2% (9GM/BOT) N208143 001 Jan 15, 2016 Apr CPOT

READI-CAT 2 SMOOTHIES

+! BRACCO 2% (9GM/BOT) N208143 002 Jan 15, 2016 Apr CPOT

TAGITOL V

+! BRACCO 40% (8GM/BOT) N208143 005 Aug 04, 2017 Apr CPOT

VARIBAR HONEY

+! BRACCO 40% (100GM/250ML) N208143 007 Mar 26, 2018 Mar NEWA

VARIBAR THIN HONEY

+! BRACCO 40% (100GM/250ML) N208143 006 Jan 23, 2018 Jan NEWA

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

>A> +! WYETH PHARMS EQ 20MG BASE; 0.45MG N022247 001 Oct 03, 2013 Aug CAHN
>D> +! WYETH PHARMS PFIZER EQ 20MG BASE; 0.45MG N022247 001 Oct 03, 2013 Aug CAHN

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+ @ TEVA BRANDED PHARM 0.04MG/INH N020911 002 Sep 15, 2000 Jun DISC

QVAR 80

+ @ TEVA BRANDED PHARM 0.08MG/INH N020911 001 Sep 15, 2000 Jun DISC

QVAR REDIHALER

+ NORTON WATERFORD 0.04MG/INH N207921 001 Aug 03, 2017 Jul CMFD

+ @ 0.04MG/INH N207921 001 Aug 03, 2017 Jun DISC

+! 0.04MG/INH N207921 001 Aug 03, 2017 Jan CHRS

+ 0.08MG/INH N207921 002 Aug 03, 2017 Jul CMFD

+ @ 0.08MG/INH N207921 002 Aug 03, 2017 Jun DISC

BELINOSTAT

POWDER; INTRAVENOUS

BELEODAQ

+! SPECTRUM PHARMS 500MG/VIAL N206256 001 Jul 03, 2014 Jun CDFR

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB CASI PHARMS INC 5MG A076402 001 Feb 11, 2004 Mar CAHN
AB 10MG A076402 002 Feb 11, 2004 Mar CAHN
AB 20MG A076402 003 Feb 11, 2004 Mar CAHN
AB 40MG A076402 004 Feb 11, 2004 Mar CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP MYLAN LABS LTD 25MG/VIAL A204104 001 Apr 26, 2018 Apr NEWA
AP 100MG/VIAL A204104 002 Apr 26, 2018 Apr NEWA

SOLUTION;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

+! EAGLE PHARMS	100MG/4ML (25MG/ML)
+	100MG/4ML (25MG/ML)
TREANDA	
+ @ CEPHALON	45MG/0.5ML (90MG/ML)
+ @	180MG/2ML (90MG/ML)

N205580	001	May 15, 2018	Jul CHRS
N205580	001	May 15, 2018	May NEWA
N022249	003	Sep 13, 2013	May DISC
N022249	004	Sep 13, 2013	May DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Mar NEWA
----	-------------------	-------	---------	-----	--------------	----------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TARO	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May NEWA
AB		5%;EQ 1% BASE	A208776	001	May 25, 2018	May NEWA
AB	TARO PHARMS	5%;1.2%	A206218	001	Dec 15, 2017	May CAHN
	ONEXTON					
AB	+! DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Jul CAHN
----	------------	------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

>A>	@ CHARTWELL RX	1MG	A081265	002	Jan 23, 1992	Aug CMS1
	@	2MG	A081265	001	Jan 23, 1992	Jan CAHN

BETAINE

FOR SOLUTION;ORAL

CYSTADANE

+! ORPHAN EUROPE	1GM/SCOOPFUL
------------------	--------------

N020576	001	Oct 25, 1996	May CAIN
---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	HI-TECH PHARMACAL	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Jan NEWA
	LOTION, AUGMENTED;TOPICAL					
	BETAMETHASONE DIPROPIONATE					
>D> AB	TARO	EQ 0.05% BASE	A077477	001	May 21, 2007	Aug CHRS
>A> AB	!	EQ 0.05% BASE	A077477	001	May 21, 2007	Aug CHRS
AB	TELIGENT PHARMA INC	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Jan NEWA
>D>	DIPROLENE					
>D> AB	+! MERCK SHARP DOHME	EQ 0.05% BASE	N019716	001	Aug 01, 1988	Aug DISC
>A>	+ @	EQ 0.05% BASE	N019716	001	Aug 01, 1988	Aug DISC

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL

@ G AND W LABS INC	EQ 0.1% BASE
--------------------	--------------

A070072	001	Jun 27, 1985	Jan DISC
---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETOPTIC

AT	+! SANDOZ INC	EQ 0.5% BASE	N019270	001	Aug 30, 1985	Jan CAHN
----	---------------	--------------	---------	-----	--------------	----------

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB	AMERIGEN PHARMS LTD	75MG	A209861	001	May 08, 2018	Apr NEWA
>A> AB	AMNEAL PHARMS NY	75MG	A210105	001	Sep 04, 2018	Aug NEWA
AB	UPSHER-SMITH LABS	75MG	A209886	001	Jul 25, 2018	Jul NEWA

BICALUTAMIDE

TABLET;ORAL
CASODEX
AB +! ANI PHARMS INC 50MG N020498 001 Oct 04, 1995 Jan CAHN

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
BIKTARVY
+! GILEAD SCIENCES INC EQ 50MG BASE;200MG;EQ 25MG BASE N210251 001 Feb 07, 2018 Feb NEWA

BINIMETINIB

TABLET;ORAL
MEKTOVI
+! ARRAY BIOPHARMA INC 15MG N210498 001 Jun 27, 2018 Jun NEWA

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL
@ NOVEL LABS INC 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2 A202217 001 Aug 20, 2014 May DISC
.86GM;N/A,5.6GM

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL
PYLERA
+! ALLERGAN SALES LLC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Jan CAHN

BISOPROLOL FUMARATE

TABLET;ORAL
BISOPROLOL FUMARATE
AB CASI PHARMS INC 5MG A075643 001 Nov 16, 2000 Mar CAHN
AB 10MG A075643 002 Nov 16, 2000 Mar CAHN
ZEBETA
>D> @ TEVA WOMENS 5MG N019982 002 Jul 31, 1992 Aug CRLD
>A> + @ 5MG N019982 002 Jul 31, 1992 Aug CRLD
>D> @ 10MG N019982 001 Jul 31, 1992 Aug CRLD
>A> + @ 10MG N019982 001 Jul 31, 1992 Aug CRLD

BIVALIRUDIN

INJECTABLE;INTRAVENOUS
BIVALIRUDIN
AP AUROBINDO PHARMA LTD 250MG/VIAL A205962 001 Jul 27, 2018 Jul NEWA
AP MYLAN INSTITUTIONAL 250MG/VIAL A202471 001 Jun 01, 2018 May NEWA
AP SAGENT PHARMS 250MG/VIAL A091602 001 Jul 16, 2018 Jul NEWA
SOLUTION;INTRAVENOUS
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017 Jul CDFR
+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017 Jul CDFR
SOLUTION;IV (INFUSION)
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017 Jan CAHN
+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017 Jan CAHN

BLEOMYCIN SULFATE

INJECTABLE;INJECTION
BLEOMYCIN SULFATE
AP HONG KONG EQ 15 UNITS BASE/VIAL A205030 001 Apr 20, 2018 Apr NEWA
AP EQ 30 UNITS BASE/VIAL A205030 002 Apr 20, 2018 Apr NEWA

BORTEZOMIB

POWDER;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB
+! HOSPIRA INC 2.5MG/VIAL N209191 001 Jul 12, 2018 Jul NEWA

BRIGATINIB

TABLET;ORAL
ALUNBRIG
+! ARIAD 90MG N208772 002 Apr 28, 2017 Jun CHRS
+! 180MG N208772 003 Oct 02, 2017 Jun CHRS

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

@ AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jun DISC
@ APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun DISC
@ PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jun DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA ! WOCKHARDT BIO AG	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Apr CAHN
-----------------------	---------------------------	---------	-----	--------------	----------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

>D> AB APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Aug CAHN
>A> AB RISING PHARMS	3MG	A207367	001	Apr 07, 2017	Aug CAHN
TABLET, EXTENDED RELEASE;ORAL					
BUDESONIDE					
AB ACTAVIS LABS FL INC	9MG	A205457	001	Jul 03, 2018	Jun NEWA
UCERIS					
AB +! VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Jun CFTG

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

@ ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Apr DISC
AP ! WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Apr CHRS
TABLET;ORAL					
BUMETANIDE					
AB UPSHER-SMITH LABS	0.5MG	A209916	001	Jan 23, 2018	Jan NEWA
AB	1MG	A209916	002	Jan 23, 2018	Jan NEWA
AB	2MG	A209916	003	Jan 23, 2018	Jan NEWA
AB ZYDUS PHARMS USA INC	0.5MG	A202900	001	Apr 30, 2018	Apr NEWA
AB	1MG	A202900	002	Apr 30, 2018	Apr NEWA
AB	2MG	A202900	003	Apr 30, 2018	Apr NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;SPINAL

SENSORCAINE

@ FRESENIUS KABI USA 0.75%

A071202 001 Apr 15, 1987 Jun DISC

BUPRENORPHINE

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

SUBLOCADE

+ INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017	Jul CMS1
+!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017	Jul CMS1

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION

PROBUPHINE

+! TITAN PHARMS EQ 80MG BASE/IMPLANT

N204442 001 May 26, 2016 Jun CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB CASI PHARMS INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	Mar CAHN
	EQ 8MG BASE	A090279	002	Jun 10, 2015	Mar CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A205299	001	Jun 14, 2018	May NEWA
AB	EQ 4MG BASE;EQ 1MG BASE	A205806	001	Jun 14, 2018	May NEWA
AB	EQ 8MG BASE;EQ 2MG BASE	A205299	002	Jun 14, 2018	May NEWA
AB	EQ 12MG BASE;EQ 3MG BASE	A205806	002	Jun 14, 2018	May NEWA
AB MYLAN TECHNOLOGIES	EQ 8MG BASE;EQ 2MG BASE	A207607	001	Jun 14, 2018	May NEWA
AB	EQ 12MG BASE;EQ 3MG BASE	A207607	002	Jun 14, 2018	May NEWA
	SUBOXONE				
AB + INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	May CFTG
AB +	EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	May CFTG
AB +	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	May CFTG
AB +!	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	May CFTG

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	75MG	A203013	001	Jun 08, 2018	May NEWA
AB		100MG	A203013	002	Jun 08, 2018	May NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	BUPROPION HYDROCHLORIDE					
AB2	SCIEGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan CAHN
AB3	YICHANG HUMANWELL	150MG	A210015	001	Jun 14, 2018	Jun NEWA
AB3		300MG	A210015	002	Jun 14, 2018	Jun NEWA
AB3	ZYDUS PHARMS USA INC	150MG	A201567	002	Jul 23, 2018	Jul NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+! NALPROPION 90MG;8MG

N200063 001 Sep 10, 2014 Jul CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb CAHN
AB		10MG	A078246	002	Feb 27, 2009	Feb CAHN
AB		15MG	A078246	003	Feb 27, 2009	Feb CAHN
AB		30MG	A078246	004	Feb 27, 2009	Feb CAHN
	@ FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan CAHN
	@	10MG	A075413	002	Mar 19, 2002	Jan CAHN
	@	15MG	A075413	003	Mar 19, 2002	Jan CAHN
AB	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Apr NEWA
AB		7.5MG	A209696	002	May 03, 2018	Apr NEWA
AB		10MG	A209696	003	May 03, 2018	Apr NEWA
AB		15MG	A209696	004	May 03, 2018	Apr NEWA
AB		30MG	A209696	005	May 03, 2018	Apr NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Jul NEWA
AP	MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Jul NEWA

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	! HOSPIRA	1MG/ML	A074626	001	Jan 23, 1997	Mar CHRS
AP	! STADOL	2MG/ML	A074626	002	Jan 23, 1997	Mar CHRS
	+ @ APOTHECON	2MG/ML	N017857	004		Mar CRLD
	STADOL PRESERVATIVE FREE					
	+ @ APOTHECON	1MG/ML	N017857	001		Mar CRLD
	+ @	2MG/ML	N017857	002		Mar CRLD

CABAZITAXEL

SOLUTION;INTRAVENOUS

JEVANTA KIT

+! SANOFI AVENTIS US 60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010 Jul CDFR

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB	@ APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Mar DISC
	INGENUS PHARMS LLC	0.5MG	A204735	001	Aug 01, 2018	Jul NEWA

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

+! EXELIXIS EQ 20MG BASE

+ EQ 80MG BASE

N203756 001 Nov 29, 2012 Jun CHRS

N203756 002 Nov 29, 2012 Jun CHRS

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

>D>	! HORIZON PHARMA	100MG;2MG	A 086557	001	Oct 04, 1983	Aug CAHN
>A>	! HZNP	100MG;2MG	A 086557	001	Oct 04, 1983	Aug CAHN

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB	LOTUS PHARM CO LTD	667MG	A 203298	001	Jul 26, 2016	Jun CAHN
	TABLET;ORAL					
	ELIPHOS					
	@ CYPRESS PHARM	667MG	A 078502	001	Nov 25, 2008	Apr DISC

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP	INTL MEDICATION SYS	100MG/ML	A 203477	001	May 09, 2018	Apr NEWA
----	---------------------	----------	----------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

BSS PLUS

>D> AT	+! ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M	N 018469	001		Aug CTEC
		L;0.42MG/ML				
>A>	+!	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M	N 018469	001		Aug CTEC
		L;0.42MG/ML				
>D>	ENDOSOL EXTRA					
>D> AT	+! AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M	N 020079	001	Nov 27, 1991	Aug DISC
		L;0.42MG/ML				
>A>	METHOTREXATE SODIUM					
	@ AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M	N 020079	001	Feb 26, 1999	Aug DISC
		L;0.42MG/ML				

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.2	N 021703	010	Oct 10, 2008	Jun DISC
	1GM/1000ML;7.07GM/1000ML (5000ML)				

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N 021703	013	Oct 10, 2008	Jun DISC
--------------------------	--	----------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N 021703	001	Oct 25, 2006	Jun DISC
--------------------------	---	----------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

>D>	INJECTABLE;INJECTION					
>D>	DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER					
>D>	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;86	N 020000	001	Apr 17, 1992	Aug DISC
		0MG/100ML				
>A>	@	33MG/100ML;5GM/100ML;30MG/100ML;86	N 020000	001	Apr 17, 1992	Aug DISC
		0MG/100ML				

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N 019685	005	Oct 17, 1988	Jan CRLD
	00MG/100ML;310MG/100ML				

+ @	20MG/100ML;5GM/100ML;179MG/100ML;6	N 019685	006	Oct 17, 1988	Jan CRLD
	00MG/100ML;310MG/100ML				

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N 019685	007	Oct 17, 1988	Jan CRLD
	00MG/100ML;310MG/100ML				

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
+ ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML	N 019685	002	Oct 17, 1988	Jan CRLD	
+ @	20MG/100ML;5GM/100ML;328MG/100ML;6 00MG/100ML;310MG/100ML	N 019685	008	Oct 17, 1988	Jan DISC	
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
+ @ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6 00MG/100ML;310MG/100ML	N 019685	003	Oct 17, 1988	Jan CRLD	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
+ @ ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;6 00MG/100ML;310MG/100ML	N 019685	004	Oct 17, 1988	Jan DISC	
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
+ @ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6 00MG/100ML;310MG/100ML	N 019685	001	Oct 17, 1988	Jan CRLD	

CALCIUM GLUCONATESOLUTION; INTRAVENOUS
CALCIUM GLUCONATE

+! FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N 208418	001	Jun 15, 2017	May CDFR
+!	5GM/50ML (100MG/ML)	N 208418	002	Jun 15, 2017	May CDFR
+!	10GM/100ML (100MG/ML)	N 208418	003	Jun 15, 2017	May CDFR

CANDESARTAN CILEXETILTABLET; ORAL
ATACAND

AB + ANI PHARMS INC	4MG	N 020838	001	Jun 04, 1998	Jan CAHN
AB +	8MG	N 020838	002	Jun 04, 1998	Jan CAHN
AB +	16MG	N 020838	003	Jun 04, 1998	Jan CAHN
AB +!	32MG	N 020838	004	Jun 04, 1998	Jan CAHN
CANDESARTAN CILEXETIL					
@ APOTEX INC	4MG	A 202079	001	Jan 10, 2014	Mar DISC
@	8MG	A 202079	002	Jan 10, 2014	Mar DISC
@	16MG	A 202079	003	Jan 10, 2014	Mar DISC
@	32MG	A 202079	004	Jan 10, 2014	Mar DISC
AB MYLAN PHARMS INC	4MG	A 078702	001	May 03, 2013	Apr CAHN
AB	8MG	A 078702	002	May 03, 2013	Apr CAHN
AB	16MG	A 078702	003	May 03, 2013	Apr CAHN
AB	32MG	A 078702	004	May 03, 2013	Apr CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDETABLET; ORAL
ATACAND HCT

AB + ANI PHARMS INC	16MG;12.5MG	N 021093	001	Sep 05, 2000	Feb CAHN
AB +	32MG;12.5MG	N 021093	002	Sep 05, 2000	Feb CAHN
AB +!	32MG;25MG	N 021093	003	May 16, 2008	Feb CAHN
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE					
@ APOTEX INC	16MG;12.5MG	A 202884	001	Dec 04, 2012	Mar DISC
@	32MG;12.5MG	A 202884	002	Dec 04, 2012	Mar DISC
@	32MG;25MG	A 202884	003	Jun 03, 2013	Mar DISC
AB PRINSTON INC	16MG;12.5MG	A 207455	001	Apr 11, 2018	Mar NEWA
AB	32MG;12.5MG	A 207455	002	Apr 11, 2018	Mar NEWA
AB	32MG;25MG	A 207455	003	Apr 11, 2018	Mar NEWA

CANGRELOLPOWDER; INTRAVENOUS
KENGREAL

+! CHIESI USA INC	50MG/VIAL	N 204958	001	Jun 22, 2015	Jul CDFR
-------------------	-----------	----------	-----	--------------	----------

CAPECITABINETABLET; ORAL
CAPECITABINE

AB EUGIA PHARMA	150MG	A 210604	001	Apr 17, 2018	Apr NEWA
AB	500MG	A 210604	002	Apr 17, 2018	Apr NEWA
AB MSN LABS PVT LTD	150MG	A 209365	001	Jul 02, 2018	Jun NEWA
AB	500MG	A 209365	002	Jul 02, 2018	Jun NEWA

CAPTOPRILTABLET; ORAL
CAPTOPRIL

@ OXFORD PHARMS	12.5MG	A 074418	001	Feb 13, 1996	Jul CAHN
@	25MG	A 074418	002	Feb 13, 1996	Jul CAHN
@	50MG	A 074418	003	Feb 13, 1996	Jul CAHN

TABLET;ORAL CARISOPRODOL @ FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989	Jan CAHN
<u>CARMUSTINE</u>					
INJECTABLE;INJECTION BICNU					
>D> +! EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Aug CFTG
>A> AP +!	100MG/VIAL	N017422	001		Aug CFTG
>A> CARMUSTINE					
>A> AP NAVINTA LLC	100MG/VIAL	A210179	001	Sep 11, 2018	Aug NEWA
<u>CARVEDILOL</u>					
TABLET;ORAL CARVEDILOL					
AB CHARTWELL MOLECULAR	3.125MG	A077474	001	Sep 05, 2007	Mar CAHN
AB	6.25MG	A077474	002	Sep 05, 2007	Mar CAHN
AB	12.5MG	A077474	003	Sep 05, 2007	Mar CAHN
AB	25MG	A077474	004	Sep 05, 2007	Mar CAHN
<u>CARVEDILOL PHOSPHATE</u>					
CAPSULE, EXTENDED RELEASE;ORAL CARVEDILOL PHOSPHATE					
AB IMPAX LABS INC	10MG	A204717	001	May 07, 2018	Apr NEWA
AB	20MG	A204717	002	May 07, 2018	Apr NEWA
AB	40MG	A204717	003	May 07, 2018	Apr NEWA
AB	80MG	A204717	004	May 07, 2018	Apr NEWA
<u>CASPOFUNGIN ACETATE</u>					
POWDER;INTRAVENOUS CANCIDAS					
AP +! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	May CDFR
AP +!	70MG/VIAL	N021227	002	Jan 26, 2001	May CDFR
CASPOFUNGIN ACETATE					
AP CIPLA LTD	50MG/VIAL	A209489	001	Jul 12, 2018	Jul NEWA
AP	70MG/VIAL	A209489	002	Jul 12, 2018	Jul NEWA
AP FRESENIUS KABI USA	50MG/VIAL	N206110	001	Dec 30, 2016	May CDFR
AP	70MG/VIAL	N206110	002	Dec 30, 2016	May CDFR
AP GLAND PHARMA LTD	50MG/VIAL	A207092	001	Sep 29, 2017	May CDFR
AP	70MG/VIAL	A207092	002	Sep 29, 2017	May CDFR
AP MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017	May CDFR
AP	70MG/VIAL	A207650	002	Sep 29, 2017	May CDFR
AP SANDOZ INC	50MG/VIAL	A200833	001	Jun 28, 2018	Jun NEWA
AP	70MG/VIAL	A200833	002	Jun 28, 2018	Jun NEWA
AP XELLIA PHARMS APS	50MG/VIAL	A205923	001	Jul 02, 2018	Jun NEWA
AP	70MG/VIAL	A205923	002	Jul 02, 2018	Jun NEWA
<u>CEFADROXIL/CEFADROXIL HEMIHYDRATE</u>					
CAPSULE;ORAL CEFADROXIL					
@ CSPC OUYI PHARM CO	EQ 500MG BASE	A205072	001	Jul 28, 2017	Jun DISC
<u>CEFAZOLIN SODIUM</u>					
INJECTABLE;INJECTION ANCEF IN PLASTIC CONTAINER					
@ BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991	Jun DISC
<u>CEFEPIMIDE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION CEFEPIMIDE HYDROCHLORIDE					
@ FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jan CAHN
@	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jan CAHN
@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jan CAHN
POWDER;INTRAVENOUS CEFEPIMIDE HYDROCHLORIDE IN PLASTIC CONTAINER					
>A> SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Aug NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

AP !	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Apr CHRS
AP !		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Apr CHRS
AP !		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Apr CHRS
AP !		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Apr CHRS
	CLAFORAN					
+ @	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Apr DISC
+ @		EQ 1GM BASE/VIAL	N050547	002		Apr DISC
+ @		EQ 2GM BASE/VIAL	N050547	003		Apr DISC
+ @		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Apr DISC

CEFOXITIN SODIUM

POWDER; INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

SAMSON MEDCL EQ 100GM BASE

A200938 001 Nov 16, 2015 Jul CDFR

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB	CASI PHARMS INC	250MG	A065235	001	Nov 14, 2005	Mar CAHN
AB		500MG	A065235	002	Nov 14, 2005	Mar CAHN

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

TEFLARO

+ !	ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010	Jul CDFR
+ !		600MG/VIAL	N200327	002	Oct 29, 2010	Jul CDFR

POWDER; IV (INFUSION)

TEFLARO

+ !	ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010	Jan CAHN
+ !		600MG/VIAL	N200327	002	Oct 29, 2010	Jan CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

@ ACS DOBFAR 500MG/VIAL

A062640 001 Nov 20, 1985 Jun DISC

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+ @	TELIGENT	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May DISC
+ @		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

@ SI PHARMS EQ 400MG BASE

N050685 002 Dec 20, 1995 Jan CAHN

FOR SUSPENSION; ORAL

CEDAX

+ @	SI PHARMS	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jan CAHN
+ @		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jan CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; INTRAVENOUS

ZERBAXA

+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Jul CDFR
----	-------------------	--------------------------------------	---------	-----	--------------	----------

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP	SAGENT PHARMS	EQ 250MG BASE/VIAL	A091049	001	Jun 11, 2018	May NEWA
AP		EQ 500MG BASE/VIAL	A091049	002	Jun 11, 2018	May NEWA
AP		EQ 1GM BASE/VIAL	A091049	003	Jun 11, 2018	May NEWA
AP		EQ 2GM BASE/VIAL	A091049	004	Jun 11, 2018	May NEWA

CEFURGXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

+ @ GLAXOSMITHKLINE

EQ 125MG BASE/5ML

N050672 001 Jun 30, 1994 Jul DISC

+ @

EQ 250MG BASE/5ML

N050672 002 Apr 29, 1997 Jul DISC

TABLET;ORAL

CEFTIN

+ @ GLAXOSMITHKLINE

EQ 125MG BASE

N050605 001 Dec 28, 1987 May DISC

+ @

EQ 250MG BASE

N050605 002 Dec 28, 1987 May DISC

+ @

EQ 500MG BASE

N050605 003 Dec 28, 1987 May DISC

CEFURGXIME AXETIL

@ FOSUN PHARMA

EQ 250MG BASE

A065126 001 Oct 28, 2003 Jan CAHN

@

EQ 500MG BASE

A065126 002 Oct 28, 2003 Jan CAHN

AB ! LUPIN

EQ 500MG BASE

A065135 002 Jul 25, 2003 May CHRS

CEFURGXIME SODIUM

INJECTABLE;INJECTION

ZINACEF IN PLASTIC CONTAINER

+ @ TELIGENT

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 May DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB AMNEAL PHARMS

50MG

A208833 001 May 31, 2018 May NEWA

AB 100MG

A208833 002 May 31, 2018 May NEWA

AB 200MG

A208833 003 May 31, 2018 May NEWA

AB 400MG

A208833 004 May 31, 2018 May NEWA

AB CSPC OUYI PHARM CO

50MG

A210071 001 Jan 23, 2018 Jan NEWA

AB 100MG

A210071 002 Jan 23, 2018 Jan NEWA

AB 200MG

A210071 003 Jan 23, 2018 Jan NEWA

AB MICRO LABS

50MG

A204776 001 Apr 30, 2018 Apr NEWA

AB 100MG

A204776 002 Apr 30, 2018 Apr NEWA

AB 200MG

A204776 003 Apr 30, 2018 Apr NEWA

AB 400MG

A204776 004 Apr 30, 2018 Apr NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA LANNETT CO INC

5MG/5ML

A078496 001 Sep 25, 2009 May CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

@ APOTEX INC

30MG

A091260 001 Aug 25, 2011 Mar DISC

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

TUXARIN ER

@ SPRIASO LLC

8MG;54.3MG

N206323 001 Jun 22, 2015 Jul CTNA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

CODEPREX

>A> @ LANNETT CO INC

EQ 4MG MALEATE/5ML;EQ 20MG
BASE/5ML

N021369 001 Jun 21, 2004 Aug CAHN

>D> @ UCB INC

EQ 4MG MALEATE/5ML;EQ 20MG
BASE/5ML

N021369 001 Jun 21, 2004 Aug CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB ! NEOS THERAP INC

EQ 8MG MALEATE/5ML;EQ 10MG
BITARTRATE/5ML

A091671 001 Jun 29, 2012 Apr CHRS

TUSSIONEX PENNKNETIC

+ @ UCB INC

EQ 8MG MALEATE/5ML;EQ 10MG
BITARTRATE/5ML

N019111 001 Dec 31, 1987 Apr DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SONAZINE

@ FOSUN PHARMA	30MG/ML	A080983 004	Jan CAHN
@	100MG/ML	A080983 005	Jan CAHN

SYRUP; ORAL

SONAZINE

@ FOSUN PHARMA	10MG/5ML	A083040 001	Jan CAHN
----------------	----------	-------------	----------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A> AB	AMNEAL PHARMS CO	10MG	A209755 001	Sep 10, 2018	Aug NEWA
>A> AB		25MG	A209755 002	Sep 10, 2018	Aug NEWA
>A> AB		50MG	A209755 003	Sep 10, 2018	Aug NEWA
>A> AB		100MG	A209755 004	Sep 10, 2018	Aug NEWA
>A> AB		200MG	A209755 005	Sep 10, 2018	Aug NEWA
>D>	USL PHARMA	10MG	A083386 001		Aug CTEC
>A> AB		10MG	A083386 001		Aug CTEC
>D>	!	25MG	A084112 001		Aug CTEC
>A> AB	!	25MG	A084112 001		Aug CTEC
>D>		50MG	A084113 001		Aug CTEC
>A> AB		50MG	A084113 001		Aug CTEC
>D>	!	100MG	A084114 001		Aug CTEC
>A> AB	!	100MG	A084114 001		Aug CTEC
>D>		200MG	A084115 001		Aug CTEC
>A> AB		200MG	A084115 001		Aug CTEC

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC	100MG	A088921 001	Apr 12, 1985	Jul DISC	
@	250MG	A088922 001	Apr 12, 1985	Jul DISC	
MYLAN	100MG	A088549 002	Jun 01, 1984	Jul CTEC	
!	250MG	A088549 001	Jun 01, 1984	Jul CTEC	
AB	!	250MG	A088549 001	Jun 01, 1984	Jul CHRS
DIABINESE					
+ @ PFIZER	100MG	N011641 003		Jul DISC	
+ @	250MG	N011641 006		Jul DISC	
GLUCAMIDE					
@ ANI PHARMS INC	250MG	A088641 001	Oct 11, 1984	Jul DISC	

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	UMEDICA LABS PVT LTD	25MG	A207222 001	May 24, 2018	May NEWA
AB		50MG	A207222 002	May 24, 2018	May NEWA
THALITONE					
+ @ CASPER PHARMA LLC	15MG		N019574 001	Dec 20, 1988	Apr CRLD

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

@ MYLAN	15MG; 0.1MG	A071325 003	Feb 09, 1987	Mar DISC
@	15MG; 0.2MG	A071325 002	Feb 09, 1987	Mar DISC
@	15MG; 0.3MG	A071325 001	Feb 09, 1987	Mar DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554 001	Oct 02, 1996	Jun CMFD
AB		EQ 4GM RESIN/SCOOPFUL	A074554 002	Oct 02, 1996	Jun CMFD
AB	ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL	A202901 001	Jul 02, 2018	Jun NEWA

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	TELIGENT PHARMA INC	1%	A209975 001	Apr 05, 2018	Mar NEWA
SOLUTION; TOPICAL					
CICLOPIROX					
AT	INGENUS PHARMS LLC	8%	A078124 001	Sep 18, 2007	Jan CAHN

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS
 IMIPENEM AND CILASTATIN
 ! ACS DOBFAR EQ 250MG BASE/VIAL;250MG/VIAL A090577 001 Dec 21, 2011 Apr CHRS
 @ HOSPIRA INC EQ 250MG BASE/VIAL;250MG/VIAL A090825 001 Nov 16, 2011 Apr DISC
 PRIMAXIN
 + @ MERCK EQ 250MG BASE/VIAL;250MG/VIAL N050587 001 Nov 26, 1985 Apr DISC

CILOSTAZOL

TABLET; ORAL
 CILOSTAZOL
 AB CASI PHARMS INC 50MG A077310 001 Nov 08, 2005 Mar CAHN
 AB 100MG A077021 001 Nov 23, 2004 Mar CAHN
 >D> @ FRONTIDA BIOPHARM 50MG A077208 002 Mar 29, 2006 Aug CMFD
 >A> AB 50MG A077208 002 Mar 29, 2006 Aug CMFD
 >D> @ 100MG A077208 001 Mar 29, 2006 Aug CMFD
 >A> AB 100MG A077208 001 Mar 29, 2006 Aug CMFD

CIMETIDINE

TABLET; ORAL
 CIMETIDINE
 @ CHARTWELL MOLECULES 200MG A074329 002 May 17, 1994 Jan CMS1
 @ 300MG A074329 003 May 17, 1994 Jan CMS1
 @ 400MG A074329 004 May 17, 1994 Jan CMS1
 @ YAOPHARMA CO LTD 200MG A074100 001 Jan 31, 1995 Jan CAHN
 @ 300MG A074100 002 Jan 31, 1995 Jan CAHN
 @ 400MG A074100 003 Jan 31, 1995 Jan CAHN
 @ 800MG A074100 004 Jan 31, 1995 Jan CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
 CIMETIDINE HYDROCHLORIDE
 @ LANNETT CO INC EQ 300MG BASE/5ML A074251 001 Dec 22, 1994 May CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL
 CINACALCET HYDROCHLORIDE
 AB AUROBINDO PHARMA LTD EQ 30MG BASE A206125 001 Mar 08, 2018 Feb NEWA
 AB EQ 60MG BASE A206125 002 Mar 08, 2018 Feb NEWA
 AB EQ 90MG BASE A206125 003 Mar 08, 2018 Feb NEWA
 AB CIPLA LTD EQ 30MG BASE A208915 001 Mar 08, 2018 Feb NEWA
 AB EQ 60MG BASE A208915 002 Mar 08, 2018 Feb NEWA
 AB EQ 90MG BASE A208915 003 Mar 08, 2018 Feb NEWA
 AB PIRAMAL HLTHCARE UK EQ 30MG BASE A210207 001 Aug 01, 2018 Jul NEWA
 AB EQ 60MG BASE A210207 002 Aug 01, 2018 Jul NEWA
 AB EQ 90MG BASE A210207 003 Aug 01, 2018 Jul NEWA
 AB STRIDES PHARMA EQ 30MG BASE A209226 001 Apr 30, 2018 Apr NEWA
 AB EQ 60MG BASE A209226 002 Apr 30, 2018 Apr NEWA
 AB EQ 90MG BASE A209226 003 Apr 30, 2018 Apr NEWA
 AB ZYDUS PHARMS USA INC EQ 30MG BASE A208971 001 Apr 23, 2018 Apr NEWA
 AB EQ 60MG BASE A208971 002 Apr 23, 2018 Apr NEWA
 AB EQ 90MG BASE A208971 003 Apr 23, 2018 Apr NEWA
 SENSIPAR
 AB + AMGEN EQ 30MG BASE N021688 001 Mar 08, 2004 Feb CFTG
 AB + EQ 60MG BASE N021688 002 Mar 08, 2004 Feb CFTG
 AB +! EQ 90MG BASE N021688 003 Mar 08, 2004 Feb CFTG

CIPROFLOXACIN

INJECTABLE; INJECTION
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
 AP INFORLIFE 200MG/100ML A078252 001 Mar 18, 2008 Jan CAHN
 AP 400MG/200ML A078252 002 Mar 18, 2008 Jan CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
 CIPROFLOXACIN HYDROCHLORIDE
 AT ALTAIRE PHARMS INC EQ 0.3% BASE A204613 001 May 03, 2018 Apr NEWA
 TABLET; ORAL
 CIPRO
 + @ BAYER HLTHCARE EQ 100MG BASE N019537 001 Apr 08, 1996 Mar DISC
 + @ EQ 750MG BASE N019537 004 Oct 22, 1987 Mar DISC

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN
@	MYLAN	EQ 100MG BASE	A075817	001	Jun 25, 2007	Jun DISC
@		EQ 250MG BASE	A075817	002	Jun 09, 2004	Jun DISC
@		EQ 750MG BASE	A075817	004	Jun 09, 2004	Jun DISC
AB	YILING PHARM LTD	EQ 250MG BASE	A208921	001	Jun 22, 2018	Jun NEWA
AB		EQ 500MG BASE	A208921	002	Jun 22, 2018	Jun NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ FOSUN PHARMA 212.6MG;EQ 287.5MG BASE

A078712 001 Dec 11, 2007 Jan CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar NEWA
AP		EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Mar NEWA
AP		EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Mar NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan CAHN
AB	+!		EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan CAHN
	@		EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan CAHN
		CITALOPRAM HYDROBROMIDE					
AB		CHARTWELL MOLECULAR	EQ 10MG BASE	A077044	001	Nov 05, 2004	Mar CAHN
AB			EQ 20MG BASE	A077044	002	Nov 05, 2004	Mar CAHN
AB			EQ 40MG BASE	A077044	003	Nov 05, 2004	Mar CAHN
	@	FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan CAHN
	@		EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan CAHN
	@		EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan CAHN
	@		EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan CAHN
	@		EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan CAHN
	@		EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

+! FERRING PHARMS INC 12GM/BOT;3.5GM/BOT;10MG/BOT N209589 001 Nov 28, 2017 Apr CPOT

CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN

+	@	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993	Apr DISC
+	@		250MG/5ML	N050698	002	Dec 23, 1993	Apr DISC

AB	!	SANDOZ	250MG/5ML	A065283	003	Sep 04, 2007	Apr CHRS
----	---	--------	-----------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		SUNSHINE LAKE	500MG	A208987	001	Jul 09, 2018	Jun NEWA
----	--	---------------	-------	---------	-----	--------------	----------

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	May CTEC
@	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May DISC
		EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May CAHN

TABLET;ORAL

TAVIST

+ @ NOVARTIS 2.68MG N017661 001 May CRLD

CLEVIDIPIINE

EMULSION; INTRAVENOUS
CLEVIPREX
+ @ CHIESI USA INC 125MG/250ML (0.5MG/ML)

N022156 003 Nov 08, 2013 Jun DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE
AA APPCO PHARMA LLC EQ 75MG BASE/5ML

A207047 001 May 11, 2018 Apr NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
@ ABBOTT LABS EQ 6MG BASE/ML
@ EQ 12MG BASE/ML
@ EQ 18MG BASE/ML

A065027 001 Jun 29, 2001 Mar CAHN
A065027 002 Jun 29, 2001 Mar CAHN
A065027 003 Jun 29, 2001 Mar CAHN

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT GLASSHOUSE PHARMS EQ 1% BASE
@ WOCKHARDT BIO AG EQ 1% BASE
AT ZYDUS PHARMS USA INC EQ 1% BASE

A209846 001 Feb 08, 2018 Jan NEWA
A063304 001 Jul 15, 1997 May DISC
A063304 001 Jul 15, 1997 May CAHN
A208767 001 Jul 16, 2018 Jul NEWA

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1 CHEMO RESEARCH SL 0.05%
AB1 GLENMARK PHARMS 0.05%
AB1 LUPIN LTD 0.05%
AB1 TELIGENT PHARMA INC 0.05%
IMPOYZ

A210034 001 Jun 15, 2018 Jun NEWA
A209095 001 May 10, 2018 Apr NEWA
A210208 001 Jan 30, 2018 Jan NEWA
A209974 001 Apr 17, 2018 Apr NEWA

+! ENCORE DERMAT 0.025%

N209483 001 Nov 28, 2017 Jan CAHN

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

>A> AB AMNEAL PHARMS LLC 0.05%
AB CHEMO RESEARCH SL 0.05%
AB NOVEL LABS INC 0.05%

A210551 001 Aug 21, 2018 Aug NEWA
A209701 001 Apr 17, 2018 Apr NEWA
A208841 001 May 04, 2018 Apr NEWA

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT GLENMARK PHARMS LTD 0.05%

A210190 001 Apr 18, 2018 Apr NEWA

SPRAY; TOPICAL
CLOBETASOL PROPIONATE

AT APOTEX INC 0.05%
AT GLENMARK PHARMS 0.05%
AT LUPIN LTD 0.05%
AT TARO 0.05%

A210446 001 Apr 17, 2018 Apr NEWA
A209004 001 Mar 26, 2018 Mar NEWA
A208125 001 Mar 26, 2018 Mar NEWA
A208842 001 Mar 26, 2018 Mar NEWA

CLOFARABINE

SOLUTION; INTRAVENOUS
CLOFARABINE

AP ABON PHARMS LLC 20MG/20ML (1MG/ML)
AP AMNEAL PHARMS CO 20MG/20ML (1MG/ML)
AP DR REDDYS LABS LTD 20MG/20ML (1MG/ML)
AP MSN LABS PVT LTD 20MG/20ML (1MG/ML)
AP MYLAN LABS LTD 20MG/20ML (1MG/ML)
CLOLAR

A204029 001 May 09, 2017 May CDFR
A208857 001 Nov 06, 2017 May CDFR
A205375 001 Nov 06, 2017 May CDFR
A209775 001 Dec 06, 2017 May CDFR
A208860 001 Nov 06, 2017 May CDFR

AP +! GENZYME 20MG/20ML (1MG/ML)

N021673 001 Dec 28, 2004 May CDFR

CLOMIPHENE CITRATE

TABLET; ORAL
CLOMID
+ @ SANOFI AVENTIS US 50MG

N016131 002 Jul DISC

CLOMIPHENE CITRATE
! PAR PHARM 50MG

A075528 001 Aug 30, 1999 Jul CHRS
A075528 001 Aug 30, 1999 Jul CTEC

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	X-GEN PHARMS INC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	May CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	May CAHN
TABLET; ORAL						
CLONIDINE HYDROCHLORIDE						
@	AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	Jan CMS1
@		0.3MG	A070886	003	Aug 31, 1988	Jan CMS1
@	CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Apr CMS1
@		0.2MG	A071785	003	Apr 05, 1988	Apr CMS1
TABLET, EXTENDED RELEASE; ORAL						
CLONIDINE HYDROCHLORIDE						
AB1	JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan NEWA
AB1	MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Apr NEWA

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018	Apr NEWA
AB		EQ 300MG BASE	A206376	002	May 07, 2018	Apr NEWA

CLOZAPINE

TABLET; ORAL

CLOZAPINE

IVAX SUB TEVA PHARMS 12.5MG
@ MYLAN 12.5MGA074949 003 Jul 31, 2003 Jul CTEC
A075417 003 Apr 15, 2010 Jul DISCTABLET, ORALLY DISINTEGRATING; ORAL
CLOZAPINE

AB	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Mar NEWA
AB	FAZACLO ODT		N021590	004	May 30, 2007	Mar CTEC

COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

SYMTUZA

+!	JANSSEN PRODS	150MG; EQ 800MG BASE; 200MG; EQ 10MG BASE	N210455	001	Jul 17, 2018	Jul NEWA
----	---------------	--	---------	-----	--------------	----------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Jul NEWA
AB		3.75GM/PACKET	A202190	002	Jul 16, 2018	Jul NEWA
WELCHOL						
AB	+ DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Jul CFTG
AB	+!	3.75GM/PACKET	N022362	002	Oct 02, 2009	Jul CFTG
TABLET; ORAL						
COLESEVELAM HYDROCHLORIDE						
AB	GLENMARK PHARMS LTD	625MG	A203480	001	May 18, 2018	May NEWA
AB	IMPAK LABS INC	625MG	A091600	001	May 16, 2018	Apr NEWA
WELCHOL						
AB	+! DAIICHI SANKYO	625MG	N021176	001	May 26, 2000	Apr CFTG

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	NEXUS PHARMS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Jun CAHN
----	--------------	--------------------	---------	-----	--------------	----------

CONIVAPTAN HYDROCHLORIDE

>A> INJECTABLE; INTRAVENOUS

VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005 Aug CDFR

>A> VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+! CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008 Aug CDFR

>D> INJECTABLE; IV (INFUSION)

VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005 Aug CDFR

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+! CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008 Aug CDFR

<u>COPANLISIB DIHYDROCHLORIDE</u>					
	POWDER; INTRAVENOUS ALIQOPA				
+!	BAYER HEALTHCARE	60MG/VIAL	N 209936	001 Sep 14, 2017	Jul CDFR
<u>CROFELEMER</u>					
	TABLET, DELAYED RELEASE; ORAL MYTESI		N 202292	001 Dec 31, 2012	Mar CTNA
+!	NAPO PHARMS INC	125MG			
<u>CROMOLYN SODIUM</u>					
	SOLUTION; INHALATION CROMOLYN SODIUM		A 075437	001 Apr 21, 2000	Mar CAHN
@	FERA PHARMS LLC	10MG/ML			
	SOLUTION/DROPS; OPHTHALMIC CROMOLYN SODIUM				
AT	SANDOZ INC	4%	A 075282	001 Jun 16, 1999	Jan CAHN
<u>CROTAMITON</u>					
	CREAM; TOPICAL EURAX		N 006927	001	Feb CAHN
+!	SUN PHARM IND'S INC	10%			
	LOTION; TOPICAL EURAX		N 009112	003	Feb CAHN
AT	+! SUN PHARM IND'S INC	10%			
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>					
	CAPSULE, EXTENDED RELEASE; ORAL AMRIX		N 021777	001 Feb 01, 2007	Jul CFTG
AB	+ TEVA PHARMS INT'L	15MG	N 021777	002 Feb 01, 2007	Jul CFTG
AB	+!	30MG			
	CYCLOBENZAPRINE HYDROCHLORIDE				
AB	APOTEX INC	15MG	A 206703	001 Jul 24, 2018	Jul NEWA
AB		30MG	A 206703	002 Jul 24, 2018	Jul NEWA
<u>CYCLOPENTOLATE HYDROCHLORIDE</u>					
	SOLUTION/DROPS; OPHTHALMIC CYCLOGYL		A 084109	001	Feb CAHN
AT	! ALCON LABS INC	0.5%	A 084110	001	Feb CAHN
AT	!	1%	A 084108	001	Feb CAHN
	!	2%			
<u>CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE</u>					
	SOLUTION/DROPS; OPHTHALMIC CYCLOMYSRIL		A 084300	001	Feb CAHN
!	ALCON LABS INC	0.2%; 1%			
<u>CYCLOPHOSPHAMIDE</u>					
	CAPSULE; ORAL CYCLOPHOSPHAMIDE				
AB	AMERIGEN PHARMS LTD	25MG	A 207014	001 Mar 19, 2018	Mar NEWA
AB		50MG	A 207014	002 Mar 19, 2018	Mar NEWA
AB	STI PHARMA LLC	25MG	A 209872	001 May 07, 2018	Apr NEWA
AB		50MG	A 209872	002 May 07, 2018	Apr NEWA
AB	+ WEST-WARD PHARMS INT	25MG	N 203856	001 Sep 16, 2013	Mar CFTG
AB	+!	50MG	N 203856	002 Sep 16, 2013	Mar CFTG
	INJECTABLE; INJECTION CYCLOPHOSPHAMIDE				
AP	AMNEAL PHARMS CO	500MG/VIAL	A 210046	001 May 25, 2018	May NEWA
AP		1GM/VIAL	A 210046	002 May 25, 2018	May NEWA
AP		2GM/VIAL	A 210046	003 May 25, 2018	May NEWA
<u>CYCLOSPORINE</u>					
	CAPSULE; ORAL CYCLOSPORINE				
	IVAX SUB TEVA PHARMS	50MG	A 065110	001 Mar 29, 2005	May CTEC
	GENGRAF				
	@ ABBVIE	50MG	A 065003	002 May 12, 2000	May DISC

>A>	SOLUTION;OPHTHALMIC					
>A>	CEQUA					
>A>	+! SUN PHARMA GLOBAL	0.09%		N 210913	001 Aug 14, 2018	Aug NEWA
	<u>CYPROHEPTADINE HYDROCHLORIDE</u>					
	TABLET;ORAL					
	CYPROHEPTADINE HYDROCHLORIDE					
AA	APNAR PHARMA LP	4MG		A 207555	001 Jan 31, 2017	Apr CAHN
	@ FOSUN PHARMA	4MG		A 086808	001	Jan CAHN
AA	MOUNTAIN	4MG		A 040537	001 Sep 30, 2003	Jan CAHN
AA	STRIDES PHARMA	4MG		A 209172	001 Apr 11, 2018	Mar NEWA
	<u>CYTARABINE</u>					
	INJECTABLE;INJECTION					
	CYTARABINE					
AP	HONG KONG	100MG/ML		A 205696	001 Jul 17, 2018	Jul NEWA
AP	MYLAN LABS LTD	20MG/ML		A 200916	001 Dec 13, 2011	Jan CAHN
	<u>INJECTABLE, LIPOSOMAL;INJECTION</u>					
>D>	DEPOCYT					
>D>	+! PACIRA PHARMS INC	10MG/ML		N 021041	001 Apr 01, 1999	Aug DISC
>A>	+ @	10MG/ML		N 021041	001 Apr 01, 1999	Aug DISC
	<u>CYTARABINE; DAUNORUBICIN</u>					
	POWDER;INTRAVENOUS					
	VYXEOS					
	+! CELATOR PHARMS	100MG;44MG		N 209401	001 Aug 03, 2017	Jul CDFR
	<u>DACIATASVIR DIHYDROCHLORIDE</u>					
	TABLET;ORAL					
	DAKLINZA					
+!	BRISTOL-MYERS SQUIBB	EQ 60MG BASE		N 206843	002 Jul 24, 2015	Jun CHRS
+!		EQ 90MG BASE		N 206843	003 Apr 13, 2016	Jun CHRS
	<u>DALBAVANCIN HYDROCHLORIDE</u>					
	POWDER;INTRAVENOUS					
	DALVANCE					
+!	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL		N 021883	001 May 23, 2014	Jul CDFR
	<u>DALFAMPRIDINE</u>					
	TABLET, EXTENDED RELEASE;ORAL					
	DALFAMPRIDINE					
AB	ACCORD HLTHCARE	10MG		A 206863	001 Jul 11, 2018	Jun NEWA
AB	ALKEM LABS LTD	10MG		A 206765	001 Jul 30, 2018	Jul NEWA
	<u>DALFOPRISTIN; QUINUPRISTIN</u>					
>A>	INJECTABLE;INTRAVENOUS					
>A>	SYNERCID					
>A>	+! KING PHARMS	350MG/VIAL;150MG/VIAL		N 050748	001 Sep 21, 1999	Aug CDFR
>A>	@	420MG/VIAL;180MG/VIAL		N 050748	002 Aug 24, 2000	Aug CDFR
>D>	INJECTABLE;IV (INFUSION)					
>D>	SYNERCID					
>D>	+! KING PHARMS	350MG/VIAL;150MG/VIAL		N 050748	001 Sep 21, 1999	Aug CDFR
>D>	@	420MG/VIAL;180MG/VIAL		N 050748	002 Aug 24, 2000	Aug CDFR
	<u>DAPAGLIFLOZIN</u>					
	TABLET;ORAL					
	FARXIGA					
+!	ASTRAZENECA AB	5MG		N 202293	001 Jan 08, 2014	Mar CAIN
+!		10MG		N 202293	002 Jan 08, 2014	Mar CAIN
	<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE</u>					
	TABLET, EXTENDED RELEASE;ORAL					
	XIGDUO XR					
+!	ASTRAZENECA AB	2.5MG;1GM		N 205649	005 Jul 28, 2017	Mar CAIN
+!		5MG;500MG		N 205649	001 Oct 29, 2014	Mar CAIN
+!		5MG;1GM		N 205649	002 Oct 29, 2014	Mar CAIN
+!		10MG;500MG		N 205649	003 Oct 29, 2014	Mar CAIN
+!		10MG;1GM		N 205649	004 Oct 29, 2014	Mar CAIN

DAPAGLIFLOZIN; SAXagliptin Hydrochloride

TABLET;ORAL

QTERN

+! ASTRazeneca AB

10MG;EQ 5MG BASE

N209091 001 Feb 27, 2017 Mar CAIN

Daptomycin

POWDER;INTRAVENOUS

DAPTOMYCIN

AP FRESENIUS KABI USA

500MG/VIAL

A206077 001 Apr 11, 2018 Mar NEWA

AP MYLAN LABS LTD

500MG/VIAL

A205037 001 Jun 05, 2018 May NEWA

AP TEVA PHARMS USA

500MG/VIAL

A091039 001 Mar 25, 2016 Feb CAHN

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP SAGENT PHARMS

50MG/VIAL

A207100 001 Mar 16, 2018 Mar NEWA

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

+! APOPHARMA INC

80MG/ML

N208030 002 Apr 20, 2018 Apr NEWA

DEFIBROTIDE SODIUM

SOLUTION;INTRAVENOUS

DEFITELIO

+! JAZZ PHARMS INC

200MG/2.5ML (80MG/ML)

N208114 001 Mar 30, 2016 Jul CDFR

DELAfloxacin Meglumine

POWDER;INTRAVENOUS

BAXDELA

+! MELINTA

EQ 300MG BASE/VIAL

N208611 001 Jun 19, 2017 Jul CDFR

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN SHANGHAI HENGRI

100%

A208234 001 Feb 26, 2018 Feb NEWA

SUPRANE

AN +! BAXTER HLTHCARE

100%

N020118 001 Sep 18, 1992 Feb CFTG

Desipramine Hydrochloride

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB ANI PHARMS INC

10MG

A205153 001 Oct 28, 2016 May CAHN

@

25MG

A071803 002 Dec 08, 1987 Apr CMS1

AB @

25MG

A205153 002 Oct 28, 2016 May CAHN

@

50MG

A071803 003 Dec 08, 1987 Apr CMS1

AB @

50MG

A205153 003 Oct 28, 2016 May CAHN

@

75MG

A071803 004 Dec 08, 1987 Apr CMS1

AB @

75MG

A205153 004 Oct 28, 2016 May CAHN

AB @

100MG

A205153 005 Oct 28, 2016 May CAHN

@

150MG

A071803 005 May 29, 1997 Apr CMS1

AB MOUNTAIN

150MG

A205153 006 Oct 28, 2016 May CAHN

10MG

A205153 001 Oct 28, 2016 Feb CAHN

25MG

A205153 002 Oct 28, 2016 Feb CAHN

50MG

A205153 003 Oct 28, 2016 Feb CAHN

75MG

A205153 004 Oct 28, 2016 Feb CAHN

100MG

A205153 005 Oct 28, 2016 Feb CAHN

150MG

A205153 006 Oct 28, 2016 Feb CAHN

Desmopressin Acetate

TABLET;SUBLINGUAL

NOCDURNA

+! FERRING PHARMS INC

0.0277MG

N022517 001 Jun 21, 2018 Jun NEWA

+!

0.0553MG

N022517 002 Jun 21, 2018 Jun NEWA

Desoximetasone

CREAM;TOPICAL

DESOXIMETASONE

AB GROUPE PARIMA INC

0.25%

A205594 001 Jul 02, 2018 Jun NEWA

AB RISING PHARMS

0.25%

A205594 001 Jul 02, 2018 Jul CAHN

CREAM;TOPICALTOPICORT

AB	! TARO PHARM INDUS LTD	0.05%	A073210	001	Nov 30, 1990	May CAHN
AB	!	0.25%	A073193	001	Nov 30, 1990	May CAHN
+ @	TOPICORT LP	0.25%	N017856	001		May CAHN
+ @ TARO PHARM INDUS LTD	0.05%		N018309	001		May CAHN
GEL;TOPICAL						
TOPICORT						
AB	! TARO PHARM INDUS LTD	0.05%	A074904	001	Jul 14, 1998	May CAHN
+ @	0.05%		N018586	001	Mar 29, 1982	May CAHN
OINTMENT;TOPICAL						
TOPICORT						
AB	+! TARO PHARM INDUS LTD	0.05%	N018594	001	Jan 17, 1985	May CAHN
AB	!	0.25%	A074286	001	Jun 07, 1996	May CAHN
+ @	0.25%		N018763	001	Sep 30, 1983	May CAHN
SPRAY;TOPICAL						
DESOXIMETASONE						
AT	LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar NEWA
TOPICORT						
AT	+! TARO PHARMS	0.25%	N204141	001	Apr 11, 2013	May CAHN

DESVENLAFAKINE FUMARATETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAKINE

+ @ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun DISC
+ @	EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun DISC

DESVENLAFAKINE SUCCINATETABLET, EXTENDED RELEASE;ORAL
DESVENLAFAKINE SUCCINATE

AB	CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar CAHN
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar CAHN

DEXAMETHASONEELIXIR;ORALDEXAMETHASONE

AA	LANNETT CO INC	0.5MG/5ML	A091188	001	May 11, 2011	May CAHN
	HEXDROL		N012674	001		Feb CAHN
@ ASPEN GLOBAL INC	0.5MG/5ML					
SUSPENSION;INTRAOOCULAR						
DEXYCU KIT						
+! EYEPOINT PHARMS	9%		N208912	001	Feb 09, 2018	Apr CAHN
+! ICON BIOSCIENCE	9%		N208912	001	Feb 09, 2018	Feb NEWA
TABLET;ORAL						
DEXAMETHASONE						
BP	FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983	May CMS1
BP		0.75MG	A088481	003	Apr 28, 1983	May CMS1
BP		4MG	A088481	004	Apr 28, 1983	May CMS1
BP		6MG	A088481	001	Nov 28, 1983	Jan CAHN

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE;INJECTIONDEXAMETHASONE SODIUM PHOSPHATE

>A> AP	AMNEAL PHARMS CO	EQ 4MG PHOSPHATE/ML	A208689	001	Aug 22, 2018	Aug NEWA
AP	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A209192	001	Jul 06, 2018	Jun NEWA
AP	SOMERSET THERAPS LLC	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018	May NEWA
	DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE					
>A> AP	AMNEAL PHARMS CO	EQ 10MG PHOSPHATE/ML	A208690	001	Aug 22, 2018	Aug NEWA
AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442	001	Apr 19, 2018	Apr NEWA
	HEXDROL					
+ @ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML		N014694	002		Feb CAHN
+ @	EQ 10MG PHOSPHATE/ML		N014694	003		Feb CAHN
@	EQ 20MG PHOSPHATE/ML		N014694	004		Feb CAHN

DEXCHLORPHENIRAMINE MALEATESYRUP;ORALDEXCHLORPHENIRAMINE MALEATE

AA	! WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Jul CTEC
AA	POLMON					
	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Jul NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

>A>	DEXMEDETOMIDINE HYDROCHLORIDE			
>A> AP	BAXTER HLTHCARE CORP	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A208532	001 Aug 21, 2018 Aug NEWA
>A> AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A208532	002 Aug 21, 2018 Aug NEWA
AP	ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001 Feb 27, 2018 Feb NEWA
	PRECEDEX			
>D>	+! HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002 Mar 13, 2013 Aug CFTG
>A> AP	+!	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002 Mar 13, 2013 Aug CFTG
>D>	+!	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003 Mar 13, 2013 Aug CFTG
>A> AP	+!	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003 Mar 13, 2013 Aug CFTG
	SOLUTION;IV (INFUSION)			
	DEXMEDETOMIDINE HYDROCHLORIDE			
+ HQ SPCLT PHARMA	EQ 200MG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003 Jun 22, 2018 Jun NEWA	
+	EQ 400MG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004 Jun 22, 2018 Jun NEWA	

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	ARBOR PHARMS LLC	2.5MG	A090533	001 Oct 25, 2011 Apr CAHN
		5MG	A090533	002 Oct 25, 2011 Apr CAHN
		7.5MG	A090533	003 Oct 25, 2011 Apr CAHN
AA		10MG	A090533	004 Oct 25, 2011 Apr CAHN
		15MG	A090533	005 Oct 25, 2011 Apr CAHN
		20MG	A090533	006 Oct 25, 2011 Apr CAHN
		30MG	A090533	007 Oct 25, 2011 Apr CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

@ G AND W LABS INC 15MG/5ML; 6.25MG/5ML

A088762 001 Oct 31, 1984 Jan DISC

DEXTROSE

INJECTABLE; INJECTION

AP	DEXTROSE 10% IN PLASTIC CONTAINER			
	FRESENIUS KABI USA 10GM/100ML	A209448	001 Jul 16, 2018 Jul NEWA	
	DEXTROSE 20% IN PLASTIC CONTAINER			
+ @	BAXTER HLTHCARE 20GM/100ML	N017521	004 Jun DISC	
+!	ICU MEDICAL INC 20GM/100ML	N018564	001 Mar 23, 1982 Jun CTEC	
	DEXTROSE 30% IN PLASTIC CONTAINER			
+ @	BAXTER HLTHCARE 30GM/100ML	N017521	003 Jun DISC	
+!	ICU MEDICAL INC 30GM/100ML	N019345	001 Jan 26, 1985 Jun CTEC	
	DEXTROSE 40% IN PLASTIC CONTAINER			
+ @	BAXTER HLTHCARE 40GM/100ML	N017521	002 Jun DISC	
+!	ICU MEDICAL INC 40GM/100ML	N018562	001 Mar 23, 1982 Jun CTEC	
	DEXTROSE 5% IN PLASTIC CONTAINER			
+ @	ICU MEDICAL INC 50MG/ML	N019222	001 Jul 13, 1984 Mar DISC	
+!	50MG/ML	N019222	001 Jul 13, 1984 Feb CAHN	
	DEXTROSE 50% IN PLASTIC CONTAINER			
+ @	BAXTER HLTHCARE 50GM/100ML	N017521	001 Jun DISC	
	DEXTROSE 60% IN PLASTIC CONTAINER			
+ @	BAXTER HLTHCARE 60GM/100ML	N017521	005 Mar 26, 1982 Jun DISC	
	DEXTROSE 70% IN PLASTIC CONTAINER			
AP	+! B BRAUN 70GM/100ML	N019626	005 Feb 18, 2015 Feb NEWA	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AP	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
+!	ICU MEDICAL INC 5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009 Jul 05, 1983 Mar CHRS	
AP	+! 5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	005 Mar 28, 1988 Mar CPOT	
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	BAXTER HLTHCARE 5GM/100ML; 75MG/100ML; 900MG/100ML	N019308	004 Apr 05, 1985 Mar CTEC	
	5GM/100ML; 150MG/100ML; 900MG/100ML	N019308	002 Apr 05, 1985 Mar CTEC	
+ @	ICU MEDICAL INC 5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002 Mar 24, 1988 Mar DISC	

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ @ 5GM/100ML;149MG/100ML;900MG/100ML N019691 004 Mar 24, 1988 Mar DISC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
+ @ ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N018362 006 Mar 28, 1988 Mar DISC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ @ ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N019691 006 Mar 24, 1988 Mar DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP +! ICU MEDICAL INC 5GM/100ML;149MG/100ML;450MG/100ML N018362 010 Jul 05, 1983 Mar CHRS
+ @ 5GM/100ML;298MG/100ML;450MG/100ML N018362 007 Mar 28, 1988 Mar DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;300MG/100ML;900MG/100ML N019308 003 Apr 05, 1985 Mar CTEC
AP +! ICU MEDICAL INC 5GM/100ML;149MG/100ML;900MG/100ML N019691 005 Mar 24, 1988 Mar CRLD
+ @ 5GM/100ML;298MG/100ML;900MG/100ML N019691 008 Mar 24, 1988 Mar DISC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP +! ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N018362 002 Mar CHRS
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;224MG/100ML;900MG/100ML N019308 006 Apr 05, 1985 Mar CTEC
+ @ ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML N019691 007 Mar 24, 1988 Mar DISC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP +! ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML N018362 003 Mar CHRS
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP +! ICU MEDICAL INC 5GM/100ML;298MG/100ML;900MG/100ML N019691 009 Mar 24, 1988 Mar CRLD
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;150MG/100ML;450MG/100ML N018008 004 Mar CTEC
+ @ ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML N018362 008 Mar 28, 1988 Mar DISC
+ @ 5GM/100ML;149MG/100ML;450MG/100ML N018362 004 Mar 28, 1988 Mar DISC
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;150MG/100ML;900MG/100ML N019308 001 Apr 05, 1985 Mar CTEC
+ @ ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML N019691 001 Mar 24, 1988 Mar DISC
+ @ 5GM/100ML;149MG/100ML;900MG/100ML N019691 003 Mar 24, 1988 Mar DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP + ICU MEDICAL INC 5GM/100ML;450MG/100ML N017607 001 Jan CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
RENOGRAFIN-76
+ @ BRACCO 66%;10% N010040 001 May DISC

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE
SINOGRAPHIN
+ @ BRACCO 52.7%;26.8% N011324 002 May DISC

DIAZEPAM

TABLET; ORAL
DIAZEPAM
@ DAVA PHARMS INC 2MG A070228 002 Sep 26, 1985 Apr CMS1
@ 5MG A070228 003 Sep 26, 1985 Apr CMS1

DICLOFENAC POTASSIUM

CAPSULE; ORAL
ZIPSOR
>A> AB +! ASSERTIO 25MG N022202 001 Jun 16, 2009 Aug CAHN
>D> AB +! DEPOMED INC 25MG N022202 001 Jun 16, 2009 Aug CAHN
FOR SOLUTION; ORAL
CAMBIA
>A> AB +! ASSERTIO 50MG N022165 001 Jun 17, 2009 Aug CAHN
>D> AB +! DEPOMED INC 50MG N022165 001 Jun 17, 2009 Aug CAHN
TABLET; ORAL
DICLOFENAC POTASSIUM
AB CASI PHARMS INC 50MG A075229 001 Nov 20, 1998 Mar CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	CIPLA LTD	1%	A209903	001	Aug 03, 2018	Jul NEWA
AB	GAGE DEVELOPMENT	3%	A210893	001	Jul 27, 2018	Jul NEWA
	SOLUTION; INTRAVENOUS DYLOJECT					
	+ @ JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014	Jun DISC
	SOLUTION; TOPICAL					
	DICLOFENAC SODIUM					
AT	TWI PHARMS	1.5%	A202393	001	Nov 24, 2014	Jul CAHN
AT	ZYDUS PHARMS USA INC	1.5%	A206411	001	Apr 17, 2018	Apr NEWA
	PENNSAID					
>D>	+! HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	Aug CAHN
>A>	+! HZNP	2%	N204623	001	Jan 16, 2014	Aug CAHN
	TABLET, DELAYED RELEASE; ORAL					
	DICLOFENAC SODIUM					
AB	! CASI PHARMS INC	25MG	A074376	001	Sep 28, 1995	Mar CAHN
AB	!	50MG	A074376	002	Sep 28, 1995	Mar CAHN
AB	!	75MG	A074394	001	Nov 30, 1995	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

AB	+! ALLERGAN SALES LLC	10MG	N007409	003	Oct 15, 1984	Jan CAHN
	INJECTABLE; INJECTION BENTYL					
AP	+! ALLERGAN SALES LLC	10MG/ML	N008370	001	Oct 15, 1984	Jan CAHN
	BENTYL PRESERVATIVE FREE					
AP	+! ALLERGAN SALES LLC	10MG/ML	N008370	002	Oct 15, 1984	Jan CAHN
	DICYCLOMINE HYDROCHLORIDE					
AP	AKORN INC	10MG/ML	A207084	001	May 04, 2018	Apr NEWA
AP	APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Jun NEWA
	TABLET; ORAL BENTYL					
AB	+! ALLERGAN SALES LLC	20MG	N007409	001	Oct 15, 1984	Jan CAHN

DIDANOSINECAPSULE, DELAYED REL PELLETS; ORAL
DIDANOSINE

@ BARR

200MG

A077167 001 Dec 03, 2004

Mar DISC

@

250MG

A077167 002 Dec 03, 2004

Mar DISC

@

400MG

A077167 003 Dec 03, 2004

Mar DISC

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	TELIGENT PHARMA INC	0.05%	A210753	001	Jun 12, 2018	May NEWA
----	---------------------	-------	---------	-----	--------------	----------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ SOCORRO

250MG

A073562 001 Nov 27, 1992

Jun CAHN

@

500MG

A073563 001 Nov 27, 1992

Jul CAHN

DIGOXIN

TABLET; ORAL

LANOXIN

+ @ CONCORDIA PHARMS INC 0.1875MG

N020405 003 Sep 30, 1997

May DISC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP	SAGENT PHARMS	1MG/ML	A207264	001	Jul 11, 2018	Jun NEWA
----	---------------	--------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB3	PAR PHARM	360MG	A209766	001	May 30, 2018	May NEWA
>A> AB3	TWI PHARMS	120MG	A205231	001	Aug 30, 2018	Aug NEWA
>A> AB3		180MG	A205231	002	Aug 30, 2018	Aug NEWA
>A> AB3		240MG	A205231	003	Aug 30, 2018	Aug NEWA
>A> AB3		300MG	A205231	004	Aug 30, 2018	Aug NEWA
>A> AB3		360MG	A205231	005	Aug 30, 2018	Aug NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

@ FOSUN PHARMA	25MG	A080832	001	Jan CAHN		
@	25MG	A080845	002	Jan CAHN		
@	50MG	A080832	002	Jan CAHN		
@	50MG	A080845	001	Jan CAHN		
INJECTABLE; INJECTION						
DIPHENHYDRAMINE HYDROCHLORIDE						
>A> AP	MICRO LABS	50MG/ML	A205723	001	Aug 22, 2018	Aug NEWA

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

AB	APOTEX INC	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Apr CAHN
AB		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Apr CAHN
AB		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Apr CAHN

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

+ @ ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun DISC	
+ @	80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun DISC	
AP	AMNEAL PHARMS CO	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Jan NEWA
AP		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Jan NEWA
AP		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Jan NEWA
>A> AP	CIPLA LTD	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Aug NEWA
>A> AP		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Aug NEWA
>A> AP		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Aug NEWA
AP	EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jun CTEC
		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jun CDFR
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jun CTEC
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jun CDFR
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jun CTEC
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jun CDFR
AP	MYLAN LABS LTD	20MG/2ML (10MG/ML)	A210072	001	Jul 02, 2018	Jun NEWA
AP		80MG/8ML (10MG/ML)	A210848	001	Jul 06, 2018	Jun NEWA

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP	MYLAN LABS LTD	160MG/16ML (10MG/ML)	A208859	001	Apr 30, 2018	Apr NEWA
----	----------------	----------------------	---------	-----	--------------	----------

DOFETILIDE

CAPSULE;ORAL
DOFETILIDE

AB	APICORE US	0.125MG	A208625	001	Apr 10, 2018	Mar NEWA
AB		0.25MG	A208625	002	Apr 10, 2018	Mar NEWA
AB		0.5MG	A208625	003	Apr 10, 2018	Mar NEWA
AB	BIONPHARMA INC	0.125MG	A208625	001	Apr 10, 2018	May CAHN
AB		0.25MG	A208625	002	Apr 10, 2018	May CAHN
AB		0.5MG	A208625	003	Apr 10, 2018	May CAHN
AB	SIGMAPHARM LABS LLC	0.125MG	A207746	001	Mar 26, 2018	Mar NEWA
AB		0.25MG	A207746	002	Mar 26, 2018	Mar NEWA
AB		0.5MG	A207746	003	Mar 26, 2018	Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

@ APOTEX	5MG	A078841	001	Jun 02, 2011	Mar DISC
@	10MG	A078841	002	Jun 02, 2011	Mar DISC
>A> AB	HISUN PHARM HANGZHOU 23MG	A202410	001	Mar 24, 2017	Aug CAHN
@ SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr DISC
@	10MG	A076786	002	Nov 26, 2010	Apr DISC
>D> AB	ZHEJIANG HISUN PHARM 23MG	A202410	001	Mar 24, 2017	Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL					
>D>	ARICEPT ODT				
>D> AB	+ EISAI INC 5MG	N021720	001	Oct 18, 2004	Aug DISC
>A>	+ @ 5MG	N021720	001	Oct 18, 2004	Aug DISC
>D> AB	+! 10MG	N021720	002	Oct 18, 2004	Aug DISC
>A>	+ @ 10MG	N021720	002	Oct 18, 2004	Aug DISC
DONEPEZIL HYDROCHLORIDE					
>D> AB	BARR 5MG	A078388	002	Nov 26, 2010	Aug DISC
>A>	@ 5MG	A078388	002	Nov 26, 2010	Aug DISC
>D> AB	10MG	A078388	001	Nov 26, 2010	Aug DISC
>A>	@ 10MG	A078388	001	Nov 26, 2010	Aug DISC
AB	HISUN PHARM HANGZHOU 5MG	A205269	001	Jul 27, 2018	Jul NEWA
AB	10MG	A205269	002	Jul 27, 2018	Jul NEWA
>D> AB	SANDOZ 10MG	A091198	002	May 10, 2011	Aug CHRS
>A> AB	! 10MG	A091198	002	May 10, 2011	Aug CHRS
>D> AB	ZYDUS PHARMS USA INC 5MG	A090175	001	May 10, 2011	Aug DISC
>A>	@ 5MG	A090175	001	May 10, 2011	Aug DISC
>D> AB	10MG	A090175	002	May 10, 2011	Aug DISC
>A>	@ 10MG	A090175	002	May 10, 2011	Aug DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

AB	+ ALLERGAN SALES LLC 10MG;7MG	N206439	003	Jul 18, 2016	Jun CAHN
AB	+ 10MG;14MG	N206439	001	Dec 23, 2014	Jun CAHN
AB	+ 10MG;21MG	N206439	004	Jul 18, 2016	Jun CAHN
AB	+! 10MG;28MG	N206439	002	Dec 23, 2014	Jun CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

AP	HIKMA INTL PHARMS 40MG/ML	A207707	001	Apr 11, 2018	Mar NEWA
AP	80MG/ML	A207707	002	Apr 11, 2018	Mar NEWA
>D>	! LUITPOLD 160MG/ML	A070826	001	Feb 11, 1987	Aug DISC
>A>	@ 160MG/ML	A070826	001	Feb 11, 1987	Aug DISC

>A> DORAVIRINE

>A>	TABLET;ORAL				
>A>	PIFELTRO				
>A>	+! MSD MERCK CO 100MG	N210806	001	Aug 30, 2018	Aug NEWA

>A> DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

>A>	TABLET;ORAL				
>A>	DELSTRIGO				
>A>	+! MSD MERCK CO 100MG;300MG;300MG	N210807	001	Aug 30, 2018	Aug NEWA

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

@ TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008	Jun DISC
@ WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	May DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
COSOPT PF

AT	+! OAK PHARMS INC EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Jul CFTG
AT	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE				
AT	AUROBINDO PHARMA LTD EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	Jul NEWA
	@ WATSON LABS INC EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May DISC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	APPCO PHARMA LLC	EQ 1MG BASE	A209013	001	Apr 17, 2018	Apr NEWA
AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Apr NEWA
AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Apr NEWA
AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Apr NEWA
AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Jan NEWA
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan NEWA
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan NEWA
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan NEWA
@	YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIН HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan DISC
@		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan DISC
SILENOR						
+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan CTEC
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan CTEC

DOXERCALCIFEROL

CAPSULE;ORAL

HECTOROL

>D> AB	+	GENZYME CORP	0.5MCG	N020862	002	Apr 23, 2004	Aug CAHN
>D> AB	+		1MCG	N020862	003	Jul 13, 2009	Aug CAHN
>D> AB	+!		2.5MCG	N020862	001	Jun 09, 1999	Aug CAHN
>A> AB	+	SANOFI	0.5MCG	N020862	002	Apr 23, 2004	Aug CAHN
>A> AB	+		1MCG	N020862	003	Jul 13, 2009	Aug CAHN
>A> AB	+!		2.5MCG	N020862	001	Jun 09, 1999	Aug CAHN
		INJECTABLE; INJECTION					
		DOXERCALCIFEROL					
AP	+	HOSPIRA INC	4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018	Jul NEWA
	+!		10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jul NEWA
		HECTOROL					
>D> AP	+	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Aug CAHN
>D> AP	+!		4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug CAHN
>A> AP	+	SANOFI	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Aug CAHN
>A> AP	+!		4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug CAHN

DOXYCYCLINE

TABLET;ORAL

DOXYCYCLINE

AB	SUN PHARM INDNS LTD	EQ 150MG BASE	A065356	004	Jul 29, 2010	Jul NEWA
----	---------------------	---------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

+ @	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	May DISC
	DOXYCYCLINE HYCLATE					
AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210527	001	Jun 13, 2018	May NEWA
AB		EQ 100MG BASE	A210527	002	Jun 13, 2018	May NEWA
	HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005	Jul DISC
AB	SUN PHARM INDUSTRIES	EQ 50MG BASE	A062676	002	Jul 10, 1986	Jun CMS1
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A207774	001	May 31, 2018	May NEWA
AB		EQ 100MG BASE	A207774	002	May 31, 2018	May NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

CARIBE HOLDINGS

LYMEPAK

+!	CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018	Jun NEWA
	TABLET, DELAYED RELEASE;ORAL					
	DORYX					
+ @	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr DISC
	DOXYCYCLINE HYCLATE					
AB	ACTAVIS ELIZABETH	EQ 50MG BASE	A090134	003	May 22, 2018	May NEWA
AB		EQ 200MG BASE	A090134	004	May 22, 2018	May NEWA

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

@ MYLAN

EQ 80MG BASE

A090431 004 Apr 29, 2016 Apr DISC

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB	LANNETT CO INC	2.5MG	A201463	001	May 18, 2018	May NEWA
AB		5MG	A201463	002	May 18, 2018	May NEWA
AB		10MG	A201463	003	May 18, 2018	May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Mar CAHN
AB	AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb NEWA
AB	TABLET;ORAL-28	ZUMANDIMINE				

AB	AUROBINDO PHARMA LTD	3MG;0.03MG	A209407	001	Mar 26, 2018	Mar NEWA
----	----------------------	------------	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB	LUPIN LTD	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A205947	001	Jun 13, 2018	May NEWA
----	-----------	------------------------------------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARM	EQ 40MG BASE	A203088	004	May 18, 2018	May NEWA
AB	LUPIN LTD	EQ 40MG BASE	A090694	003	Dec 11, 2013	May CTEC
AB	MARKSANS PHARMA	EQ 20MG BASE	A090723	001	Dec 11, 2013	Jul CAHN
AB		EQ 30MG BASE	A090723	002	Dec 11, 2013	Jul CAHN
AB		EQ 60MG BASE	A090723	003	Dec 11, 2013	Jul CAHN

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB	@ MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	Jun DISC
AB	PHARMACEUTICS	0.5MG	A208227	001	Jun 22, 2018	Jun NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	0.5MG;0.4MG	A207769	001	May 24, 2018	May NEWA
----	----------------------	-------------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Mar CAHN
AB	MYLAN PHARMS INC	1%	A210364	001	Apr 18, 2018	Apr NEWA

EDARAVONE

SOLUTION;INTRAVENOUS

RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML)

N209176 001 May 05, 2017 Jul CDFR

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

>A> AB	AUROBINDO PHARMA LTD	600MG	A205322	001	Aug 30, 2018	Aug NEWA
AB	CIPLA LTD	600MG	A204766	001	Jun 15, 2018	Jun NEWA
AB	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Apr NEWA
AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA

>D>	+! GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Aug CFTG
>A> AB	+!	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Aug CFTG
	+!	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Mar CAHN

		TABLET;ORAL EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE AUROBINDO PHARMA LTD 600MG;200MG;300MG	A203041 001 Sep 04, 2018 Aug NEWA
<u>EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE</u>			
>A>	AB	TABLET;ORAL EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE AUROBINDO PHARMA LTD 600MG;300MG;300MG SYMFI +! MYLAN LABS LTD 600MG;300MG;300MG SYMFI LO +! MYLAN PHARMS INC 400MG;300MG;300MG	N022343 001 Aug 15, 2018 Aug NEWA N022142 001 Mar 22, 2018 Mar NEWA N208255 001 Feb 05, 2018 Feb NEWA
<u>ELAGOLIX SODIUM</u>			
		TABLET;ORAL ORILISSA + ABBVIE INC EQ 150MG BASE +! EQ 200MG BASE	N210450 001 Jul 23, 2018 Jul NEWA N210450 002 Jul 23, 2018 Jul NEWA
<u>ELETRIPTAN HYDROBROMIDE</u>			
		TABLET;ORAL ELETRIPTAN HYDROBROMIDE AMNEAL PHARMS CO EQ 20MG BASE AB EQ 40MG BASE	A206787 001 May 25, 2018 May NEWA A206787 002 May 25, 2018 May NEWA
<u>EMTRICITABINE</u>			
		CAPSULE;ORAL EMTRICITABINE AB CIPLA LTD 200MG AB +! GILEAD 200MG	A091168 001 Jul 02, 2018 Jun NEWA N021500 001 Jul 02, 2003 Jun CFTG
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>			
		TABLET;ORAL EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE >A> AB AMNEAL PHARMS CO 100MG;150MG >A> AB 133MG;200MG >A> AB 167MG;250MG >A> AB 200MG;300MG AB AUROBINDO PHARMA LTD 200MG;300MG AB MYLAN PHARMS INC 200MG;300MG TRUVADA >D> + GILEAD 100MG;150MG >A> AB + 100MG;150MG >D> + 133MG;200MG >A> AB + 133MG;200MG >D> + 167MG;250MG >A> AB + 167MG;250MG	A209721 001 Aug 22, 2018 Aug NEWA A209721 002 Aug 22, 2018 Aug NEWA A209721 003 Aug 22, 2018 Aug NEWA A209721 004 Aug 22, 2018 Aug NEWA A090513 001 Jan 26, 2018 Jan NEWA A206436 001 Apr 09, 2018 Mar NEWA N021752 002 Mar 10, 2016 Aug CFTG N021752 002 Mar 10, 2016 Aug CFTG N021752 003 Mar 10, 2016 Aug CFTG N021752 003 Mar 10, 2016 Aug CFTG N021752 004 Mar 10, 2016 Aug CFTG N021752 004 Mar 10, 2016 Aug CFTG
<u>ENCORAFENIB</u>			
		CAPSULE;ORAL BRAFTOVI + ARRAY BIOPHARMA INC 50MG +! 75MG	N210496 001 Jun 27, 2018 Jun NEWA N210496 002 Jun 27, 2018 Jun NEWA
<u>ENTECAVIR</u>			
		TABLET;ORAL ENTECAVIR AB BRECKENRIDGE PHARM 0.5MG AB 1MG AB CASI PHARMS INC 0.5MG AB 1MG	A208721 001 Mar 15, 2018 Apr NEWA A208721 002 Mar 15, 2018 Apr NEWA A206672 001 May 11, 2017 Mar CAHN A206672 002 May 11, 2017 Mar CAHN
<u>EPHEDRINE SULFATE</u>			
		SOLUTION;INTRAVENOUS CORPHEDRA AP PAR STERILE PRODUCTS 50MG/ML (50MG/ML)	N208943 001 Jan 27, 2017 Apr CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN
----	-----------------	-------	---------	-----	--------------	----------

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENAClick

>A> BX	+! IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Aug CAHN
>A> BX	+!	EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Aug CAHN
>D> BX	+! IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Aug CAHN
>D> BX	+!	EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Aug CAHN
	EPINEPHRINE (AUTOINJECTOR)					
AB	TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul NEWA
AB		0.3MG/DELIVERY	A090589	001	Aug 16, 2018	Jul NEWA
	EPIPEN					
AB	+! MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul CFTG
	EPIPEN JR.					
AB	+! MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CFTG
	TWINJECT 0.15					
>A>	@ IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Aug CAHN
>D>	@ IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Aug CAHN
	TWINJECT 0.3					
>A>	@ IMPAX	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Aug CAHN
>D>	@ IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Aug CAHN
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
	ADRENALIN					
AP	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jun CFTG
	EPINEPHRINE					
AP	LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Jun NEWA
	SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
	EPINEPHRINE					
+!	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Apr CRLD

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
@ EASTMAN KODAK 0.01MG/ML;2%
@ 0.02MG/ML;2%

A040057	002	Feb 26, 1993	Mar DISC
A040057	001	Feb 26, 1993	Mar DISC

ERPROSARTAN MESYLATE

TABLET;ORAL

ERPROSARTAN MESYLATE

AB	! MYLAN PHARMS INC	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar CHRS
	TEVETEN					
+ +	@ ABBVIE	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar DISC
+ +	@	EQ 600MG BASE	N020738	006	May 27, 1999	Mar DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Jul NEWA
AP		75MG/100ML	A203258	002	Jul 20, 2018	Jul NEWA
AP	SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb NEWA
AP		75MG/100ML	A204693	002	Mar 07, 2018	Feb NEWA

>A> ERAVACYCLINE DIHYDROCHLORIDE

>A>	POWDER;INTRAVENOUS					
>A>	XERAVA					
>A>	+! TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018	Aug NEWA

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)

ERTAPENEM SODIUM

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790	001	Apr 16, 2018	Apr NEWA
AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Jun NEWA
	INVANZ					
AP	+! MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Apr CFTG

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

+ MERCK SHARP DOHME

5MG;EQ 100MG BASE

N209805 001 Dec 19, 2017

Jan CMS1

+!

15MG;EQ 100MG BASE

N209805 002 Dec 19, 2017

Jan CMS1

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

AB AMNEAL PHARMS CO

250MG

A209720 001 Mar 09, 2018

Feb NEWA

AB

500MG

A209720 002 Mar 09, 2018

Feb NEWA

AB ARBOR PHARMS LLC

250MG

A061621 001

Feb CTEC

AB !

500MG

A061621 002

Feb CTEC

TABLET, COATED PARTICLES;ORAL
PCE

+ @ ARBOR PHARMS LLC

333MG

N050611 001 Sep 09, 1986

Jun DISC

+ @

500MG

N050611 002 Aug 22, 1990

Jun DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

@ HOSPIRA

EQ 1GM BASE/VIAL

A062638 002 Oct 31, 1986

Jul DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

LEXAPRO

AA +! ALLERGAN SALES LLC

EQ 5MG BASE/5ML

N021365 001 Nov 27, 2002

Jan CAHN

TABLET;ORAL

LEXAPRO

AB + ALLERGAN SALES LLC

EQ 5MG BASE

N021323 001 Aug 14, 2002

Jan CAHN

AB +

EQ 10MG BASE

N021323 002 Aug 14, 2002

Jan CAHN

AB +!

EQ 20MG BASE

N021323 003 Aug 14, 2002

Jan CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP MYLAN LABS LTD

10MG/ML

A206608 001 Jun 08, 2018

May NEWA

AP

20MG/ML

A206608 002 Jun 08, 2018

May NEWA

AP SAGENT PHARMS

10MG/ML

A207107 001 Jun 08, 2018

May NEWA

AP

20MG/ML

A207107 002 Jun 08, 2018

May NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>A> AB HEC PHARM

EQ 20MG BASE

A207265 002 May 18, 2018

Aug CAHN

>A> AB

EQ 40MG BASE

A207265 001 May 18, 2018

Aug CAHN

>D> AB HEC PHARM CO LTD

EQ 20MG BASE

A207265 002 May 18, 2018

Aug CAHN

AB

EQ 20MG BASE

A207265 002 May 18, 2018

May NEWA

>D> AB

EQ 40MG BASE

A207265 001 May 18, 2018

Aug CAHN

AB

EQ 40MG BASE

A207265 001 May 18, 2018

May NEWA

AB SUN PHARM INDs LTD

EQ 20MG BASE

A209735 001 Apr 30, 2018

Apr NEWA

AB

EQ 40MG BASE

A209735 002 Apr 30, 2018

Apr NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

VIMOVO

>A> + HORIZON

EQ 20MG BASE;375MG

N022511 002 Apr 30, 2010

Aug CTEC

>A> AB +

EQ 20MG BASE;375MG

N022511 002 Apr 30, 2010

Aug CAHN

>A> +!

EQ 20MG BASE;500MG

N022511 001 Apr 30, 2010

Aug CTEC

>A> AB +!

EQ 20MG BASE;500MG

N022511 001 Apr 30, 2010

Aug CAHN

>D> AB + HORIZON PHARMA USA

EQ 20MG BASE;375MG

N022511 002 Apr 30, 2010

Aug CAHN

>D> AB +!

EQ 20MG BASE;500MG

N022511 001 Apr 30, 2010

Aug CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB ALVOGEN PINE BROOK

0.01%

A209767 001 Mar 05, 2018

Feb NEWA

AB

PERRIGO UK FINCO

0.01%

A210194 001 Jan 22, 2018

Jan NEWA

AB

TEVA PHARMS USA

0.01%

A210488 001 Mar 30, 2018

Mar NEWA

FILM, EXTENDED RELEASE;TRANSDERMALESTRADIOL

AB	MYLAN TECHNOLOGIES	0.025MG/24HR	A206685	001	Aug 15, 2018	Jul NEWA
AB		0.0375MG/24HR	A206685	002	Aug 15, 2018	Jul NEWA
AB		0.05MG/24HR	A206685	003	Aug 15, 2018	Jul NEWA
AB		0.075MG/24HR	A206685	004	Aug 15, 2018	Jul NEWA
AB		0.1MG/24HR	A206685	005	Aug 15, 2018	Jul NEWA
	<u>MINIVELLE</u>					
AB	+ NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jul CFTG
AB	+ NOVEN	0.0375MG/24HR	N203752	001	Oct 29, 2012	Jul CFTG
AB	+ NOVEN	0.05MG/24HR	N203752	003	Oct 29, 2012	Jul CFTG
AB	+ NOVEN	0.075MG/24HR	N203752	002	Oct 29, 2012	Jul CFTG
AB	+! NOVEN	0.1MG/24HR	N203752	004	Oct 29, 2012	Jul CFTG
	<u>GEL;TRANSDERMAL</u>					
	<u>DIVIGEL</u>					
+ VERTICAL PHARMS LLC	0.1%		N022038	001	Jun 04, 2007	Jul CPOT
	<u>INSERT;VAGINAL</u>					
	<u>IMVEXXY</u>					
+ THERAPEUTICSMD INC	0.004MG		N208564	001	May 29, 2018	May NEWA
+! THERAPEUTICSMD INC	0.01MG		N208564	002	May 29, 2018	May NEWA

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINALFEMRING

+ MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May CAHN
+! MILLICENT	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May CAHN

ESTRADIOL HEMIHYDRATEEMULSION;TOPICALESTRASORB

+ @ EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun DISC
---------------------	-------	---------	-----	--------------	----------

ESTRADIOL VALERATEINJECTABLE;INJECTIONESTRADIOL VALERATE

@ FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan CAHN
@ FOSUN PHARMA	20MG/ML	A040628	002	Oct 04, 2007	Jan CAHN
@ FOSUN PHARMA	40MG/ML	A040628	003	Oct 04, 2007	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATETABLET;ORALESTRADIOL AND NORETHINDRONE ACETATE

AB	ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb NEWA
----	-----------------	-----------	---------	-----	--------------	----------

ESTROGENS, CONJUGATEDCREAM;TOPICAL, VAGINALPREMARIN

+! WYETH PHARMS	0.625MG/GM	N020216	001		Jun CAHN
INJECTABLE;INJECTION					
PREMARIN					
+! WYETH PHARMS	25MG/VIAL	N010402	001		Jun CAHN
TABLET;ORAL					
PREMARIN					
+ WYETH PHARMS	0.3MG	N004782	003		Jun CAHN
+ WYETH PHARMS	0.45MG	N004782	006	Jul 16, 2003	Jun CAHN
+!	0.625MG	N004782	004		Jun CAHN
+!	0.9MG	N004782	005	Jan 26, 1984	Jun CAHN
+!	1.25MG	N004782	001		Jun CAHN
@	2.5MG	N004782	002		Jun CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATETABLET;ORAL-28PREMPHASE 14/14

+! WYETH PHARMS	0.625MG, 0.625MG;N/A, 5MG	N020527	002	Nov 17, 1995	Jun CAHN
PREMPRO					
+! WYETH PHARMS	0.3MG;1.5MG	N020527	005	Jun 04, 2003	Jun CAHN
+!	0.45MG;1.5MG	N020527	004	Mar 12, 2003	Jun CAHN
+!	0.625MG;2.5MG	N020527	001	Nov 17, 1995	Jun CAHN
+!	0.625MG;5MG	N020527	003	Jan 09, 1998	Jun CAHN

ETEPLIRSEN

SOLUTION; INTRAVENOUS
EXONDYS 51

+! SAREPTA THERAPS INC 100MG/2ML (50MG/ML)
+! 500MG/10ML (50MG/ML)

N206488 001 Sep 19, 2016 Jul CDFR
N206488 002 Sep 19, 2016 Jul CDFR

ETHACRYNIC ACID

TABLET; ORAL
ETHACRYNIC ACID

AB ALVOGEN 25MG
AB AMNEAL PHARMS CO 25MG

A205709 001 Jul 24, 2018 Jul NEWA
A208805 001 May 08, 2018 Apr NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28
MALMOREDE

AB NOVAST LABS LTD 0.05MG; 1MG

A209547 001 Jul 25, 2018 Jul NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

BALCOLTRA

AVION PHARMS 0.02MG; 0.1MG

N208612 001 Jan 09, 2018 Feb CAHN

NEUVOSYN LABS LLC 0.02MG; 0.1MG

N208612 001 Jan 09, 2018 Jan NEWA

ICLEVIA

AB AUROBINDO PHARMA LTD 0.03MG; 0.15MG

A206850 001 Jun 29, 2018 Jun NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB LABS LEON FARMA 0.02MG, 0.1MG; 0.01MG, N/A

A205131 001 Dec 14, 2017 Apr CPOT

AB LUPIN LTD 0.02MG, 0.1MG; 0.01MG, N/A

A091674 001 Oct 26, 2011 Apr CPOT

AB MAYNE PHARMA 0.02MG, 0.1MG; 0.01MG, N/A

A200407 001 Oct 25, 2011 Apr CPOT

AB MYLAN LABS LTD 0.02MG, 0.1MG; 0.01MG, N/A

A200493 001 Jun 17, 2015 Apr CPOT

LO SIMPESSE

AB AUROBINDO PHARMA LTD 0.02MG, 0.1MG; 0.01MG, N/A

A206852 001 Apr 28, 2017 Apr CPOT

LOSEASONIQUE

AB TEVA BRANDED PHARM 0.02MG, 0.1MG; 0.01MG, N/A

N022262 001 Oct 24, 2008 Apr CPOT

TABLET; ORAL-21

ALESSE

+ @ WYETH PHARMS 0.02MG; 0.1MG

N020683 001 Mar 27, 1997 May CAHN

TRIPHASICL-21

+ @ WYETH PHARMS 0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075M G, 0.125MG

N019192 001 Nov 01, 1984 May CAHN

TABLET; ORAL-28

ALESSE

+ @ WYETH PHARMS 0.02MG; 0.1MG

N020683 002 Mar 27, 1997 May CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075M G, 0.125MG

A202970 001 Mar 23, 2018 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BALZIVA-28

>D> AB BARR 0.035MG; 0.4MG

A076238 001 Apr 22, 2004 Aug CHRS

>A> AB ! 0.035MG; 0.4MG

A076238 001 Apr 22, 2004 Aug CHRS

MODICON 28

+ @ JANSSEN PHARMS 0.035MG; 0.5MG

N017735 001 Feb DISC

NORETHINDRONE AND ETHINYL ESTRADIOL

>D> AB ! MYLAN LABS LTD 0.035MG; 0.4MG

A200897 001 May 11, 2015 Aug DISC

>A> AB @ 0.035MG; 0.4MG

A200897 001 May 11, 2015 Aug DISC

WERA

AB ! NOVAST LABS LTD 0.035MG; 0.5MG

A091204 001 Mar 27, 2012 Feb CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LO LOESTRIN FE

+! APIL 0.01MG, 0.01MG; 1MG, N/A

N022501 001 Oct 21, 2010 Apr CTEC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@ MYLAN LABS LTD 0.01MG, 0.01MG; 1MG, N/A

A205049 001 May 31, 2016 Apr DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB APOTEX INC 0.02MG; 1MG

A208639 001 Mar 21, 2018 Mar NEWA

TABLET; ORAL-28

HAILEY 1.5/30

AB GLENMARK PHARMS 0.03MG; 1.5MG

A209297 001 Jun 05, 2018 May NEWA

TABLET;ORAL-28

HAILEY FE 1.5/30

AB	GLENMARK PHARMS	0.03MG;1.5MG	A209031	001	Jun 05, 2018	May NEWA
AB	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
AB	MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Jun NEWA
	TABLET, CHEWABLE;ORAL					
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	CHEMO RESEARCH SL	0.02MG;1MG	A209609	001	Jul 16, 2018	Jul NEWA
	TABLET, CHEWABLE, TABLET;ORAL					
	LO MINASTRIN FE					
+ @ APIL		0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan DISC

>A> ETHINYL ESTRADIOL; SEGESTERONE ACETATE

>A> RING;VAGINAL

>A> ANNOVERA

>A>	+! POPULATION COUNCIL	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Aug NEWA
-----	-----------------------	--------------------------	---------	-----	--------------	----------

ETHIONAMIDE

TABLET;ORAL

TRECATOR

+! WYETH PHARMS

250MG

N013026

002 May CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

AB	AMNEAL PHARMS CO	400MG	A208834	001	Jun 07, 2018	May NEWA
AB		500MG	A208834	002	Jun 07, 2018	May NEWA

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB	WEST-WARD PHARMS INT	0.25MG	A206133	001	Apr 12, 2018	Apr NEWA
AB		0.5MG	A206133	002	Apr 12, 2018	Apr NEWA
AB		0.75MG	A206133	003	Apr 12, 2018	Apr NEWA
	ZORTRESS					
AB	+ NOVARTIS	0.25MG	N021560	001	Apr 20, 2010	Apr CFTG
AB	+	0.5MG	N021560	002	Apr 20, 2010	Apr CFTG
AB	+!	0.75MG	N021560	003	Apr 20, 2010	Apr CFTG

EXEMESTANE

TABLET;ORAL

EXEMESTANE

AB	CIPLA LTD	25MG	A210323	001	Apr 27, 2018	Apr NEWA
----	-----------	------	---------	-----	--------------	----------

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB	ANI PHARMS INC	10MG;10MG	A201890	001	Apr 26, 2017	May CAHN
AB		10MG;20MG	A201890	002	Apr 26, 2017	May CAHN
AB		10MG;40MG	A201890	003	Apr 26, 2017	May CAHN
AB		10MG;80MG	A201890	004	Apr 26, 2017	May CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

@ PLD ACQUISITIONS

20MG

A075302

001 Apr 16, 2001 Feb CAHN

@

40MG

A075302

002 Apr 16, 2001 Feb CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

DUEXIS

>A>	+! HORIZON	26.6MG;800MG	N022519	001	Apr 23, 2011	Aug CAHN
>D>	+! HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Aug CAHN

FELBAMATE

TABLET;ORAL

FELBAMATE

AB	ANI PHARMS INC	400MG	A202284	001	Nov 04, 2015	May CAHN
AB		600MG	A202284	002	Nov 04, 2015	May CAHN

FINAFLOXACIN

SUSPENSION/DROPS;OTIC
XTORO
+! MERLION PHARMS GMBH 0.3% N206307 001 Dec 17, 2014 Jul CAHN

FINASTERIDE

TABLET;ORAL
FINASTERIDE
@ MYLAN PHARMS INC 1MG A078161 001 Nov 05, 2013 Jul DISC

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
GILENYA
+ NOVARTIS EQ 0.25MG BASE N022527 002 May 11, 2018 May NEWA
+! EQ 0.5MG BASE N022527 001 Sep 21, 2010 May CAIN

FISH OIL TRIGLYCERIDES

EMULSION;INTRAVENOUS
OMEGAVEN
+! FRESENIUS KABI USA 5GM/50ML (0.1GM/ML) N210589 001 Jul 27, 2018 Jul NEWA
+! 10GM/100ML (0.1GM/ML) N210589 002 Jul 27, 2018 Jul NEWA

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS
SMOFLIPID 20%
>A> +! FRESENIUS KABI USA 3GM/100ML;6GM/100ML;5GM/100ML;6GM/ N207648 004 Aug 10, 2018 Aug NEWA
100ML (1000ML)

FLOXURIDINE

INJECTABLE;INJECTION
FLOXURIDINE
AP LUITPOLD 500MG/VIAL A203008 001 Nov 22, 2017 Jul CAHN

FLUCONAZOLE

INJECTABLE;INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP ! INFORLIFE 200MG/100ML (2MG/ML) A079104 001 Jul 30, 2009 Jan CAHN
AP ! 400MG/200ML (2MG/ML) A079104 002 Jul 30, 2009 Jan CAHN

FLUCYTOSINE

CAPSULE;ORAL
FLUCYTOSINE
AB RECIPHARM 250MG A207536 001 Jun 18, 2018 Jun NEWA
AB 500MG A207536 002 Jun 18, 2018 Jun NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE
AP AREVA PHARMS 50MG/2ML (25MG/ML) A090724 001 Sep 27, 2010 Jul CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18
+ @ FEINSTEIN 20-200mCi/ML N021870 001 Aug 19, 2005 May DISC
@ MIDWEST MEDCL 20-200mCi/ML A203736 001 Nov 19, 2015 May DISC
AP ! PETNET 20-200mCi/ML A079086 001 Feb 25, 2011 May CHRS

FLUNISOLIDE

SPRAY, METERED;NASAL
FLUNISOLIDE
@ APOTEX INC 0.029MG/SPRAY A077436 001 Aug 09, 2007 Jun DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL
FLUOCINOLONE ACETONIDE
@ G AND W LABS 0.025% A089525 001 Jul 26, 1988 Jan DISC
OIL/DROPS;OTIC
FLAC

AT PATRIN PHARMA INC 0.01% A210736 001 Apr 11, 2018 Mar NEWA

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE
@ G AND W LABS INC 0.01%

A207441 001 Sep 28, 2016 Jan DISC

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

>A> AB1	AMNEAL PHARMS LLC	0.05%	A210554 001 Aug 21, 2018 Aug NEWA
AB		0.1%	A211111 001 Jun 04, 2018 May NEWA
	FLUOCINONIDE EMULSIFIED BASE		
AB2	! TARO PHARM INDS LTD	0.05%	A072494 001 Jan 19, 1989 May CAHN
	GEL;TOPICAL		
	FLUOCINONIDE		
AB	TELIGENT PHARMA INC	0.05%	A209030 001 Jun 19, 2018 Jun NEWA
	SOLUTION;TOPICAL		
	FLUOCINONIDE		
AT	GLASSHOUSE PHARMS	0.05%	A209118 001 Apr 23, 2018 Apr NEWA
AT	MACLEODS PHARMS LTD	0.05%	A209283 001 Apr 23, 2018 Apr NEWA
AT	ZYDUS PHARMS USA INC	0.05%	A208948 001 Jul 17, 2018 Jul NEWA

FLUORESCIN SODIUM

INJECTABLE;INTRAVENOUS
FLUORESCITE

AP	+! ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980 001 Mar 28, 2006 Feb CAHN
----	-------------------	--------------------------------------	-----------------------------------

FLUOROURACIL

CREAM;TOPICAL
FLUOROURACIL

AB	MAYNE PHARMA	5%	A077524 001 Apr 11, 2008 Jul CAHN
----	--------------	----	-----------------------------------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE

AB1	MARKSANS PHARMA	EQ 10MG BASE	A075465 001 Jan 29, 2002 Jul CAHN
AB1		EQ 20MG BASE	A075465 002 Jan 29, 2002 Jul CAHN
AB		EQ 40MG BASE	A075465 003 Aug 02, 2001 Jul CAHN
	TABLET;ORAL		
	FLUOXETINE HYDROCHLORIDE		
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A076006 001 Jan 30, 2002 Apr CAHN
AB		EQ 20MG BASE	A076006 002 Apr 23, 2018 Apr NEWA
AB		EQ 20MG BASE	A076006 002 Apr 23, 2018 Apr CAHN
	@ FOSUN PHARMA	EQ 10MG BASE	A076024 001 Jan 29, 2002 Jan CAHN

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION
FLUPHENAZINE DECANOATE

AO	MYLAN LABS LTD	25MG/ML	A075918 001 Aug 17, 2001 Jun CMFD
----	----------------	---------	-----------------------------------

FLUTAMIDE

CAPSULE;ORAL
FLUTAMIDE
@ YAOPHARMA CO LTD 125MG

A075818 001 Sep 18, 2001 Jan CAHN

FLUTEMETAMOL F-18

INJECTABLE;INTRAVENOUS
VIZAMYL
+ @ GE HEALTHCARE

40.5mCi/10ML (4.05mCi/ML)

N203137 001 Oct 25, 2013 Jun DISC

FLUTICASONE FUROATE

POWDER;INHALATION
ARNUITY ELLIPTA
+! GLAXOSMITHKLINE

0.05MG/INH

N205625 003 May 17, 2018 May NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
FLONASE
+ @ GLAXOSMITHKLINE 0.05MG/SPRAY
XHANCE
+! OPTINOSE US INC 0.093MG

N020121 001 Oct 19, 1994 Jul CAHN

N209022 001 Sep 18, 2017 Jan CMS1

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA CHARTWELL MOLECULAR 1MG A090035 001 Jun 09, 2009 Jun CAHN

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

FONDAPARINUX SODIUM

AP JIANGSU HENGRUI MED 2.5MG/0.5ML A206812 001 May 15, 2018 Apr NEWA
AP 5MG/0.4ML A206812 002 May 15, 2018 Apr NEWA
AP 7.5MG/0.6ML A206812 003 May 15, 2018 Apr NEWA
AP 10MG/0.8ML A206812 004 May 15, 2018 Apr NEWAFOSFOMYCIN TROMETHAMINE

>A> FOR SOLUTION;ORAL

>A> MONUROL

>A> +! ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996 Aug CDFR

>D> FOR SUSPENSION;ORAL

>D> MONUROL

>D> +! ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996 Aug CDFR

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB EMCURE PHARMS LTD 10MG;12.5MG A079025 001 Sep 17, 2010 Jan CAHN
AB ! 20MG;12.5MG A079025 002 Sep 17, 2010 Jan CAHNFOSNETUPITANT CHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS

AKYNZEOT

+! HELSINN HLTHCARE EQ 235MG BASE;EQ 0.25MG BASE N210493 001 Apr 19, 2018 Apr NEWA

FOSTAMATINIB DISODIUM

TABLET;ORAL

TAVALISSE

+! RIGEL PHARMS INC EQ 100MG BASE N209299 001 Apr 17, 2018 Apr NEWA
+! EQ 150MG BASE N209299 002 Apr 17, 2018 Apr NEWAGABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB ACI HEALTHCARE LTD 100MG A206943 001 May 14, 2018 Apr NEWA
AB 300MG A206943 002 May 14, 2018 Apr NEWA
AB 400MG A206943 003 May 14, 2018 Apr NEWA

TABLET;ORAL

GABAPENTIN

>A> AB LUPIN LTD 600MG A209306 001 Aug 24, 2018 Aug NEWA
>A> AB 800MG A209306 002 Aug 24, 2018 Aug NEWA

GRALISE

>A> BX +! ASSERTIO 300MG N022544 001 Jan 28, 2011 Aug CAHN
>A> BX +! 600MG N022544 002 Jan 28, 2011 Aug CAHN
>D> BX +! DEPOMED INC 300MG N022544 001 Jan 28, 2011 Aug CAHN
>D> BX +! 600MG N022544 002 Jan 28, 2011 Aug CAHNGADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

>D> +! LIEBEL-FLARSHEIM 1654.5MG/5ML (330.9MG/ML) N020937 001 Dec 08, 1999 Aug DISC
>A> + @ 1654.5MG/5ML (330.9MG/ML) N020937 001 Dec 08, 1999 Aug DISC
>D> +! 3309MG/10ML (330.9MG/ML) N020937 002 Dec 08, 1999 Aug DISC
>A> + @ 3309MG/10ML (330.9MG/ML) N020937 002 Dec 08, 1999 Aug DISC
>D> +! 4963.5MG/15ML (330.9MG/ML) N020937 003 Dec 08, 1999 Aug DISC
>A> + @ 4963.5MG/15ML (330.9MG/ML) N020937 003 Dec 08, 1999 Aug DISC
>D> +! 6618MG/20ML (330.9MG/ML) N020937 004 Dec 08, 1999 Aug DISC
>A> + @ 6618MG/20ML (330.9MG/ML) N020937 004 Dec 08, 1999 Aug DISC
>D> +! 16.545GM/50ML (330.9MG/ML) N020975 001 Dec 08, 1999 Aug DISC
>A> + @ 16.545GM/50ML (330.9MG/ML) N020975 001 Dec 08, 1999 Aug DISC
>D> OPTIMARK IN PLASTIC CONTAINER N020976 002 Dec 08, 1999 Aug DISC
>D> +! LIEBEL-FLARSHEIM 3309MG/10ML (330.9MG/ML) N020976 002 Dec 08, 1999 Aug DISC
>A> + @ 3309MG/10ML (330.9MG/ML) N020976 002 Dec 08, 1999 Aug DISC
>D> +! 4963.5MG/15ML (330.9MG/ML) N020976 003 Dec 08, 1999 Aug DISC

**INJECTABLE; INJECTION
OPTIMARK IN PLASTIC CONTAINER**

>A>	+ @	4963.5MG/15ML (330.9MG/ML)	N 020976	003	Dec 08, 1999	Aug DISC
>D>	+ !	6618MG/20ML (330.9MG/ML)	N 020976	004	Dec 08, 1999	Aug DISC
>A>	+ @	6618MG/20ML (330.9MG/ML)	N 020976	004	Dec 08, 1999	Aug DISC
>D>	+ !	9927MG/30ML (330.9MG/ML)	N 020976	001	Dec 08, 1999	Aug DISC
>A>	+ @	9927MG/30ML (330.9MG/ML)	N 020976	001	Dec 08, 1999	Aug DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
GALANTAMINE HYDROBROMIDE

@ MYLAN	EQ 8MG BASE	A 090900	001	Jan 24, 2011	Jun DISC
@	EQ 16MG BASE	A 090900	002	Jan 24, 2011	Jun DISC
@	EQ 24MG BASE	A 090900	003	Jan 24, 2011	Jun DISC

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

>D> AT	MICRO LABS	0.5%	A 206446	001	Jun 08, 2018	Aug CAHN
AT		0.5%	A 206446	001	Jun 08, 2018	May NEWA
>A> AT	MYLAN PHARMS INC	0.5%	A 206446	001	Jun 08, 2018	Aug CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	SAGENT PHARMS	200MG/5.26ML (38MG/ML)	A 209077	001	Jul 20, 2018	Jul NEWA
AP		1GM/26.3ML (38MG/ML)	A 209077	002	Jul 20, 2018	Jul NEWA
AP		2GM/52.6ML (38MG/ML)	A 209077	003	Jul 20, 2018	Jul NEWA
	SOLUTION; INTRAVENOUS INFUGEM					
>D>	+! SUN PHARM INDs INC	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N 208313	001	Jul 16, 2018	Aug CAHN
	+!	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N 208313	001	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N 208313	002	Jul 16, 2018	Aug CAHN
	+!	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N 208313	002	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N 208313	003	Jul 16, 2018	Aug CAHN
	+!	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N 208313	003	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N 208313	004	Jul 16, 2018	Aug CAHN
	+!	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N 208313	004	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N 208313	005	Jul 16, 2018	Aug CAHN
	+!	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N 208313	005	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N 208313	006	Jul 16, 2018	Aug CAHN
	+!	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N 208313	006	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N 208313	007	Jul 16, 2018	Aug CAHN
	+!	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N 208313	007	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N 208313	008	Jul 16, 2018	Aug CAHN
	+!	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N 208313	008	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N 208313	009	Jul 16, 2018	Aug CAHN
	+!	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N 208313	009	Jul 16, 2018	Jul NEWA
>D>	+!	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N 208313	010	Jul 16, 2018	Aug CAHN
	+!	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N 208313	010	Jul 16, 2018	Jul NEWA
>A>	+! SUN PHARM INDs LTD	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N 208313	001	Jul 16, 2018	Aug CAHN
>A>	+!	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N 208313	002	Jul 16, 2018	Aug CAHN
>A>	+!	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N 208313	003	Jul 16, 2018	Aug CAHN
>A>	+!	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N 208313	004	Jul 16, 2018	Aug CAHN

**SOLUTION; INTRAVENOUS
INFUGEM**

>A>	+!	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N 208313 005 Jul 16, 2018	Aug CAHN
>A>	+!	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N 208313 006 Jul 16, 2018	Aug CAHN
>A>	+!	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N 208313 007 Jul 16, 2018	Aug CAHN
>A>	+!	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N 208313 008 Jul 16, 2018	Aug CAHN
>A>	+!	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N 208313 009 Jul 16, 2018	Aug CAHN
>A>	+!	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N 208313 010 Jul 16, 2018	Aug CAHN

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

>A> AB	@ YAOPHARMA CO LTD ZYDUS PHARMS USA INC	600MG 600MG	A 074615 001 Sep 29, 1995 A 204189 001 Aug 28, 2018	Jan CAHN Aug NEWA
--------	--	----------------	--	----------------------

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT	G AND W LABS INC	EQ 0.1% BASE	A 064054 001 Apr 29, 1994	Jan CMFD
----	------------------	--------------	---------------------------	----------

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

GLATOPA

AP	SANDOZ INC	40MG/ML	A 206921 001 Feb 12, 2018	Jan NEWA
----	------------	---------	---------------------------	----------

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

@ TEVA PHARMS USA	1MG; 4MG	A 078709 001 Apr 01, 2016	Jul DISC
@	2MG; 4MG	A 078709 002 Apr 01, 2016	Jul DISC
@	2MG; 8MG	A 078709 004 Apr 01, 2016	Jul DISC
@	4MG; 4MG	A 078709 003 Apr 01, 2016	Jul DISC
@	4MG; 8MG	A 078709 005 Apr 01, 2016	Jul DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@ OXFORD PHARMS	5MG	A 074378 001 Nov 28, 1994	Jul CAHN
@	10MG	A 074378 002 Nov 28, 1994	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	ZYDUS PHARMS USA INC	2.5MG	A 203499 001 Jul 16, 2018	Jul NEWA
AB		5MG	A 203499 002 Jul 16, 2018	Jul NEWA
AB		10MG	A 203499 003 Jul 16, 2018	Jul NEWA

GLUCAGON

INJECTABLE; INJECTION

GLUCAGON

+! LILLY	1MG/VIAL	N 020928 001 Sep 11, 1998	Apr CAIN
----------	----------	---------------------------	----------

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGEN

+! NOVO NORDISK	EQ 1MG BASE/VIAL	N 020918 001 Jun 22, 1998	Apr CAIN
-----------------	------------------	---------------------------	----------

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

@ YAOPHARMA CO LTD	1.5MG	A 075174 001 Jun 22, 1998	Jan CAHN
@	3MG	A 075174 002 Jun 22, 1998	Jan CAHN

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	+! BAXTER HLTHCARE	1.5GM/100ML	N 017865 001	Mar CRLD
----	--------------------	-------------	--------------	----------

GLYCOPYRROLATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

EXELA PHARMA SCS LLC 0.2MG/ML (0.2MG/ML)
 0.4MG/2ML (0.2MG/ML)N210997 001 Jul 11, 2018 Jul NEWA
N210997 002 Jul 11, 2018 Jul NEWA

TABLET; ORAL

GLYCOPYRROLATE

AA	OXFORD PHARMS	1MG	A090020	001	Oct 19, 2011	Jul CAHN
AA		2MG	A090020	002	Oct 19, 2011	Jul CAHN
AA	! PAR PHARM	1MG	A040653	001	Aug 31, 2006	May CHRS
AA	!	2MG	A040653	002	Aug 31, 2006	May CHRS
	@ RENATA	1MG	A040568	001	Dec 22, 2004	Apr CAHN
	@	2MG	A040568	002	Dec 22, 2004	Apr CAHN
	ROBINUL					
+ @	CASPER PHARMA LLC	1MG	N012827	001		May DISC
	ROBINUL FORTE					
+ @	CASPER PHARMA LLC	2MG	N012827	002		May DISC

GLYCOPYRONIUM TOSYLATE

CLOTH; TOPICAL

QBREXZA

+! DERMIRA INC EQ 2.4% BASE

N210361 001 Jun 28, 2018 Jun NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

@ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A077963 001 Jan 03, 2008 Feb DISC

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB CHARTWELL MOLECULAR EQ 1MG BASE A078037 001 Feb 27, 2008 Mar CAHN

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZE

AB MOUNTAIN 125MG A204371 001 Jan 09, 2014 Jan CAHN
AB 250MG A204371 002 Jan 09, 2014 Jan CAHNGUAIFENESIN; HYDROCODONE BITARTRATE

>D> SOLUTION; ORAL

>D> FLOWTUSS

>D> BKK PHARMS

200MG/5ML; 2.5MG/5ML

N022424 001 May 14, 2015 Aug DISC

>A>

@

200MG/5ML; 2.5MG/5ML

N022424 001 May 14, 2015 Aug DISC

>A>

200MG/5ML; 2.5MG/5ML

N022424 001 May 14, 2015 May CAHN

TABLET; ORAL

HYDROCODONE BITARTRATE AND GUAIFENESIN

+! ECI PHARMS LLC 400MG; 5MG

N208085 001 Apr 25, 2018 Apr NEWA

>D> GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

>D> SOLUTION; ORAL

HYCOFENIX

>D> +! BKK PHARMS

200MG/5ML; 2.5MG/5ML; 30MG/5ML

N022279 001 May 14, 2015 Aug DISC

>A>

+ @

200MG/5ML; 2.5MG/5ML; 30MG/5ML

N022279 001 May 14, 2015 Aug DISC

+ !

200MG/5ML; 2.5MG/5ML; 30MG/5ML

N022279 001 May 14, 2015 May CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

@ YAOPHARMA CO LTD EQ 4MG BASE

A074517 001 Sep 30, 1998 Jan CAHN

@

EQ 8MG BASE

A074517 002 Sep 30, 1998 Jan CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	! MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jun CHRS
AB	!	EQ 2MG BASE	A074796	002	Jan 27, 1997	Jun CHRS
	TENEX					
+ @	PROMIUS PHARMA	EQ 1MG BASE	N019032	001	Oct 27, 1986	Jun DISC
+ @		EQ 2MG BASE	N019032	002	Nov 07, 1988	Jun DISC

**TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE**

AB	APOTEX INC	EQ 1MG BASE	A205430	001	Jul 25, 2018	Jul NEWA
AB		EQ 2MG BASE	A205430	002	Jul 25, 2018	Jul NEWA
AB		EQ 3MG BASE	A205430	003	Jul 25, 2018	Jul NEWA
AB		EQ 4MG BASE	A205430	004	Jul 25, 2018	Jul NEWA

HALCINONIDE

CREAM;TOPICAL

HALOG

+! SUN PHARM INDs INC 0.1%

N017556

001 Feb CAHN

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

HALOBETASOL PROPIONATE

+! THERAPS INC 0.05%

N210566 001 May 24, 2018 May NEWA

CREAM;TOPICAL

ULTRAVATE

AB + SUN PHARM INDs INC 0.05% OINTMENT;TOPICAL

N019967 001 Dec 27, 1990 Feb CAHN

HALOBETASOL PROPIONATE

AB TELIGENT PHARMA INC 0.05% ULTRAVATE

A209978 001 Mar 20, 2018 Mar NEWA

AB + SUN PHARM INDs INC 0.05%

N019968 001 Dec 17, 1990 Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO SOMERSET THERAPS LLC EQ 50MG BASE/ML

A209101 001 Jul 03, 2018 Jun NEWA

AO EQ 100MG BASE/ML

A209101 002 Jul 03, 2018 Jun NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@ FOSUN PHARMA EQ 5MG BASE/ML

A076464 001 Sep 29, 2004 Jan CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP	CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011	Mar CAHN
>D>	@ WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Aug CRLD
>A>	+ @	1,000 UNITS/ML	N017007	001		Aug CRLD
>D>	@	2,500 UNITS/ML	N017007	007		Aug CRLD
>A>	+ @	2,500 UNITS/ML	N017007	007		Aug CRLD
>D>	@	5,000 UNITS/ML	N017007	002		Aug CRLD
>A>	+ @	5,000 UNITS/ML	N017007	002		Aug CRLD
>D>	@	5,000 UNITS/0.5ML	N017007	010		Aug CRLD
>A>	+ @	5,000 UNITS/0.5ML	N017007	010		Aug CRLD
>D>	@	7,500 UNITS/ML	N017007	003		Aug CRLD
>A>	+ @	7,500 UNITS/ML	N017007	003		Aug CRLD
>D>	@	10,000 UNITS/ML	N017007	004		Aug CRLD
>A>	+ @	10,000 UNITS/ML	N017007	004		Aug CRLD
>D>	@	15,000 UNITS/ML	N017007	005		Aug CRLD
>A>	+ @	15,000 UNITS/ML	N017007	005		Aug CRLD
>D>	@	20,000 UNITS/ML	N017007	006		Aug CRLD
>A>	+ @	20,000 UNITS/ML	N017007	006		Aug CRLD

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYCODAN

>D> + @ ENDO PHARMS 1.5MG/5ML;5MG/5ML

N005213 002 Jul 26, 1988 Aug CAHN

>A> + @ GENUS LIFESCIENCES 1.5MG/5ML;5MG/5ML

N005213 002 Jul 26, 1988 Aug CAHN

TABLET;ORAL

HYCODAN

>D> + @ ENDO PHARMS 1.5MG;5MG

N005213 001 Jul 26, 1988 Aug CAHN

>A> + @ GENUS LIFESCIENCES 1.5MG;5MG

N005213 001 Jul 26, 1988 Aug CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA	APPCO PHARMA LLC	10MG	A209251	001	Jul 09, 2018	Jun NEWA
AA		25MG	A209251	002	Jul 09, 2018	Jun NEWA
AA		50MG	A209251	003	Jul 09, 2018	Jun NEWA
AA		100MG	A209251	004	Jul 09, 2018	Jun NEWA
AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	Feb CAHN
AA		25MG	A205236	002	May 26, 2017	Feb CAHN
AA		50MG	A205236	003	May 26, 2017	Feb CAHN
AA		100MG	A205236	004	May 26, 2017	Feb CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

	@ APOTEX	12.5MG	A078389	001	May 16, 2008	Mar DISC
	TABLET;ORAL					
	HYDROCHLOROTHIAZIDE					
	@ APOTEX	25MG	A040774	001	Oct 03, 2007	Mar DISC
	@	50MG	A040774	002	Oct 03, 2007	Mar DISC
	@ DAVA PHARMS INC	100MG	A087060	001		Jul CAHN
AB	OXFORD PHARMS	25MG	A087059	001		Jul CAHN
AB		50MG	A087068	001		Jul CAHN
AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jan CAHN
AB		50MG	A203018	002	Jul 23, 2014	Jan CAHN
	@ YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982	Jan CAHN
	@	50MG	A084912	001		Jan CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>D> AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Aug DISC
>A>	@	12.5MG;150MG	A203036	001	Jan 15, 2016	Aug DISC
>D> AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Aug DISC
>A>	@	12.5MG;300MG	A203036	002	Jan 15, 2016	Aug DISC
>D> AB		25MG;300MG	A203036	003	Jan 15, 2016	Aug DISC
>A>	@	25MG;300MG	A203036	003	Jan 15, 2016	Aug DISC
>D> AB	HISUN PHARM	12.5MG;150MG	A207896	001	Oct 14, 2016	Aug CAHN
>D> AB		12.5MG;300MG	A207896	002	Oct 14, 2016	Aug CAHN
>A> AB	HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016	Aug CAHN
>A> AB		12.5MG;300MG	A207896	002	Oct 14, 2016	Aug CAHN
	@ MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012	Jun DISC
	@	12.5MG;300MG	A077969	002	Sep 27, 2012	Jun DISC
	@	25MG;300MG	A077969	003	Jul 20, 2016	Jun DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

@ APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004	Apr DISC
@	12.5MG;20MG	A076674	002	Oct 05, 2004	Apr DISC
@	25MG;20MG	A076674	003	Oct 05, 2004	Apr DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

+ @ MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995	Apr DISC
+ @	25MG;100MG	N020387	002	Nov 10, 1998	Apr DISC
	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE				
@ APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010	Mar DISC
@	12.5MG;100MG	A090150	002	Aug 11, 2010	Mar DISC
@	25MG;100MG	A090150	003	Oct 06, 2010	Mar DISC
AB ! AUROBINDO PHARMA	25MG;100MG	A091629	003	Jan 06, 2010	Apr CHRS

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986	Jan CAHN
@	25MG;250MG	A070183	001	Jan 15, 1986	Jan CAHN
@	30MG;500MG	A070543	001	Jan 15, 1986	Jan CAHN
@	50MG;500MG	A070544	001	Jan 15, 1986	Jan CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 @ YAOPHARMA CO LTD 25MG;40MG
 @ 25MG;80MG

A071060 001 Aug 26, 1987 Jan CAHN
 A071061 001 Aug 26, 1987 Jan CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
 @ YAOPHARMA CO LTD 25MG;25MG

A086881 001 Jan CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	! CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Mar CAHN
TABLET; ORAL						
AB	ZYDUS PHARMS USA INC	25MG;37.5MG	A208360	001	Jun 29, 2018	Jun NEWA
AB		50MG;75MG	A208360	002	Jun 29, 2018	Jun NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

@	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar DISC
@		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar DISC
@		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar DISC
@		25MG;160MG	A203026	004	Mar 21, 2013	Mar DISC
@		25MG;320MG	A203026	005	Mar 21, 2013	Mar DISC
>D> AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	Aug DISC
>A>	@	12.5MG;80MG	A091519	001	Mar 21, 2013	Aug DISC
>D> AB		12.5MG;160MG	A091519	002	Mar 21, 2013	Aug DISC
>A>	@	12.5MG;160MG	A091519	002	Mar 21, 2013	Aug DISC
>D> AB		12.5MG;320MG	A091519	003	Mar 21, 2013	Aug DISC
>A>	@	12.5MG;320MG	A091519	003	Mar 21, 2013	Aug DISC
>D> AB		25MG;160MG	A091519	004	Mar 21, 2013	Aug DISC
>A>	@	25MG;160MG	A091519	004	Mar 21, 2013	Aug DISC
>D> AB		25MG;320MG	A091519	005	Mar 21, 2013	Aug DISC
>A>	@	25MG;320MG	A091519	005	Mar 21, 2013	Aug DISC

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004	May CAHN
	@ TARO PHARM INDs LTD	1%	A086155	001		May CAHN
AT		2.5%	A088799	001	Nov 09, 1984	May CAHN
AT		2.5%	A088799	001	Nov 09, 1984	May CAHN
AT	TELIGENT PHARMA INC	2.5%	A203810	001	Jul 23, 2018	Jul NEWA

LOTION; TOPICAL

HYDROCORTISONE

AT	LANNETT CO INC	2.5%	A040417	001	Jul 30, 2003	May CAHN
AT	TELIGENT PHARMA INC	2.5%	A203804	001	Jul 27, 2018	Jul NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

>A>	@ GENUS LIFESCIENCES	1%;1%	A089440	001	May 17, 1988	Aug CAHN
>D>	@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Aug CAHN

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

HYDROCORTISONE BUTYRATE

>A> AB	LUPIN LTD	0.1%	A210209	001	Aug 17, 2018	Aug NEWA
--------	-----------	------	---------	-----	--------------	----------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

+ @ SUN PHARM INDs INC 0.2%

N017950 001 Mar CAHN

OINTMENT; TOPICAL

WESTCORT

+ @ SUN PHARM INDs INC 0.2%

N018726 001 Aug 08, 1983 Feb CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

>D>							
>D> AT	+!	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N 050479	001	Aug DISC	
>A>	+	@	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N 050479	001	Aug DISC	
			NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
>D> AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 065216	001	Oct 31, 2005	Aug DISC
>A>		@	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 065216	001	Oct 31, 2005	Aug DISC
>D> AT		BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 064053	001	Dec 29, 1995	Aug CHRS
>A> AT	!		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 064053	001	Dec 29, 1995	Aug CHRS

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

>D> AP	+!	FRESENIUS KABI USA	4MG/ML	N 019034	005	Apr 30, 2009	Aug DISC
>A>	+	@	4MG/ML	N 019034	005	Apr 30, 2009	Aug DISC
		DILAUDID-HP					
>D> AP	+!	FRESENIUS KABI USA	10MG/ML	N 019034	001	Jan 11, 1984	Aug DISC
>A>	+	@	10MG/ML	N 019034	001	Jan 11, 1984	Aug DISC
		HYDROMORPHONE HYDROCHLORIDE					
AP		EUROHLTH INTL SARL	2MG/ML	A 202159	001	Apr 27, 2018	Apr NEWA
		TABLET; ORAL					
		HYDROMORPHONE HYDROCHLORIDE					
AB		ASCENT PHARMS INC	2MG	A 210506	001	Jan 17, 2018	Jan NEWA
AB			4MG	A 210506	002	Jan 17, 2018	Jan NEWA
AB			8MG	A 210506	003	Jan 17, 2018	Jan NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ALKALOIDA ZRT	200MG	A 201691	001	May 08, 2018	Apr NEWA
AB		AMNEAL PHARMS CO	200MG	A 210577	001	May 15, 2018	Apr NEWA
AB		APPCO PHARMA LLC	200MG	A 210441	001	May 01, 2018	Apr NEWA
AB		LUPIN LTD	200MG	A 210543	001	Jul 06, 2018	Jun NEWA

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP		LUITPOLD	250MG/ML (250MG/ML)	A 210723	001	Jun 21, 2018	Jun NEWA
		MAKENA PRESERVATIVE FREE					
AP	+!	AMAG PHARMA USA	250MG/ML (250MG/ML)	N 021945	002	Feb 19, 2016	Jun CFTG
		SOLUTION; SUBCUTANEOUS					
		MAKENA (AUTOINJECTOR)					
AP	+!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N 021945	004	Feb 14, 2018	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

>D> AP	!	FRESENIUS KABI USA	25MG/ML	A 087329	001		Aug DISC
>A>	@		25MG/ML	A 087329	001		Aug DISC
>D> AP	!		50MG/ML	A 087329	002		Aug DISC
>A>	@		50MG/ML	A 087329	002		Aug DISC
>D> AP		LUITPOLD	25MG/ML	A 087408	001		Aug CTEC
>A>	!		25MG/ML	A 087408	001		Aug CHRS
>A>			25MG/ML	A 087408	001		Aug CTEC
>D> AP			50MG/ML	A 087408	002		Aug CTEC
>A>	!		50MG/ML	A 087408	002		Aug CHRS
>A>			50MG/ML	A 087408	002		Aug CTEC
		TABLET; ORAL					
		ATARAX					
	+ @	PFIZER	10MG	N 010392	001		Feb CRLD
	+ @		25MG	N 010392	004		Feb CRLD
	+ @		50MG	N 010392	006		Feb CRLD
	+ @		100MG	N 010392	005		Feb CRLD

IBRUTINIB

TABLET;ORAL
IMBRUVICA

+ PHARMACYCLICS INC	140MG	N 210563	001	Feb 16, 2018	Feb NEWA
+	280MG	N 210563	002	Feb 16, 2018	Feb NEWA
+	420MG	N 210563	003	Feb 16, 2018	Feb NEWA
+!	560MG	N 210563	004	Feb 16, 2018	Feb NEWA

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN

AUROBINDO PHARMA LTD	100MG/5ML	A 209178	001	Feb 16, 2018	Feb NEWA
----------------------	-----------	----------	-----	--------------	----------

TABLET;ORAL
IBUPROFEN

>A> AB HEC PHARM	400MG	A 204062	001	Sep 10, 2018	Aug NEWA
>A> AB	600MG	A 204062	002	Sep 10, 2018	Aug NEWA
>A> AB	800MG	A 204062	003	Sep 10, 2018	Aug NEWA

IBUTILIDE FUMARATE

INJECTABLE;INJECTION
IBUTILIDE FUMARATE

@ MYLAN INSTITUTIONAL	0.1MG/ML	A 090924	001	Jan 11, 2010	Jan DISC
-----------------------	----------	----------	-----	--------------	----------

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

AB DR REDDYS LABS LTD	EQ 100MG BASE	A 206547	001	Aug 13, 2018	Jul NEWA
AB	EQ 400MG BASE	A 206547	002	Aug 13, 2018	Jul NEWA
AB WEST-WARD PHARMS INT	EQ 100MG BASE	A 207586	001	Jul 13, 2018	Jul NEWA
AB	EQ 400MG BASE	A 207586	002	Jul 13, 2018	Jul NEWA

IMIQUIMOD

CREAM;TOPICAL
IMIQUIMOD

@ G AND W LABS INC	5%	A 200481	001	Apr 18, 2011	Jan DISC
@ STRIDES PHARMA	5%	A 202002	001	Jun 24, 2014	Jun DISC

INDAPAMIDE

TABLET;ORAL
INDAPAMIDE

@ YAOPHARMA CO LTD	1.25MG	A 074594	001	May 23, 1996	Jan CAHN
@	2.5MG	A 074594	002	May 23, 1996	Jan CAHN

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

AP +! GE HEALTHCARE	1mCi/ML	N 019044	001	Dec 24, 1985	Jul CFTG
AP NORDION INC	1mCi/ML	A 202586	001	Jul 25, 2018	Jul NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXTOUCH

+ @ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N 020986	005	Oct 31, 2013	Jun DISC
----------------------	------------------------------	----------	-----	--------------	----------

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS
TOUJEO MAX SOLOSTAR

+! SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N 206538	002	Mar 26, 2018	Mar NEWA
TOUJEO SOLOSTAR					
+! SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N 206538	001	Feb 25, 2015	Mar CPOT

TOBENGUANE I-131

SOLUTION;INTRAVENOUS
AZEDRA

+! PROGENICS PHARMS INC	15mCi/ML	N 209607	001	Jul 30, 2018	Jul NEWA
-------------------------	----------	----------	-----	--------------	----------

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL OMNIPQUE 240	51.8%	N020608 001 Oct 24, 1995	May DISC
@ GE HEALTHCARE			
SOLUTION; ORAL OMNIPQUE 12	2.6%	N018956 009 Apr 17, 2018	Jun NEWA
+! GE HEALTHCARE			
OMNIPQUE 9			
+! GE HEALTHCARE	1.9%	N018956 008 Apr 17, 2018	Jun NEWA

IOTHALAMATE MEGLUMINE

>D> INJECTABLE; INJECTION CONRAY 30			
>D> +! LIEBEL-FLARSHEIM	30%	N016983 001	Aug DISC
>A> + @	30%	N016983 001	Aug DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL IPRATROPIUM BROMIDE			
AB ! WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664 001 Nov 05, 2003	Jan CHRS
AB !	0.042MG/SPRAY	A076598 001 Nov 05, 2003	Jan CHRS

IRBESARTAN

TABLET; ORAL IRBESARTAN			
AB AMNEAL PHARMS	75MG	A204740 001 Apr 17, 2018	Apr NEWA
AB	150MG	A204740 002 Apr 17, 2018	Apr NEWA
AB	300MG	A204740 003 Apr 17, 2018	Apr NEWA
@ APOTEX INC	75MG	A200832 001 Oct 15, 2012	Mar DISC
@	150MG	A200832 002 Oct 15, 2012	Mar DISC
@	300MG	A200832 003 Oct 15, 2012	Mar DISC
AB CHARTWELL MOLECULAR	75MG	A077205 001 Nov 14, 2012	Apr CAHN
AB	150MG	A077205 002 Nov 14, 2012	Apr CAHN
AB	300MG	A077205 003 Nov 14, 2012	Apr CAHN
>D> AB DR REDDYS LABS LTD	75MG	A203161 001 Sep 27, 2012	Aug CAHN
>D> AB	150MG	A203161 002 Sep 27, 2012	Aug CAHN
>D> AB	300MG	A203161 003 Sep 27, 2012	Aug CAHN
>D> AB HISUN PHARM	75MG	A206194 001 Jun 14, 2016	Aug CAHN
>D> AB	150MG	A206194 002 Jun 14, 2016	Aug CAHN
>D> AB	300MG	A206194 003 Jun 14, 2016	Aug CAHN
>A> AB HISUN PHARM HANGZHOU	75MG	A206194 001 Jun 14, 2016	Aug CAHN
>A> AB	150MG	A206194 002 Jun 14, 2016	Aug CAHN
>A> AB	300MG	A206194 003 Jun 14, 2016	Aug CAHN
>A> AB NEOPHARMA	75MG	A203161 001 Sep 27, 2012	Aug CAHN
>A> AB	150MG	A203161 002 Sep 27, 2012	Aug CAHN
>A> AB	300MG	A203161 003 Sep 27, 2012	Aug CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION IRINOTECAN HYDROCHLORIDE			
>D> AP DR REDDYS LABS LTD	40MG/2ML (20MG/ML)	A078953 001 Apr 15, 2010	Aug CAHN
>D> AP	100MG/5ML (20MG/ML)	A078953 002 Apr 15, 2010	Aug CAHN
>A> AP NEOPHARMA	40MG/2ML (20MG/ML)	A078953 001 Apr 15, 2010	Aug CAHN
>A> AP	100MG/5ML (20MG/ML)	A078953 002 Apr 15, 2010	Aug CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION ISOPROTERENOL HYDROCHLORIDE			
AP AMPHASTAR PHARMS INC	0.2MG/ML	A210106 001 Jun 18, 2018	Jun NEWA
ISOPROTERENOL HYDROCHLORIDE			
AP CIPILA LTD	0.2MG/ML	A210322 001 Jun 12, 2018	May NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL ISOSORBIDE MONONITRATE			
@ ACCORD HLTHCARE	30MG	A209684 001 Oct 24, 2017	Apr DISC
@	60MG	A209684 002 Oct 24, 2017	Apr DISC
@	120MG	A209684 003 Oct 24, 2017	Apr DISC
>A> AB DEXCEL LTD	120MG	A210822 001 Aug 29, 2018	Aug NEWA

ITRACONAZOLE

CAPSULE;ORAL	ITRACONAZOLE					
>A> AB	TORRENT PHARMS LTD	100MG	A209460	001	Aug 24, 2018	Aug NEWA
SOLUTION;ORAL	ITRACONAZOLE					
>D>	@ AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Aug CMFD
>A> AA		10MG/ML	A205573	001	Oct 30, 2015	Aug CMFD
SPORANOX						
>D>	+! JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Aug CTEC
>A> AA	+!	10MG/ML	N020657	001	Feb 21, 1997	Aug CTEC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET;ORAL	SYMDEKO (COPACKAGED)					
+! VERTEX PHARMS INC	150MG,N/A;150MG, 100MG		N210491	001	Feb 12, 2018	Feb NEWA

IVACAFTOR; LUMACAFTOR

>A>	GRANULE;ORAL					
>A>	ORKAMBI					
>A>	+ VERTEX PHARMS INC	125MG/PACKET;100MG/PACKET	N211358	001	Aug 07, 2018	Aug NEWA
>A>	+!	188MG/PACKET;150MG/PACKET	N211358	002	Aug 07, 2018	Aug NEWA

IVOSIDENIB

TABLET;ORAL	TIBSOVO					
+! AGIOS PHARMS INC	250MG		N211192	001	Jul 20, 2018	Jul NEWA

KANAMYCIN SULFATE

INJECTABLE;INJECTION	KANAMYCIN SULFATE					
@ FRESENIUS KABI USA	EQ 500MG BASE/2ML		A065111	001	Dec 17, 2002	Jun DISC
@	EQ 1GM BASE/3ML		A065111	002	Dec 17, 2002	Jun DISC

KETOCONAZOLE

TABLET;ORAL	KETOCONAZOLE					
AB	STRIDES PHARMA	200MG	A210457	001	Jun 18, 2018	Jun NEWA

KETOPROFEN

CAPSULE;ORAL	KETOPROFEN					
@ MYLAN	50MG		A074035	002	Dec 31, 1996	Jun DISC
@	75MG		A074035	003	Dec 31, 1996	Jun DISC
CAPSULE, EXTENDED RELEASE;ORAL	KETOPROFEN					
@ ACTAVIS LABS FL INC	100MG		A075270	002	Mar 24, 1999	Jun DISC
@	150MG		A075270	003	Mar 24, 1999	Jun DISC
@	200MG		A075270	001	Mar 24, 1999	Jun DISC
@ MYLAN	100MG		A075679	003	Feb 20, 2002	Jun DISC
@	150MG		A075679	002	Feb 20, 2002	Jun DISC
!	200MG		A075679	001	Feb 20, 2002	Jun CTEC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION	KETOROLAC TROMETHAMINE					
AP	CYCLE PHARMS LTD	15MG/ML	A209900	002	Jul 25, 2018	Jul NEWA

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

AT	SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	Jan CAHN
TABLET;ORAL	KETOROLAC TROMETHAMINE					

>A> AB	CYCLE PHARMS LTD	10MG	A210616	001	Aug 16, 2018	Aug NEWA
--------	------------------	------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION	LABETALOL HYDROCHLORIDE					
>D> AP	AKORN INC	5MG/ML	A075524	001	Nov 29, 1999	Aug DISC
>A>	@	5MG/ML	A075524	001	Nov 29, 1999	Aug DISC

TABLET;ORALLABETALOL HYDROCHLORIDE

>D> AB	APPCO PHARMA LLC	100MG	A209603	001	Jun 20, 2018	Aug CAHN
	AB	100MG	A209603	001	Jun 20, 2018	Jun NEWA
>D> AB		200MG	A209603	002	Jun 20, 2018	Aug CAHN
	AB	200MG	A209603	002	Jun 20, 2018	Jun NEWA
>D> AB		300MG	A209603	003	Jun 20, 2018	Aug CAHN
	AB	300MG	A209603	003	Jun 20, 2018	Jun NEWA
>A> AB	TWI PHARMS	100MG	A209603	001	Jun 20, 2018	Aug CAHN
>A> AB		200MG	A209603	002	Jun 20, 2018	Aug CAHN
>A> AB		300MG	A209603	003	Jun 20, 2018	Aug CAHN

LACTULOSESOLUTION;ORALLACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A207786	001	Jun 11, 2018	May NEWA
AA	LANNETT CO INC	10GM/15ML	A075993	001	Jul 26, 2001	May CAHN

LAMIVUDINETABLET;ORALLAMIVUDINE

AB	STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018	Apr NEWA
AB		300MG	A090457	002	Apr 19, 2018	Apr NEWA

>A> LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE>A> TABLET;ORAL>A> LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

>A>	+ @ MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018	Aug NEWA
-----	----------------	-------------------	---------	-----	--------------	----------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORALCIMDUO

+! MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	Feb NEWA
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE		N022344	001	May 15, 2018	Jul DISC
@ AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	May NEWA
	300MG;300MG				

LAMIVUDINE; ZIDOVUDINETABLET;ORALLAMIVUDINE AND ZIDOVUDINE

>A> AB	CIPLA LTD	150MG;300MG	A077411	001	Sep 07, 2018	Aug NEWA
>A> AB	MACLEODS PHARMS LTD	150MG;300MG	A090679	001	Aug 29, 2018	Aug NEWA
	@ PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Jun DISC
AB	SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018	Mar NEWA

LEFLUNOMIDETABLET;ORALLEFLUNOMIDE

@ FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan CAHN
@	20MG	A077087	002	Sep 13, 2005	Jan CAHN

LETROZOLETABLET;ORALLETROZOLE

@ MYLAN	2.5MG	A078190	001	Dec 24, 2008	Jun DISC
---------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUMINJECTABLE;INJECTIONLEUCOVORIN CALCIUM

FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Mar NEWA
--------------------	-----------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Jul NEWA
----	--------------------	-----------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	! WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Jul CTEC
----	------------------------	-----------------	---------	-----	--------------	----------

LEUPROLIDE ACETATEFOR SUSPENSION;INTRAMUSCULARLUTRATE DEPOT KIT

>A>	+! GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Aug NEWA
-----	----------------	-------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

LUPRON

+ @ ABBVIE ENDOCRINE INC 1MG/0.2ML
 LUPRON DEPOT
 + ABBVIE ENDOCRINE INC 22.5MG/VIAL
 +! 45MG/VIAL

N019010 001 Apr 09, 1985 Feb CRLD
 N020517 001 Dec 22, 1995 Jun CHRS
 N020517 003 Jun 17, 2011 Jun CHRS

LEVETIRACETAMINJECTABLE; IV (INFUSION)
LEVETIRACETAM

AP	AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Apr NEWA
AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Mar NEWA
SOLUTION; ORAL						
LEVETIRACETAM						
AA	ACI HEALTHCARE LTD	100MG/ML	A078582	001	Jan 15, 2009	May CAHN
AA	LANNETT CO INC	100MG/ML	A090079	001	Apr 11, 2012	May CAHN
TABLET; ORAL						
LEVETIRACETAM						
	@ FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009	Jan CAHN
	@	500MG	A077324	002	Jan 15, 2009	Jan CAHN
	@	750MG	A077324	003	Jan 15, 2009	Jan CAHN
	@	1GM	A077324	004	Jan 15, 2009	Jan CAHN
AB	OXFORD PHARMS	250MG	A077319	001	Mar 20, 2009	Jul CAHN
AB		500MG	A077319	002	Mar 20, 2009	Jul CAHN
AB		750MG	A077319	003	Mar 20, 2009	Jul CAHN
TABLET, EXTENDED RELEASE; ORAL						
LEVETIRACETAM						
	@ VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Jun DISC
	@	750MG	A091291	002	Sep 12, 2011	Jun DISC

LEVOCECTIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCECTIRIZINE DIHYDROCHLORIDE

>D> AB	ALLIED PHARMA INC	5MG	A204323	001	Dec 20, 2016	Aug CAHN
>A> AB	@ FOSUN PHARMA	5MG	A090486	001	Mar 26, 2013	Jan CAHN
	NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Aug CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

+ @ JANSSEN PHARMS EQ 500MG/20ML (EQ 25MG/ML)
 + @ EQ 750MG/30ML (EQ 25MG/ML)

N020635 001 Dec 20, 1996 Feb DISC
 N020635 004 Dec 20, 1996 Feb DISC

LEVOFLOXACIN

AP	! AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Mar CHRS
AP	!	EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Mar CHRS
	@ EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Mar DISC
	@	EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Mar DISC
	@ MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun DISC
	@	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun DISC
	@ ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb DISC
	@	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb DISC
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	! INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan CAHN
AP	!	EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan CAHN
AP	!	EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan CAHN

SOLUTION; ORAL

LEVOFLOXACIN

AA	! HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	May CTEC
AA	LANNETT CO INC	250MG/10ML	A205222	001	May 25, 2018	May NEWA

TABLET; ORAL

LEVAQUIN

+ @ JANSSEN PHARMS 250MG
 + @ 500MG
 + @ 750MG

N020634 001 Dec 20, 1996 Feb DISC
 N020634 002 Dec 20, 1996 Feb DISC
 N020634 003 Sep 08, 2000 Feb DISC

LEVOFLOXACIN

AB	! AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb CHRS
----	------------------------	-------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

	POWDER; INTRAVENOUS FUSILEV						
AP	+! SPECTRUM PHARMS LEVOLEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL		N020140	001	Mar 07, 2008	May CDFR
AP	ACTAVIS LLC	EQ 50MG BASE/VIAL		A206516	001	Feb 13, 2017	May CDFR
	+!	EQ 175MG BASE/VIAL		N208723	001	Sep 29, 2016	May CDFR
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL		A207547	001	Feb 13, 2017	May CDFR
AP	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL		A206263	001	Jun 16, 2016	May CDFR
	SOLUTION; INTRAVENOUS FUSILEV						
	+ @ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		N020140	002	Apr 29, 2011	May CDFR
	+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		N020140	003	Apr 29, 2011	May CDFR
	LEVOLEUCOVORIN CALCIUM						
AP	AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A207548	001	Sep 08, 2017	May CDFR
AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018	May CDFR
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018	May CDFR
AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203576	001	Oct 20, 2015	May CDFR
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203576	002	Oct 20, 2015	May CDFR
AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A203563	001	Mar 09, 2015	May CDFR
AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203563	002	Mar 09, 2015	May CDFR
	SOLUTION; IV (INFUSION) LEVOLEUCOVORIN CALCIUM						
AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018	Apr NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018	Apr NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL FETZIMA						
+	ALLERGAN SALES LLC	EQ 20MG BASE		N204168	001	Jul 25, 2013	Jan CAHN
+		EQ 40MG BASE		N204168	002	Jul 25, 2013	Jan CAHN
+		EQ 80MG BASE		N204168	003	Jul 25, 2013	Jan CAHN
+	!	EQ 120MG BASE		N204168	004	Jul 25, 2013	Jan CAHN

LEVORPHANOL TARTRATE

	TABLET; ORAL LEVORPHANOL TARTRATE						
	SENTYNL THERAPS INC	1MG		A074278	002	Jun 18, 2018	Jun NEWA
		3MG		A074278	003	Jun 18, 2018	Jun NEWA

LEVOTHYROXINE SODIUM

	CAPSULE; ORAL TIROSINT						
+	INSTITUT BIOCHIMIQUE	0.15MG		N021924	007	Oct 13, 2006	May CHRS
+	!	0.200MG		N021924	012	Apr 25, 2017	May CHRS
	POWDER; INTRAVENOUS LEVOTHYROXINE SODIUM						
AP	PIRAMAL CRITICAL	100MCG/VIAL		A206163	001	Jun 29, 2016	Jan CAHN
AP		500MCG/VIAL		A206163	002	Jun 29, 2016	Jan CAHN

LIDOCAINE

	OINTMENT; TOPICAL LIDOCAINE						
AT	TEVA PHARMS USA	5%		A210256	001	Jan 16, 2018	Jan NEWA
	PATCH; TOPICAL ZTLIDO						
+	! SCILEX PHARMS INC	1.8%		N207962	001	Feb 28, 2018	Feb NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP	B BRAUN MEDICAL INC	1%	A208474	001	Aug 03, 2018	Jul NEWA
AP	SPECTRA MDCL DEVICES	1%	A208017	001	Apr 18, 2018	Apr NEWA
	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE				
	@ INTL MEDICATION	20%	N017702	001		Jun DISC
	JELLY; TOPICAL					
	LIDOCAINE HYDROCHLORIDE					
>D> AT	WATSON LABS INC	2%	A040837	001	Mar 23, 2011	Aug DISC
>A>	@	2%	A040837	001	Mar 23, 2011	Aug DISC
	SOLUTION; ORAL					
	LIDOCAINE HYDROCHLORIDE VISCOUS					
AT	! LANNETT CO INC	2%	A040708	001	Feb 27, 2007	May CAHN
	SOLUTION; TOPICAL					
	LIDOCAINE HYDROCHLORIDE					
AT	LANNETT CO INC	4%	A040710	001	Feb 27, 2007	May CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	TELIGENT PHARMA INC	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun NEWA
----	---------------------	-----------	---------	-----	--------------	----------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan CAHN
+		145MCG	N202811	001	Aug 30, 2012	Jan CAHN
+!		290MCG	N202811	002	Aug 30, 2012	Jan CAHN

LINDANE

LOTION; TOPICAL

LINDANE

!	OLTA PHARMS	1%	A087313	001		Jun CHRS
		1%	A087313	001		Jun CTEC
@	WOCKHARDT	1%	A088190	001	Aug 16, 1984	Jun DISC

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	May CDFR
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	May CDFR
AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May CDFR
AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	May CDFR
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	May CDFR
AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	May CDFR
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	May CDFR
AP	NANG KUANG PHARM CO	200MG/100ML (2MG/ML)	A207354	001	Dec 20, 2016	May CDFR
AP		600MG/300ML (2MG/ML)	A207354	002	Dec 20, 2016	May CDFR
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	May CDFR
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	May CDFR
AP	SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	May CDFR
AP		600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	May CDFR
AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May CDFR
	LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+!	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	May CDFR
	ZYVOX					
AP	+ PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May CDFR
+ @		400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	Jul DISC
+		400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May CDFR
AP	+!	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May CDFR

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

+ ALLERGAN SALES LLC	0.0125MG;0.0031MG	N016807	001		Apr CAHN
THYROLAR-0.5		N016807	005		Apr CAHN
+ ALLERGAN SALES LLC	0.025MG;0.0063MG	N016807	004		Apr CAHN
THYROLAR-1					
+ ALLERGAN SALES LLC	0.05MG;0.0125MG				

TABLET;ORAL

THYROLAR-2

+ ALLERGAN SALES LLC	0.1MG;0.025MG	N 016807	002	Apr CAHN
+! ALLERGAN SALES LLC	0.15MG;0.0375MG	N 016807	003	Apr CAHN
@ ALLERGAN SALES LLC	0.25MG;0.0625MG	N 016807	006	Apr CAHN

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB CASI PHARMS INC	2.5MG	A 075994	001	Jul 01, 2002	Mar CAHN
AB	5MG	A 075994	002	Jul 01, 2002	Mar CAHN
AB	10MG	A 075994	003	Jul 01, 2002	Mar CAHN
AB	20MG	A 075994	004	Jul 01, 2002	Mar CAHN
AB	30MG	A 075994	005	Jul 01, 2002	Mar CAHN
AB	40MG	A 075994	006	Jul 01, 2002	Mar CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LUCEMYRA

+! US WORLDMEDS LLC	EQ 0.18MG BASE	N 209229	001	May 16, 2018	May NEWA
---------------------	----------------	----------	-----	--------------	----------

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+ @ CORDEN PHARMA	5MG	N 017588	004	Dec 19, 2014	Jun DISC
-------------------	-----	----------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

+ @ J AND J CONSUMER INC	2MG	N 017694	001		Jun CRLD
@ YAOPHARMA CO LTD	2MG	A 072993	001	Aug 28, 1992	Jan CAHN

LORAZEPAM

TABLET;ORAL

LORAZEPAM

@ ANDA REPOSITORY	0.5MG	A 072555	002	Mar 29, 1991	May CMS1
@	1MG	A 072555	003	Mar 29, 1991	May CMS1
@ MYLAN	0.5MG	A 071591	002	Oct 13, 1987	Jan CMS1
@	1MG	A 071591	003	Oct 13, 1987	Jan CMS1
AB OXFORD PHARMS	0.5MG	A 077754	001	May 10, 2006	Jul CAHN
AB	1MG	A 077754	002	May 10, 2006	Jul CAHN
AB	2MG	A 077754	003	May 10, 2006	Jul CAHN
@ SUN PHARM INDs LTD	0.5MG	A 076045	001	Aug 29, 2001	May DISC
@	1MG	A 076045	002	Aug 29, 2001	May DISC
@	2MG	A 076045	003	Aug 29, 2001	May DISC

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

+ @ MERCK SHARP DOHME	25MG	N 020386	001	Apr 14, 1995	Apr DISC
+ @	50MG	N 020386	002	Apr 14, 1995	Apr DISC
LOSARTAN POTASSIUM					
@ APOTEX CORP	25MG	A 090790	001	Oct 06, 2010	Mar DISC
@	50MG	A 090790	002	Oct 06, 2010	Mar DISC
@	100MG	A 090790	003	Oct 06, 2010	Mar DISC

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

INVELTYS

>A> +! KALA PHARMS INC	1%	N 210565	001	Aug 22, 2018	Aug NEWA
------------------------	----	----------	-----	--------------	----------

LUSUTROMBOPAG

TABLET;ORAL

MULPLETA

+! SHIONOGI INC	3MG	N 210923	001	Jul 31, 2018	Jul NEWA
-----------------	-----	----------	-----	--------------	----------

LUTETIUM DOTATATE LU-177

SOLUTION;IV (INFUSION)

LUTATHERA

+! AAA USA INC

10mCi/ML

N208700 001 Jan 26, 2018 Jan NEWA

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+! STRONGBRIDGE IRELAND

EQ 60MG BASE/POUCH

N205598 001 Dec 20, 2017 May CMS1

+! STRONGBRIDGE IRELAND

EQ 60MG BASE/POUCH

N205598 001 Dec 21, 2017 Jan CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML

Apr CRLD

PLASMA-LYTE A IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML

Apr CRLD

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A> AP

MYLAN LABS LTD

1GM/100ML

A209932 001 Sep 10, 2018 Aug NEWA

MALATHION

LOTION;TOPICAL

OVIDE

AT

+! TARO PHARM INDs LTD

0.5%

N018613 001 Aug 02, 1982 May CAHN

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+! HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962 001 Jun 26, 1986 Mar CRLD

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+! ICU MEDICAL INC

540MG/100ML;2.7GM/100ML

N018316 001

Mar CRLD

MAZINDOL

TABLET;ORAL

SANOREX

+ @ HEXIM

1MG

N017247 001

Jul CAHN

+ @

2MG

N017247 002

Jul CAHN

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

+ @ JANSSEN PHARMS

500MG

N208398 001

Oct 19, 2016 Feb DISC

MECHLORETHAMINE HYDROCHLORIDE

GEL;TOPICAL

VALCHLOR

>D>

+! ACTELION PHARMS LTD

EQ 0.016% BASE

N202317 001

Aug CAHN

>A>

+! HELSINN

EQ 0.016% BASE

N202317 001

Aug CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

@ FOSUN PHARMA

EQ 50MG BASE

A072262 001

Nov 29, 1988 Jan CAHN

@

EQ 100MG BASE

A072263 001

Nov 29, 1988 Jan CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB

BELCHER PHARMS INC

250MG

A091608 001

Jun 02, 2014 Jul CAHN

AB

MICRO LABS

250MG

A090562 001

Nov 19, 2010 Feb CAHN

MELOXICAM

TABLET;ORAL					
MELOXICAM					
@ MYLAN	7.5MG		A077923	001	Jul 19, 2006
@	15MG		A077923	002	Jul 19, 2006

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL					
MEMANTINE HYDROCHLORIDE					
AA APOTEX INC	2MG/ML		A209955	001	Feb 09, 2018
AA ! BIO-PHARM INC	2MG/ML		A205446	001	Dec 07, 2015
NAMENDA					
+ @ ALLERGAN SALES LLC	2MG/ML		N021627	001	Apr 18, 2005
+!	2MG/ML		N021627	001	Apr 18, 2005
TABLET;ORAL					
MEMANTINE HYDROCHLORIDE					
AB APOTEX INC	5MG		A090244	001	Jul 11, 2018
	10MG		A090244	002	Jul 11, 2018
AB CSPC OUYI PHARM CO	5MG		A209527	001	May 07, 2018
	10MG		A209527	002	May 07, 2018
NAMENDA					
AB + ALLERGAN SALES LLC	5MG		N021487	001	Oct 16, 2003
AB +!	10MG		N021487	002	Oct 16, 2003

MEROPENEM

INJECTABLE;INJECTION					
MEROPENEM					
AP ACS DOBFAR SPA	500MG/VIAL		A204139	001	Jun 09, 2016
	1GM/VIAL		A204139	002	Jun 09, 2016

MEROPENEM; VABORBACTAM

POWDER;IV (INFUSION)					
VABOMERE					
+! REMPEX PHARMS	1GM/VIAL;1GM/VIAL		N209776	001	Aug 29, 2017

MESALAMINE

ENEMA;RECTAL					
MESALAMINE					
@ G AND W LABS INC	4GM/60ML		A076841	001	Sep 30, 2004
SUPPOSITORY;RECTAL					
CANASA					
@ ALLERGAN SALES LLC	500MG		N021252	001	Jan 05, 2001
+!	1GM		N021252	002	Nov 05, 2004
TABLET, DELAYED RELEASE;ORAL					
MESALAMINE					
AB ACTAVIS LABS FL	1.2GM		A203817	001	Mar 23, 2018

MESNA

INJECTABLE;INTRAVENOUS					
MESNA					
@ MYLAN INSTITUTIONAL	100MG/ML		A076488	001	Mar 08, 2012

METARAMINOL BITARTRATE

INJECTABLE;INJECTION					
METARAMINOL BITARTRATE					
@ FRESENIUS KABI USA	EQ 10MG BASE/ML		A080722	001	

METAXALONE

TABLET;ORAL					
METAXALONE					
MOUNTAIN	400MG		A040486	001	Feb 27, 2015

METFORMIN HYDROCHLORIDE

TABLET;ORAL					
METFORMIN HYDROCHLORIDE					
>A> AB LAURUS LABS LTD	500MG		A209882	001	Aug 27, 2018
	850MG		A209882	002	Aug 27, 2018
	1GM		A209882	003	Aug 27, 2018
@ PROVIDENT PHARM	500MG		A077853	001	Jul 28, 2006
@	850MG		A077853	002	Jul 28, 2006

TABLET;ORAL

METFORMIN HYDROCHLORIDE

@	1GM	A077853	003	Jul 28, 2006	Jun DISC
@ SANDOZ	500MG	A075985	001	Jan 25, 2002	Mar DISC
@	850MG	A075985	002	Jan 25, 2002	Mar DISC
@	1GM	A075985	003	Jan 25, 2002	Mar DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1	ALIGNSCIENCE PHARMA	500MG	A209303	001	Mar 19, 2018	Mar NEWA
AB1	GRANULES INDIA LTD	500MG	A209313	001	Mar 16, 2018	Mar NEWA
AB		750MG	A209313	002	Mar 16, 2018	Mar NEWA
>A> AB1	PRINSTON INC	500MG	A208880	001	Sep 10, 2018	Aug NEWA
>A> AB		750MG	A208880	002	Sep 10, 2018	Aug NEWA

METFORMIN HYDROCHLORIDE; REPAGLINIDETABLET;ORAL

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

@ LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	May DISC
@	500MG;2MG	A200624	002	Jul 15, 2015	May DISC

METHADONE HYDROCHLORIDETABLET;ORAL

METHADONE HYDROCHLORIDE

AA	ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Jul NEWA
AA		10MG	A210484	002	Aug 02, 2018	Jul NEWA
AA	SUN PHARM INDUSTRIES	5MG	A208305	001	Mar 30, 2018	Mar NEWA
AA		10MG	A208305	002	Mar 30, 2018	Mar NEWA

METHIMAZOLETABLET;ORAL

METHIMAZOLE

AB	CASI PHARMS INC	5MG	A040411	001	Mar 27, 2001	Mar CAHN
AB		10MG	A040411	002	Mar 27, 2001	Mar CAHN

METHOCARBAMOLSOLUTION;IM-IV

METHOCARBAMOL

AP	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A209331	001	Apr 17, 2018	Apr NEWA
----	--------------------	---------------------	---------	-----	--------------	----------

TABLET;ORAL

METHOCARBAMOL

AA	ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	Feb CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	May CAHN
AA		750MG	A203550	002	Feb 08, 2017	May CAHN
	@ FOSUN PHARMA	500MG	A084616	001		Jan CAHN
	@	750MG	A084615	001		Jan CAHN
AA	GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Apr NEWA
AA		750MG	A209312	002	May 07, 2018	Apr NEWA
AA	OXFORD PHARMS	500MG	A040489	001	Jan 29, 2003	Jul CAHN
AA		750MG	A040489	002	Jan 29, 2003	Jul CAHN

METHOTREXATESOLUTION;SUBCUTANEOUS

RASUVO

+!	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr CHRS
+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr CHRS
+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr CHRS
+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr CHRS
+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr CHRS
+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr CHRS
+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr CHRS
+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr CHRS
+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CHRS

METHOTREXATE SODIUMINJECTABLE;INJECTION

METHOTREXATE SODIUM

>D> AP	! FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999	Aug DISC
>A>	@	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999	Aug DISC

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A203407	001	Aug 09, 2018	Jul NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A203407	002	Aug 09, 2018	Jul NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A203407	003	Aug 09, 2018	Jul NEWA

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+ @ PARKE DAVIS

150MG

N010596

007

Jun DISC

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

@ YAOPHARMA CO LTD

2.5MG

A089835

001

Aug 18, 1988

Jan CAHN

@

5MG

A089837

001

Aug 18, 1988

Jan CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@ YAOPHARMA CO LTD

125MG

A071700

001

Mar 02, 1988

Jan CAHN

@

250MG

N018934

001

Jun 29, 1984

Jan CAHN

@

500MG

N018934

002

Jun 29, 1984

Jan CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

>A> AB	AMNEAL PHARMS	0.2MG	A211483	001	Sep 10, 2018	Aug NEWA
AB	GRANULES PHARMS	0.2MG	A210424	001	May 15, 2018	Apr NEWA
AB	! NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr CTEC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>A>	JORNAY PM					
>A>	+ IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018	Aug NEWA
>A>	+	40MG	N209311	002	Aug 08, 2018	Aug NEWA
>A>	+	60MG	N209311	003	Aug 08, 2018	Aug NEWA
>A>	+	80MG	N209311	004	Aug 08, 2018	Aug NEWA
>A>	+	100MG	N209311	005	Aug 08, 2018	Aug NEWA

METADATE CD

AB2	+ LANNETT CO INC	10MG	N021259	003	May 27, 2003	Mar CAHN
AB2	+	20MG	N021259	001	Apr 03, 2001	Mar CAHN
AB2	+	30MG	N021259	002	Jun 19, 2003	Mar CAHN
AB2	+	40MG	N021259	004	Feb 19, 2006	Mar CAHN
AB2	+	50MG	N021259	005	Feb 19, 2006	Mar CAHN
AB2	+!	60MG	N021259	006	Feb 19, 2006	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1	MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb NEWA
FOR SUSPENSION, EXTENDED RELEASE; ORAL						

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Apr NEWA
AB	QUILLIVANT XR					

AB	+! NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Apr CFTG
TABLET; ORAL						

METHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb NEWA
AB		10MG	A209753	002	Mar 02, 2018	Feb NEWA
AB		20MG	A209753	003	Mar 02, 2018	Feb NEWA
AB	LANNETT CO INC	5MG	A086429	001		Mar CAHN
AB		10MG	A085799	001		Mar CAHN
AB		20MG	A086428	001		Mar CAHN

AB	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan CAHN
AB		10MG	A091159	002	Mar 12, 2014	Jan CAHN
AB		20MG	A091159	003	Mar 12, 2014	Jan CAHN

AB	OXFORD PHARMS	5MG	A202892	001	Sep 23, 2014	Jul CAHN
AB		10MG	A202892	002	Sep 23, 2014	Jul CAHN
AB		20MG	A202892	003	Sep 23, 2014	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

AB	@ LANNETT CO INC	10MG	A040306	001	Oct 20, 1999	Mar CAHN
AB	!	20MG	A089601	001	Jun 01, 1988	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLINE ER

>D> AB	SPECGX LLC	20MG	A075629	002	May 09, 2000	Aug CHRS
>A> AB	!	20MG	A075629	002	May 09, 2000	Aug CHRS
<u>METHYLPHENIDATE HYDROCHLORIDE</u>						
AB	ACTAVIS LABS FL	54MG	A076655	001	Mar 21, 2018	Mar NEWA
AB	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan NEWA
AB		27MG	A207515	002	Feb 01, 2018	Jan NEWA
AB		36MG	A207515	003	Feb 01, 2018	Jan NEWA
AB		54MG	A207515	004	Feb 01, 2018	Jan NEWA
AB	ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	May CAHN
AB		27MG	A208607	002	Jul 14, 2017	May CAHN
AB		36MG	A208607	003	Jul 14, 2017	May CAHN
AB		54MG	A208607	004	Jul 14, 2017	May CAHN
AB	MOUNTAIN	18MG	A208607	001	Jul 14, 2017	Jan CAHN
AB		27MG	A208607	002	Jul 14, 2017	Jan CAHN
AB		36MG	A208607	003	Jul 14, 2017	Jan CAHN
AB		54MG	A208607	004	Jul 14, 2017	Jan CAHN
!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan CHRS
>D>	RITALIN-SR					
>D> AB	+ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Aug DISC
>A>	+ @	20MG	N018029	001	Mar 30, 1982	Aug DISC
<u>TABLET, EXTENDED RELEASE, CHEWABLE;ORAL</u>						
<u>QUILLICHEW ER</u>						
>A>	+ NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015	Aug CAHN
>A>	+	30MG	N207960	002	Dec 04, 2015	Aug CAHN
>A>	+!	40MG	N207960	003	Dec 04, 2015	Aug CAHN
>D>	+ PFIZER INC	20MG	N207960	001	Dec 04, 2015	Aug CAHN
>D>	+	30MG	N207960	002	Dec 04, 2015	Aug CAHN
>D>	+!	40MG	N207960	003	Dec 04, 2015	Aug CAHN

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr NEWA
AB	ZYDUS PHARMS USA INC	4MG	A206751	001	Apr 23, 2018	Apr NEWA
AB		8MG	A206751	002	Apr 23, 2018	Apr NEWA
AB		16MG	A206751	003	Apr 23, 2018	Apr NEWA
AB		32MG	A206751	004	Apr 23, 2018	Apr NEWA

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

AB	+! PHARMACIA AND UPJOHN	20MG/ML	N011757	002		Jun CFTG
<u>METHYLPREDNISOLONE ACETATE</u>						
AB	SAGENT PHARMS	20MG/ML	A201835	001	Jun 27, 2018	Jun NEWA
AB		40MG/ML	A201835	002	Jun 27, 2018	Jun NEWA
AB		80MG/ML	A201835	003	Jun 27, 2018	Jun NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995	Jan CAHN
@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Jan CAHN
@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D> AB	NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014	Aug CTEC
>A>		EQ 5MG BASE	A202191	001	Aug 15, 2014	Aug CTEC
>D>		EQ 10MG BASE	A202191	002	Aug 15, 2014	Aug CHRS
>A>	!	EQ 10MG BASE	A202191	002	Aug 15, 2014	Aug CHRS
>D>	METOZOLV ODT					
>D> AB	+! SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug DISC
>A>	+ @	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug DISC

METOLAZONE

TABLET;ORAL

MYKROX

@	LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987	Apr CAHN
	ZAROXOLYN					
AB	+ LANNETT CO INC	2.5MG	N017386	001		Mar CAHN
AB	+!	5MG	N017386	002		Mar CAHN

	TABLET;ORAL ZAROXOLYN				
AB	+!	10MG	N 017386	003	Mar CAHN
<u>METOPROLOL SUCCINATE</u>					
CAPSULE, EXTENDED RELEASE;ORAL KAPSPARGO SPRINKLE					
+ !	SPIL	EQ 25MG TARTRATE	N 210428	001	Jan 26, 2018 Jun CTNA
+ !		EQ 25MG TARTRATE	N 210428	001	Jan 26, 2018 Jan NEWA
+ !		EQ 50MG TARTRATE	N 210428	002	Jan 26, 2018 Jun CTNA
+ !		EQ 50MG TARTRATE	N 210428	002	Jan 26, 2018 Jan NEWA
+ !		EQ 100MG TARTRATE	N 210428	003	Jan 26, 2018 Jun CTNA
+ !		EQ 100MG TARTRATE	N 210428	003	Jan 26, 2018 Jan NEWA
+ !		EQ 200MG TARTRATE	N 210428	004	Jan 26, 2018 Jun CTNA
+ !		EQ 200MG TARTRATE	N 210428	004	Jan 26, 2018 Jan NEWA
TABLET, EXTENDED RELEASE;ORAL METOPROLOL SUCCINATE					
AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A 076862	002	Aug 03, 2009 Mar CMS1
AB	NOVAST LABS LTD	EQ 25MG TARTRATE	A 204106	001	Feb 06, 2018 Jan NEWA
AB		EQ 50MG TARTRATE	A 204106	002	Feb 06, 2018 Jan NEWA
AB		EQ 100MG TARTRATE	A 204106	003	Feb 06, 2018 Jan NEWA
AB		EQ 200MG TARTRATE	A 204106	004	Feb 06, 2018 Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A 203894	001	Mar 23, 2018 Mar NEWA
AB		EQ 50MG TARTRATE	A 203894	002	Mar 23, 2018 Mar NEWA
AB		EQ 100MG TARTRATE	A 203894	003	Mar 23, 2018 Mar NEWA
AB		EQ 200MG TARTRATE	A 203894	004	Mar 23, 2018 Mar NEWA
<u>METOPROLOL TARTRATE</u>					
TABLET;ORAL METOPROLOL TARTRATE					
@ !	RENATA	50MG	A 074453	001	Apr 27, 1995 Jan CAHN
@ !		100MG	A 074453	002	Apr 27, 1995 Jan CAHN
@ !	YAOPHARMA CO LTD	50MG	A 073288	001	Mar 25, 1994 Jan CAHN
@ !		100MG	A 073289	001	Mar 25, 1994 Jan CAHN
<u>METRONIDAZOLE</u>					
TABLET;ORAL METRONIDAZOLE					
@ !	FOSUN PHARMA	250MG	N 018620	001	Mar 04, 1982 Jan CAHN
@ !		250MG	N 018740	001	Oct 22, 1982 Jan CAHN
@ !		500MG	N 018620	002	Jun 02, 1983 Jan CAHN
@ !		500MG	N 018740	002	Oct 22, 1982 Jan CAHN
AB	STRIDES VIVIMED	250MG	A 070040	001	Jan 29, 1985 Jul CAHN
TABLET, EXTENDED RELEASE;ORAL FLAGYL ER					
+ @ !	GD SEARLE LLC	750MG	N 020868	001	Nov 26, 1997 May DISC
METRONIDAZOLE					
@ !	ALEMBIC PHARMS LTD	750MG	A 090222	001	May 05, 2010 May DISC
<u>METYRAPONE</u>					
CAPSULE;ORAL METOPIRONE					
+ !	LABORATORIE HRA	250MG	N 012911	002	Aug 09, 1996 Jun CAHN
TABLET;ORAL METOPIRONE					
@ !	LABORATORIE HRA	250MG	N 012911	001	Jun CAHN
<u>MEXILETINE HYDROCHLORIDE</u>					
CAPSULE;ORAL MEXITIL					
+ @ !	BOEHRINGER INGELHEIM	150MG	N 018873	002	Dec 30, 1985 Jul CRLD
+ @ !		200MG	N 018873	003	Dec 30, 1985 Jul CRLD
+ @ !		250MG	N 018873	004	Dec 30, 1985 Jul CRLD
<u>MICAFUNGIN SODIUM</u>					
INJECTABLE;INTRAVENOUS MYCAMINE					
+ !	ASTELLAS	EQ 50MG BASE/VIAL	N 021506	002	Mar 16, 2005 May CDER
+ !		EQ 100MG BASE/VIAL	N 021506	003	Jun 27, 2006 May CDER

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

>D>	AP	AKORN INC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Aug DISC
>A>	@		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Aug DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
MIDODRINE HYDROCHLORIDE

AB	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb CTEC
AB		5MG	A077746	002	Sep 12, 2006	Feb CTEC
AB		10MG	A077746	003	Sep 12, 2006	Feb CTEC
AB	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar CAHN
AB		5MG	A076514	002	Sep 11, 2003	Mar CAHN
AB		10MG	A076514	003	Jul 02, 2004	Mar CAHN

>A> MIGALASTAT HYDROCHLORIDE

>A> CAPSULE; ORAL
>A> GALAFOLD
>A> +! AMICUS THERAPS US EQ 123MG BASE

N208623 001 Aug 10, 2018 Aug NEWA

MIGLUSTAT

CAPSULE; ORAL
MIGLUSTAT

AB	AMERIGEN PHARMS LTD	100MG	A208342	001	Apr 17, 2018	Apr NEWA
AB	+! ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003	Apr CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL
MILNACIPRAN HYDROCHLORIDE

@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Mar CAHN
@		25MG	A205071	002	Jan 27, 2016	Mar CAHN
@		50MG	A205071	003	Jan 27, 2016	Mar CAHN
@		100MG	A205071	004	Jan 27, 2016	Mar CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
MINOCIN

+! REMPEX PHARMS EQ 100MG BASE/VIAL

N050444 001 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL
MINOCYCLINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 65MG BASE	A204453	006	Mar 16, 2018	Mar NEWA
AB		EQ 115MG BASE	A204453	007	Mar 16, 2018	Mar NEWA
AB	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Jan CMFD
AB		EQ 115MG BASE	A065485	005	May 18, 2012	Jan CMFD
	SOLODYN					
AB	+ MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Mar CTEC
AB	+!	EQ 115MG BASE	N050808	005	Jul 23, 2009	Mar CTEC

MINOXIDIL

TABLET; ORAL
MINOXIDIL

AB	SUN PHARM INDUSTRIES	2.5MG	A072709	002	Dec 14, 1995	Jun CMS1
----	----------------------	-------	---------	-----	--------------	----------

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS
KYNAMRO

+ @ KASTLE THERAPS LLC 200MG/ML (200MG/ML)

N203568 001 Jan 29, 2013 Jun DISC

MIRTAZAPINE

TABLET; ORAL
REMERON

+ @ ORGANON USA INC 45MG

N020415 003 Mar 17, 1997 Jul DISC

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

@ ACTAVIS LABS FL INC 15MG

A076307 001 Dec 17, 2003 Jun DISC

@ 30MG

A076307 002 Dec 17, 2003 Jun DISC

@ 45MG

A076307 003 Feb 28, 2006 Jun DISC

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

@ WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	May DISC
@	20MG/VIAL	A064117	002	Apr 19, 1995	May DISC
@	40MG/VIAL	A064117	003	Jun 02, 1999	May CMS1

MITOTANE

TABLET; ORAL

LYSODREN

+! LABORATOIRE HRA

500MG

N016885

001

Jul CAHN

MIVACURIUM CHLORIDESOLUTION; INTRAVENOUS
MIVACRON

+ @ ABBVIE

+ @

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jun DISC
EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jun DISC

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB TORRENT PHARMS LTD

0.1%

A207899

001

Jul 13, 2018

Jul NEWA

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB TORRENT PHARMS LLC

EQ 4MG BASE/PACKET

A210431

001

Jul 31, 2018

Jul NEWA

TABLET; ORAL

MONTELUKAST SODIUM

@ APOTEX CORP

EQ 10MG BASE

A201294

001

Aug 03, 2012

Mar DISC

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

@ APOTEX INC

EQ 4MG BASE

A201508

001

Aug 03, 2012

Mar DISC

@

EQ 5MG BASE

A201508

002

Aug 03, 2012

Mar DISC

AB UNICHEM LABS LTD

EQ 4MG BASE

A208621

001

Jul 02, 2018

Jun NEWA

AB

EQ 5MG BASE

A208621

002

Jul 02, 2018

Jun NEWA

MORPHINE SULFATEINJECTABLE; INJECTION
INFUMORPH

AP +! WEST-WARD PHARMS INT

10MG/ML

N018565

003

Jul 19, 1991

Jul CFTG

AP +!

25MG/ML

N018565

004

Jul 19, 1991

Jul CFTG

MITIGO

AP PIRAMAL CRITICAL

10MG/ML

A204393

001

Jul 16, 2018

Jul NEWA

AP

25MG/ML

A204393

002

Jul 16, 2018

Jul NEWA

SOLUTION; ORAL

MORPHINE SULFATE

AA ANI PHARMS INC

10MG/5ML

A205509

001

Apr 17, 2018

Apr NEWA

AA

20MG/5ML

A205509

002

Apr 17, 2018

Apr NEWA

AA

100MG/5ML

A205509

003

Apr 17, 2018

Apr NEWA

AA LANNETT CO INC

10MG/5ML

A202309

001

Nov 25, 2015

May CAHN

AA

20MG/5ML

A202310

001

Oct 30, 2015

May CAHN

>D>

100MG/5ML

N201517

001

Jun 23, 2011

Aug DISC

>A>

100MG/5ML

N201517

001

Jun 23, 2011

Aug DISC

AA NOSTRUM LABS INC

100MG/5ML

A201011

003

Oct 06, 2016

Jul CMS1

MOXIDECTIN

TABLET; ORAL

MOXIDECTIN

+! MDGH

2MG

N210867

001

Jun 13, 2018

Jun NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+ @ GLAXOSMITHKLINE

EQ 2% BASE

N050746

001

Dec 11, 1997

Apr DISC

MUPIROCIN

! GLENMARK PHARMS INC

EQ 2% BASE

A201587

001

Jan 24, 2013

Apr CHRS

OINTMENT; NASAL

BACTROBAN

+ @ GLAXOSMITHKLINE

EQ 2% BASE

N050703

001

Sep 18, 1995

May DISC

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX CORP

250MG

A090419 001 Apr 22, 2009 Mar DISC

TABLET;ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX

500MG

A090499 001 Apr 22, 2009 Mar DISC

AB OXFORD PHARMS 500MG

A090606 001 Jul 16, 2010 Jul CAHN

NABUMETONE

TABLET;ORAL

NABUMETONE

AB CASI PHARMS INC 500MG

A075280 001 Feb 25, 2002 Mar CAHN

AB 750MG

A075280 002 Feb 25, 2002 Mar CAHN

NADOLOL

TABLET;ORAL

NADOLOL

AB BEXIMCO PHARMS USA 20MG

A210955 001 Jul 23, 2018 Jul NEWA

AB 40MG

A210955 002 Jul 23, 2018 Jul NEWA

AB 80MG

A210955 003 Jul 23, 2018 Jul NEWA

AB RICONPHARMA LLC 20MG

A210786 001 Jun 01, 2018 May NEWA

AB 40MG

A210786 002 Jun 01, 2018 May NEWA

AB 80MG

A210786 003 Jun 01, 2018 May NEWA

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

! TARO

1%

A205975 001 Sep 08, 2016 Apr CHRS

! TARO PHARMS

1%

A205975 001 Sep 08, 2016 May CAHN

AB 2%

A206901 001 Jan 06, 2016 Jun CAHN

NAFTIN

+ @ SEBELA IRELAND LTD 1%

N019599 001 Feb 29, 1988 Apr DISC

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NARCAN

+ @ ADAPT

2MG/SPRAY

N208411 002 Jan 24, 2017 Apr DISC

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

@ FOSUN PHARMA

50MG

A075434 001 Mar 08, 2000 Jan CAHN

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

@ AKORN INC

0.1%

A083590 001 Jun DISC

NAPROXEN

TABLET;ORAL

NAPROSYN

>D> AB + ATNAHS PHARMA US 250MG

N017581 002 Aug DISC

>A> + @ 250MG

N017581 002 Aug DISC

>D> AB + 375MG

N017581 003 Aug DISC

>A> + @ 375MG

N017581 003 Aug DISC

NAPROXEN

@ FOSUN PHARMA

250MG

A074140 001 Dec 21, 1993 Jan CAHN

@ 375MG

A074140 002 Dec 21, 1993 Jan CAHN

@ 500MG

A074140 003 Dec 21, 1993 Jan CAHN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

@ FOSUN PHARMA

375MG

A075061 001 Feb 18, 1998 Jan CAHN

@ 500MG

A075061 002 Feb 18, 1998 Jan CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS
BLOXIVERZ

AP	+!	AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb CAHN
AP	+!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb CAHN
NEOSTIGMINE METHYLSULFATE							
AP		AMNEAL PHARMS CO	5MG/10ML (0.5MG/ML)	A210051	001	Jun 15, 2018	Jun NEWA
AP			10MG/10ML (1MG/ML)	A210051	002	Jun 15, 2018	Jun NEWA
AP		DR REDDYS LABS LTD	5MG/10ML (0.5MG/ML)	A209135	001	Jul 10, 2018	Jun NEWA
AP			10MG/10ML (1MG/ML)	A209135	002	Jul 10, 2018	Jun NEWA
AP		LUITPOLD	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr NEWA
AP			10MG/10ML (1MG/ML)	A209182	002	May 04, 2018	Apr NEWA
>A>	AP	RENAISSANCE SSA LLC	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Aug NEWA
>A>	AP		10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Aug NEWA

NEVIRAPINE

TABLET; ORAL
NEVIRAPINE

@ APOTEX INC	200MG	A203021	001	May 22, 2012	Mar DISC
TABLET, EXTENDED RELEASE; ORAL					
NEVIRAPINE		A205258	001	Apr 03, 2014	Jan DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL
NIACIN

AB	AUROBINDO PHARMA LTD	500MG	A209236	001	Feb 01, 2018	Jan NEWA
AB		750MG	A209236	002	Feb 01, 2018	Jan NEWA
AB		1GM	A209236	003	Feb 01, 2018	Jan NEWA
AB	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Apr NEWA
AB		750MG	A209156	002	May 14, 2018	Apr NEWA
AB		1GM	A209156	003	May 14, 2018	Apr NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION
CARDENE

+ @ CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	May DISC
NICARDIPINE HYDROCHLORIDE					
EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	May CTEC
@ LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	May DISC
@ MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	May DISC
@ NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125	001	Nov 17, 2009	May DISC
@ SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	May DISC
@ WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	May DISC
@ WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	May DISC

INJECTABLE; INTRAVENOUS

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ @ CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Mar DISC
--------------------	-----------------------	---------	-----	--------------	----------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

AB1	ZYDUS PHARMS USA INC	30MG	A210184	001	Jun 29, 2018	Jun NEWA
AB1		60MG	A210184	002	Jun 29, 2018	Jun NEWA
AB1		90MG	A210184	003	Jun 29, 2018	Jun NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE; ORAL

TASIGNA

+ NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Jun CAIN
+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Jun CAIN
+	EQ 200MG BASE	N022068	001	Oct 29, 2007	Jun CAIN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

+ NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Mar NEWA
------------	--------------	---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

AB	NOVEL LABS INC	50MG	A203233	001	Jul 09, 2018	Jun NEWA
AB		100MG	A203233	002	Jul 09, 2018	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	SUNNY PHARMTECH INC	75MG;25MG	A208516	001	May 24, 2018	May NEWA
----	---------------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

INJECTABLE;INJECTION
NITROGLYCERIN IN DEXTROSE 5%

@ HOSPIRA	10MG/100ML	A071846	001	Aug 31, 1990	Jun DISC
@	20MG/100ML	A071847	001	Aug 31, 1990	Jun DISC
@	40MG/100ML	A071848	001	Aug 31, 1990	Jun DISC

OINTMENT;INTRA-ANAL
RECTIV

+! ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	Jan CAHN
-----------------------	------	---------	-----	--------------	----------

TABLET;SUBLINGUAL
NITROGLYCERIN

AB GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan CAHN
AB	0.4MG	A206391	002	Sep 19, 2017	Jan CAHN
AB	0.6MG	A206391	003	Sep 19, 2017	Jan CAHN
AB SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018	Apr NEWA
AB	0.4MG	A207745	002	May 07, 2018	Apr NEWA
AB	0.6MG	A207745	003	May 07, 2018	Apr NEWA

NORETHINDRONE ACETATE

TABLET;ORAL
AYGESTIN

+ @ DURAMED RES	5MG	N018405	001	Apr 21, 1982	May DISC
-----------------	-----	---------	-----	--------------	----------

NORETHINDRONE ACETATE

AB ! BARR	5MG	A075951	001	May 25, 2001	May CHRS
-----------	-----	---------	-----	--------------	----------

NORGESTREL

TABLET;ORAL
OPILL

>D> + @ LABORATOIRE HRA	0.075MG	N017031	001		Aug CMFD
>A> +	0.075MG	N017031	001		Aug CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AB MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992	Mar CMS1
AB	EQ 25MG BASE	A073556	003	Mar 30, 1992	Mar CMS1
AB	EQ 50MG BASE	A073556	004	Mar 30, 1992	Mar CMS1

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

@ G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Jan DISC
--------------------	------------------	---------	-----	--------------	----------

AT LYNE

AT ZYDUS PHARMS USA INC	100,000 UNITS/GM	A209082	001	May 21, 2018	May NEWA
-------------------------	------------------	---------	-----	--------------	----------

POWDER;TOPICAL
NYSTATIN

AT EPIC PHARMA LLC	100,000 UNITS/GM	A207767	001	May 25, 2018	May NEWA
--------------------	------------------	---------	-----	--------------	----------

SUSPENSION;ORAL
NYSTATIN

AA @ G AND W LABS INC	100,000 UNITS/ML	A210532	001	Apr 30, 2018	Apr NEWA
-----------------------	------------------	---------	-----	--------------	----------

AA LANNETT CO INC

AA @ SOCORRO	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Jan DISC
--------------	------------------	---------	-----	--------------	----------

AA @ SOCORRO

AA @ ODYSSEY PHARMS	100,000 UNITS/ML	A065148	001	Jun 28, 2005	May CAHN
---------------------	------------------	---------	-----	--------------	----------

TABLET;VAGINAL
NYSTATIN

AA @ ODYSSEY PHARMS	100,000 UNITS	A062832	001	Dec 27, 1991	Jun CAHN
---------------------	---------------	---------	-----	--------------	----------

AA @ ODYSSEY PHARMS

AA @ ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985	Jun DISC
---------------------	---------------	---------	-----	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	AMNEAL PHARMS LLC	100,000 UNITS/GM;0.1%	A209990	001	Feb 15, 2018	Feb NEWA
AT	LUPIN LTD	100,000 UNITS/GM;0.1%	A208205	001	May 31, 2018	May NEWA
	OINTMENT;TOPICAL					
	NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Jan NEWA

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

>A> AP	USV NORTH AMERICA	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Aug NEWA
>A> AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Aug NEWA

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	ZYDUS PHARMS USA INC	2.5MG	A090459	001	Jul 16, 2018	Jul NEWA
AB		5MG	A090459	002	Jul 16, 2018	Jul NEWA
AB		7.5MG	A090459	003	Jul 16, 2018	Jul NEWA
AB		10MG	A090459	004	Jul 16, 2018	Jul NEWA
AB		15MG	A090459	005	Jul 16, 2018	Jul NEWA
AB		20MG	A090459	006	Jul 16, 2018	Jul NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	HEC PHARM	5MG	A208146	001	Jul 02, 2018	Jul CAHN
AB		10MG	A208146	002	Jul 02, 2018	Jul CAHN
AB		15MG	A208146	003	Jul 02, 2018	Jul CAHN
AB		20MG	A208146	004	Jul 02, 2018	Jul CAHN
AB	HEC PHARM CO LTD	5MG	A208146	001	Jul 02, 2018	Jun NEWA
AB		10MG	A208146	002	Jul 02, 2018	Jun NEWA
AB		15MG	A208146	003	Jul 02, 2018	Jun NEWA
AB		20MG	A208146	004	Jul 02, 2018	Jun NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	SCIEGEN PHARMS INC	5MG	A208130	001	Jun 29, 2018	Jun NEWA
AB		20MG	A208130	002	Jun 29, 2018	Jun NEWA
AB		40MG	A208130	003	Jun 29, 2018	Jun NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar NEWA
AT	MYLAN PHARMS INC	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CAHN

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+ @ ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	Jun DISC
------------------------	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	MYLAN PHARMS INC	10MG	A205070	001	Jun 29, 2018	Jun NEWA
AB		20MG	A205070	002	Jun 29, 2018	Jun NEWA
AB		40MG	A205070	003	Jun 29, 2018	Jun NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	ZYDUS PHARMS USA INC	20MG;1.1GM	A203290	001	May 25, 2018	May NEWA
AB		40MG;1.1GM	A203290	002	May 25, 2018	May NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@ CHARTWELL MOLECULES 4MG
@ 8MGA077406 003 Dec 26, 2006 Mar CMS1
A077406 004 Dec 26, 2006 Mar CMS1ONDANSETRON HYDROCHLORIDE

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB CASI PHARMS INC EQ 4MG BASE A077517 001 Jun 25, 2007 Mar CAHN
AB EQ 8MG BASE A077517 002 Jun 25, 2007 Mar CAHN
AB EQ 24MG BASE A077517 003 Jun 25, 2007 Mar CAHNORITAVANCIN DIPHOSPHATE

POWDER;IV (INFUSION)

ORBACTIV

+! MELINTA EQ 400MG BASE/VIAL N206334 001 Aug 06, 2014 Jan CAHN
+! MELINTA THERAP EQ 400MG BASE/VIAL N206334 001 Aug 06, 2014 Mar CAHNOSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB HETERO LABS LTD III EQ 30MG BASE A209438 001 Feb 23, 2018 Feb NEWA
AB EQ 45MG BASE A209438 002 Feb 23, 2018 Feb NEWA
AB EQ 75MG BASE A209438 003 Feb 23, 2018 Feb NEWA
AB STRIDES PHARMA EQ 30MG BASE A209421 001 Jun 08, 2018 May NEWA
AB EQ 45MG BASE A209421 002 Jun 08, 2018 May NEWA
AB EQ 75MG BASE A209421 003 Jun 08, 2018 May NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE
>A> AB AMNEAL PHARMS NY EQ 6MG BASE/ML A210186 001 Feb 27, 2018 Aug NEWA
AB LUPIN ATLANTIS EQ 6MG BASE/ML A208347 001 Feb 20, 2018 Feb NEWAOXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP ! SAGENT PHARMS EQ 1GM BASE/VIAL A091246 001 Mar 30, 2012 Jun CHRS
AP ! EQ 2GM BASE/VIAL A091246 002 Mar 30, 2012 Jun CHRS
AP ! EQ 10GM BASE/VIAL A091245 001 Mar 30, 2012 Jun CHRS
@ SANDOZ EQ 1GM BASE/VIAL A061490 003 May DISC
@ EQ 2GM BASE/VIAL A061490 004 May DISC
@ EQ 10GM BASE/VIAL A061490 006 May 09, 1991 May DISC

POWDER;INTRAVENOUS
OXACILLIN SODIUM
@ SANDOZ EQ 1GM BASE/VIAL A062737 001 Dec 23, 1986 May DISC
@ EQ 2GM BASE/VIAL A062737 002 Dec 23, 1986 May DISCOXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

AP ACTAVIS LLC 50MG/10ML (5MG/ML) A204880 001 Mar 05, 2018 Feb NEWA
AP 100MG/20ML (5MG/ML) A204880 002 Mar 05, 2018 Feb NEWA
AP EUGIA PHARMA 50MG/10ML (5MG/ML) A205529 001 Sep 06, 2017 Apr CAHN
AP 100MG/20ML (5MG/ML) A205529 002 Sep 06, 2017 Apr CAHNOXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB TARO PHARMS EQ 1% BASE A205076 001 Mar 07, 2016 May CAHN

>D> OXTRIPTYLLINE

>D> TABLET, EXTENDED RELEASE;ORAL

>D> CHOLEDYL SA

>D> ! WARNER CHILCOTT LLC 400MG A087863 001 May 24, 1983 Aug DISC
>A> @ 400MG A087863 001 May 24, 1983 Aug DISC

OXYBUTYNIN CHLORIDE

	GEL; TRANSDERMAL GELNIQUE						
AB	+! ALLERGAN SALES LLC OXYBUTYNIN CHLORIDE	10% (100MG/PACKET)		N 022204	001	Jan 27, 2009	May CFTG
AB	PAR PHARM INC SYRUP; ORAL OXYBUTYNIN CHLORIDE	10% (100MG/PACKET)		A 207329	001	May 31, 2018	May NEWA
AA	LANNETT CO INC TABLET; ORAL OXYBUTYNIN CHLORIDE	5MG/5ML		A 076682	001	Dec 28, 2004	May CAHN
>A> AB	TULEX PHARMS INC TABLET, EXTENDED RELEASE; ORAL DITROPAN XL	5MG		A 210125	001	Sep 06, 2018	Aug NEWA
AB	+ JANSSEN PHARMS + @	5MG 5MG		N 020897	001	Dec 16, 1998	Jun CMFD
AB	+ + @	10MG 10MG		N 020897	002	Dec 16, 1998	Jun CMFD
AB	OXYBUTYNIN CHLORIDE			N 020897	002	Dec 16, 1998	Feb DISC
AB	! MYLAN PHARMS INC	15MG		A 076644	002	May 10, 2007	Feb CHRS

OXYCODONE HYDROCHLORIDE

	CAPSULE; ORAL OXYCODONE HYDROCHLORIDE						
AB	+! GENUS LIFESCIENCES SOLUTION; ORAL OXYCODONE HYDROCHLORIDE	5MG		N 200534	001	Oct 20, 2010	Apr CAHN
AA	+ GENUS LIFESCIENCES	5MG/5ML		N 200535	002	Aug 22, 2013	Apr CAHN
AA	+!	100MG/5ML		N 200535	001	Oct 20, 2010	Apr CAHN
AA	SPECGX LLC	5MG/5ML		A 210758	001	Apr 30, 2018	Apr NEWA
AA		100MG/5ML		A 210758	002	Apr 30, 2018	Apr NEWA

OXYMORPHONE HYDROCHLORIDE

	TABLET; ORAL OXYMORPHONE HYDROCHLORIDE						
AB	ASCENT PHARMS INC	5MG		A 210175	001	Feb 02, 2018	Jan NEWA
AB		10MG		A 210175	002	Feb 02, 2018	Jan NEWA
	TABLET, EXTENDED RELEASE; ORAL OXYMORPHONE HYDROCHLORIDE						
!	IMPAX LABS	40MG		A 079087	007	Jun 14, 2010	Jun CHRS

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

	OINTMENT; OPHTHALMIC TERRAMYCIN W/ POLYMYXIN B SULFATE						
@	CASPER PHARMA LLC	EQ 5MG BASE/GM; 10,000 UNITS/GM		N 061015	001		Jul DISC
!		EQ 5MG BASE/GM; 10,000 UNITS/GM		N 061015	001		Feb CMS2

OXYTOCIN

	INJECTABLE; INJECTION OXYTOCIN						
AP	SAGENT PHARMS	10USP UNITS/ML (10USP UNITS/ML)		A 091676	001	Jul 13, 2018	Jul NEWA
AP		100USP UNITS/10ML (10USP UNITS/ML)		A 091676	002	Jul 13, 2018	Jul NEWA

PACLITAXEL

	INJECTABLE; INJECTION PACLITAXEL						
>A> AP	ACCORD HLTHCARE	6MG/ML		A 205720	001	Aug 17, 2018	Aug NEWA

PALIPERIDONE

	TABLET, EXTENDED RELEASE; ORAL PALIPERIDONE						
AB	SUN PHARMA GLOBAL	1.5mg		A 205618	001	Apr 06, 2018	Mar NEWA
AB		3MG		A 205618	002	Apr 06, 2018	Mar NEWA
AB		6MG		A 205618	003	Apr 06, 2018	Mar NEWA
AB		9MG		A 205618	004	Apr 06, 2018	Mar NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Mar NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Mar 23, 2018	Mar NEWA

PANCRELIPIASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

+	JANSSEN PHARMS	24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Mar CPOT
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Mar CPOT
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Mar CPOT
+		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Mar CPOT
+	VIVUS INC	10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS	N022523	005	Mar 07, 2014	Jun CAHN
+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Jun CAHN
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Jun CAHN
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Jun CAHN
+		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Jun CAHN

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PROTONIX

+	WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jul CAHN
		INJECTABLE; IV (INFUSION)				
		PANTOPRAZOLE SODIUM				
AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Apr NEWA
		PROTONIX IV				
AP	+! WYETH PHARMS	EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001	Jul CAHN
		TABLET, DELAYED RELEASE; ORAL				
		PANTOPRAZOLE SODIUM				
	@ SUN PHARM IND'S LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr DISC
	@	EQ 40MG BASE	A200794	002	May 02, 2012	Apr DISC
		PROTONIX				
AB	+ WYETH PHARMS	EQ 20MG BASE	N020987	002	Jun 12, 2001	Jul CAHN
AB	+!	EQ 40MG BASE	N020987	001	Feb 02, 2000	Jul CAHN

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Jun CAHN
AB		2MCG	A206710	002	Feb 24, 2016	Jun CAHN
AB		4MCG	A206710	003	Feb 24, 2016	Jun CAHN

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	SCIECURE PHARMA INC	EQ 12.5MG BASE	A209293	001	Jun 12, 2018	May NEWA
AB		EQ 25MG BASE	A209293	002	Jun 12, 2018	May NEWA
AB		EQ 37.5MG BASE	A209293	003	Jun 12, 2018	May NEWA

PASIREOTIDE PAMOATE

FOR SUSPENSION; INTRAMUSCULAR

SIGNIFOR LAR KIT

+	NOVARTIS PHARMS CORP	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Jun NEWA
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun CDFR
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Jun NEWA
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun CDFR
+		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun CDFR
		POWDER; INTRAMUSCULAR				
		SIGNIFOR LAR KIT				
+	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun CTNA
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun CTNA

	POWDER; INTRAMUSCULAR SIGNIFOR LAR KIT +!	EQ 60MG BASE/VIAL	N 203255 003 Dec 15, 2014	Jun CTNA
>A>	<u>PATISIRAN SODIUM</u>			
>A>	SOLUTION; INTRAVENOUS ONPATRO			
>A>	+! ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N 210922 001 Aug 10, 2018	Aug NEWA
	<u>PEGADEMASE BOVINE</u>			
	INJECTABLE; INJECTION ADAGEN +! LEADIANT BIOSCI INC	250 UNITS/ML	N 019818 001 Mar 21, 1990	Jun CAHN
	<u>PEMETREXED DISODIUM</u>			
	POWDER; INTRAVENOUS ALIMTA +! LILLY +!	EQ 100MG BASE/VIAL EQ 500MG BASE/VIAL	N 021462 002 Sep 07, 2007 N 021462 001 Feb 04, 2004	Jun CDFR Jun CDFR
	<u>PEMOLINE</u>			
	TABLET; ORAL PEMOLINE @ FOSUN PHARMA @ @	18.75MG 37.5MG 75MG	A 075286 001 Dec 27, 1999 A 075286 002 Jun 30, 1999 A 075286 003 Jun 30, 1999	Jan CAHN Jan CAHN Jan CAHN
	<u>PENICILLIN G BENZATHINE</u>			
	INJECTABLE; INJECTION BICILLIN L-A + @ KING PHARMS LLC PERMAPEN @ CASPER PHARMA LLC	300,000 UNITS/ML 600,000 UNITS/ML 600,000 UNITS/ML	N 050141 003 N 060014 001 N 060014 001	Jun DISC Jul DISC Feb CMS2
BC	<u>PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE</u>			
	INJECTABLE; INJECTION BICILLIN C-R + @ KING PHARMS LLC	150,000 UNITS/ML; 150,000 UNITS/ML	N 050138 002	Jun DISC
	<u>PENTAZOCINE LACTATE</u>			
	INJECTABLE; INJECTION TALWIN + @ HOSPIRA	EQ 30MG BASE/ML	N 016194 001	Jun DISC
	<u>PERAMIVIR</u>			
	SOLUTION; INTRAVENOUS RAPIVAB +! BIOCRYST	200MG/20ML (10MG/ML)	N 206426 001 Dec 19, 2014	Jun CDFR
	<u>PERINDOPRIL ERBUMINE</u>			
	TABLET; ORAL PERINDOPRIL ERBUMINE @ APOTEX @ @	2MG 4MG 8MG	A 090463 001 Aug 30, 2010 A 090463 002 Aug 30, 2010 A 090463 003 Aug 30, 2010	Jan DISC Jan DISC Jan DISC
AB	AUROBINDO PHARMA	2MG 4MG	A 079070 001 Nov 10, 2009 A 079070 002 Nov 10, 2009	Mar CHRS Mar CHRS
	<u>PHENDIMETRAZINE TARTRATE</u>			
	CAPSULE; ORAL PHENDIMETRAZINE TARTRATE @ VIRTUS PHARMS	35MG	A 085695 001	May CAHN
	CAPSULE, EXTENDED RELEASE; ORAL PHENDIMETRAZINE TARTRATE @ VIRTUS PHARMS	105MG	A 087378 001	May CAHN
	+!	105MG	N 018074 001	Mar CAHN
	TABLET; ORAL PHENDIMETRAZINE TARTRATE @ VIRTUS PHARMS	35MG	A 085497 001	May CAHN
AA		35MG	A 085588 001	Mar CAHN

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

@ 35MG

A086365 001

May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ ELITE LABS INC 15MG

A040460 001 Jan 14, 2003 Jan CAHN

PHENYLBUTAZONE

CAPSULE;ORAL

PHENYLBUTAZONE

@ FOSUN PHARMA 100MG

A087774 001 Jun 16, 1982 Jan CAHN

TABLET;ORAL

PHENYLBUTAZONE

@ FOSUN PHARMA 100MG

A084339 001 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP	AMNEAL PHARMS CO	10MG/ML (10MG/ML)	A211079	001	Jul 05, 2018	Jun NEWA
AP		50MG/5ML (10MG/ML)	A211078	001	Jul 19, 2018	Jul NEWA
AP		100MG/10ML (10MG/ML)	A211078	002	Jul 19, 2018	Jul NEWA
AP	CIPLA LTD	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun CDFR
AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun CDFR
AP	+! WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jun CDFR
	PHENYLEPHRINE HYDROCHLORIDE					
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun CDFR
	VAZCULEP					
AP	+ AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun CTEC
		10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun CDFR
AP	+	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun CDFR
AP	+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun CDFR
	SOLUTION;IV (INFUSION)					
	PHENYLEPHRINE HYDROCHLORIDE					
AP	CIPLA LTD	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Apr NEWA
AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Apr NEWA
AP	+! WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Apr CFTG
	PHENYLEPHRINE HYDROCHLORIDE					
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Apr NEWA
	VAZCULEP					
AP	+ AVADEL LEGACY	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Apr CFTG
AP	+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Apr CFTG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	! VINTAGE	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	Jan CHRS
	PROMETH VC PLAIN		A088761	001	Nov 08, 1984	Jan DISC
	@ G AND W LABS INC	5MG/5ML; 6.25MG/5ML				

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

AB	WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan CAHN
----	------------------	-----------	---------	-----	--------------	----------

PHYTONADIONE

TABLET;ORAL

MEPHYTON

AB	+! VALEANT PHARMS	5MG	N010104	003		Apr CFTG
	PHYTONADIONE		A209373	001	May 11, 2018	Apr NEWA
	AMNEAL PHARMS CO	5MG				

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

+! ACADIA PHARMS INC

EQ 34MG BASE

N210793 001 Jun 28, 2018 Jun NEWA

TABLET;ORAL

NUPLAZID

+! ACADIA PHARMS INC

EQ 10MG BASE

N207318 002 Jun 28, 2018 Jun NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

>D>	AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383	001	Mar 12, 2013	Aug CAHN
>D>	AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Aug CAHN
>D>	AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Aug CAHN
>A>	AB	NEOPHARMA	EQ 15MG BASE	A078383	001	Mar 12, 2013	Aug CAHN
>A>	AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Aug CAHN
>A>	AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Aug CAHN
AB		PRINSTON INC	EQ 15MG BASE	A207806	001	Apr 17, 2018	Apr NEWA
AB			EQ 30MG BASE	A207806	002	Apr 17, 2018	Apr NEWA
AB			EQ 45MG BASE	A207806	003	Apr 17, 2018	Apr NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>A>	AP	APOLLO PHARMS INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Aug NEWA
AP		FRESENIUS KABI	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A203719	001	May 18, 2018	May NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A203719	002	May 18, 2018	May NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A203719	003	May 18, 2018	May NEWA
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203720	001	May 11, 2018	Apr NEWA
AP		FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Apr NEWA
AP		QILU TIANHE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Jul NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Jul NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Jul NEWA
AP		SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Apr CDFR
AP		WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CPOT
		ZOSYN					
>A>	AP	+! WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Aug CAHN
>A>	AP	+!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Aug CAHN
>A>	AP	+!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Aug CAHN
>A>	AP	+!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Aug CAHN
>D>	AP	+! WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Aug CAHN
>D>	AP	+!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Aug CAHN
>D>	AP	+!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Aug CAHN
>D>	AP	+!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Aug CAHN
		ZOSYN IN PLASTIC CONTAINER					
>A>		+! WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Aug CAHN
>A>		+!	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Aug CAHN
>A>		+!	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Aug CAHN
>D>		+! WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Aug CAHN
>D>		+!	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Aug CAHN
>D>		+!	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Aug CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb NEWA
AB			20MG	A208991	002	Feb 21, 2018	Feb NEWA
AB		MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb CRLD
AB			20MG	A206152	002	Dec 29, 2017	Feb CRLD
AB		STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan NEWA
AB			20MG	A210347	002	Jan 26, 2018	Jan NEWA
AB		ZYDUS PHARMS USA INC	10MG	A205585	001	Jul 17, 2018	Jul NEWA
AB			20MG	A205585	002	Jul 17, 2018	Jul NEWA

PLAZOMICIN SULFATE

SOLUTION; INTRAVENOUS

ZEMDRI

+! ACHAOPEN INC

EQ 500MG BASE/10ML (EQ 50MG
BASE/ML)

N210303 001 Jun 25, 2018 Jun NEWA

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

+! PROVENSIS

77.5MG/7.75ML (10MG/ML)

N205098 002 Dec 21, 2017 Jan CDFR

POSACONAZOLE

>A> SOLUTION; INTRAVENOUS

>A> NOXAFL

>A> +! MERCK SHARP DOHME

300MG/16.7ML (18MG/ML)

N205596 001 Mar 13, 2014 Aug CDFR

>D> SOLUTION; IV (INFUSION)

>D> NOXAFL

>D> +! MERCK SHARP DOHME

300MG/16.7ML (18MG/ML)

N205596 001 Mar 13, 2014 Aug CDFR

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
MICRO-K+ @ NESHER PHARMS
MICRO-K 10

8MEQ

N018238 001 Apr DISC

+ @ NESHER PHARMS
SOLUTION; ORAL
POTASSIUM CHLORIDE

10MEQ

N018238 002 May 14, 1984 Apr DISC

AA AMNEAL PHARMS LLC

20MEQ/15ML

A210041 001 Jul 19, 2018 Jul NEWA

AA 40MEQ/15ML

A210041 002 Jul 19, 2018 Jul NEWA

AA APOTEX INC

20MEQ/15ML

A211067 001 Aug 08, 2018 Jul NEWA

AA 40MEQ/15ML

A211067 002 Aug 08, 2018 Jul NEWA

AA + GENUS LIFESCIENCES

20MEQ/15ML

N206814 001 Dec 22, 2014 Jul CFTG

AA +!

40MEQ/15ML

N206814 002 Dec 22, 2014 Jul CFTG

>A> AA NOVEL LABS INC

20MEQ/15ML

A209786 001 Aug 29, 2018 Aug NEWA

>A> AA 40MEQ/15ML

A209786 002 Aug 29, 2018 Aug NEWA

TABLET, EXTENDED RELEASE; ORAL
K-TAB

AB3 + ABBVIE

10MEQ

N018279 001 Jan CTEC

AB2 +!

20MEQ

N018279 003 Nov 25, 2013 Jan CTEC

POTASSIUM CHLORIDE

AB3 PADDOCK LLC

10MEQ

A209688 001 Jan 12, 2018 Jan NEWA

AB2 20MEQ

20MEQ

A209688 002 Jan 12, 2018 Jan NEWA

>A> AB2 STRIDES PHARMA

8MEQ

A210733 001 Aug 31, 2018 Aug NEWA

>A> AB2 10MEQ

10MEQ

A210733 002 Aug 31, 2018 Aug NEWA

AB2 YICHANG HUMANWELL

8MEQ

A209314 001 Jun 22, 2018 Jun NEWA

AB2 10MEQ

10MEQ

A209314 002 Jun 22, 2018 Jun NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%

+ @ BAXTER HLTHCARE

224MG/100ML; 900MG/100ML

N017648 003 Jun DISC

POTASSIUM CITRATETABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

AB MOUNTAIN

5MEQ

A077440 001 Jun 09, 2006 Jan CAHN

AB 10MEQ

10MEQ

A077440 002 Jun 09, 2006 Jan CAHN

AB TEVA PHARMS USA INC

5MEQ

A209758 001 Mar 05, 2018 Feb NEWA

AB 10MEQ

10MEQ

A209758 002 Mar 05, 2018 Feb NEWA

AB 15MEQ

15MEQ

A209758 003 Mar 05, 2018 Feb NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

AB ACCORD HLTHCARE

EQ 5MG BASE

A205987 001 Feb 02, 2018 Jan NEWA

AB EQ 10MG BASE

EQ 10MG BASE

A205987 002 Feb 02, 2018 Jan NEWA

AB AMNEAL PHARMS

EQ 5MG BASE

A205913 001 Jun 19, 2018 Jun NEWA

AB EQ 10MG BASE

EQ 10MG BASE

A205913 002 Jun 19, 2018 Jun NEWA

AB USPHARMA WINDLAS

EQ 5MG BASE

A205790 001 Oct 16, 2017 Jan CAHN

AB EQ 10MG BASE

EQ 10MG BASE

A205790 002 Oct 16, 2017 Jan CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	APPCO PHARMA LLC	10MG	A209869	001	Apr 13, 2018	Apr NEWA
AB		20MG	A209869	002	Apr 13, 2018	Apr NEWA
AB		40MG	A209869	003	Apr 13, 2018	Apr NEWA
AB		80MG	A209869	004	Apr 13, 2018	Apr NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	May CAHN
	TABLET;ORAL					
	PREDNISOLONE					
	@ FOSUN PHARMA	5MG	A080339	001		Jan CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	! WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN
	SOLUTION/DROPS;OPHTHALMIC					
	PREDNISOLONE SODIUM PHOSPHATE					
	@ BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994	Apr CAHN

PREDNISONE

TABLET;ORAL

PREDNISONE

@ HIKMA PHARMS

2.5MG

A040538 001 Jan 08, 2004 May DISC

PREGABALINTABLET, EXTENDED RELEASE;ORAL
LYRICA CR

>A>	+ PF PRISM CV	82.5MG	N209501	001	Oct 11, 2017	Aug CAHN
>A>	+	165MG	N209501	002	Oct 11, 2017	Aug CAHN
>A>	+!	330MG	N209501	003	Oct 11, 2017	Aug CAHN
>D>	+ PFIZER INC	82.5MG	N209501	001	Oct 11, 2017	Aug CAHN
>D>	+	165MG	N209501	002	Oct 11, 2017	Aug CAHN
>D>	+!	330MG	N209501	003	Oct 11, 2017	Aug CAHN

PRILOCAINE HYDROCHLORIDEINJECTABLE;INJECTION
CITANESE PLAIN DENTAL
+ @ DENTSPLY PHARM

4%

N021382 001

May CRLD

PRIMIDONE

TABLET;ORAL

PRIMIDONE

AB	OXFORD PHARMS	50MG	A040586	001	Feb 24, 2005	Jul CAHN
AB		250MG	A040586	002	Feb 24, 2005	Jul CAHN

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB	INDICUS PHARMA	225MG	A205956	001	Jul 02, 2018	Jun NEWA
AB		325MG	A205956	002	Jul 02, 2018	Jun NEWA
AB		425MG	A205956	003	Jul 02, 2018	Jun NEWA
AB	WILSHIRE PHARMS INC	225MG	A205956	001	Jul 02, 2018	Jul CAHN
AB		325MG	A205956	002	Jul 02, 2018	Jul CAHN
AB		425MG	A205956	003	Jul 02, 2018	Jul CAHN

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB	! VINTAGE PHARMS	300MG	A075938	003	Oct 17, 2002	Jul CHRS
	RYTHMOL					
+ @ GLAXOSMITHKLINE LLC	150MG		N019151	001	Nov 27, 1989	Jul DISC
+ @	225MG		N019151	003	Nov 20, 1992	Jul DISC
+ @	300MG		N019151	002	Nov 27, 1989	Jul DISC

PROPARACAINA HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC	ALCAINE			
@ ALCON LABS INC	0.5%	A080027	001	May DISC
AT !	0.5%	A080027	001	Feb CAHN
PROPARACAINA HYDROCHLORIDE				
AT !	AKORN INC	0.5%	A040277	001 Mar 16, 2000 May CHRS

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL	PROPRANOLOL HYDROCHLORIDE			
@ MYLAN	60MG	A078022	001 Feb 15, 2007 Jun DISC	
@	80MG	A078022	002 Feb 15, 2007 Jun DISC	
@	120MG	A078022	003 Feb 15, 2007 Jun DISC	
@	160MG	A078022	004 Feb 15, 2007 Jun DISC	
INJECTABLE;INJECTION				
PROPRANOLOL HYDROCHLORIDE				
+ @ BAXTER HLTHCARE CORP	1MG/ML	N016419	001	Jul DISC
@ FOSUN PHARMA	1MG/ML	A076400	001 Feb 26, 2003 Jan CAHN	
! HIKMA FARMACEUTICA	1MG/ML	A077760	001 Jan 31, 2008 Jul CHRS	
TABLET;ORAL				
PROPRANOLOL HYDROCHLORIDE				
AB IMPAX LABS INC	20MG	A071972	002 Apr 06, 1988 May CMS1	
AB	40MG	A071972	003 Apr 06, 1988 May CMS1	
AB	60MG	A071976	002 May 13, 1986 May CMS1	
AB WATSON LABS	60MG	A070178	002 Apr 23, 2018 Jul NEWA	
@ YAOPHARMA CO LTD	10MG	A070663	001 Jun 13, 1986 Jan CAHN	
@	20MG	A070664	001 Jun 13, 1986 Jan CAHN	
@	40MG	A070665	001 Jun 13, 1986 Jan CAHN	
@	60MG	A070666	001 Oct 10, 1986 Jan CAHN	
@	80MG	A070667	001 Jun 13, 1986 Jan CAHN	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL	CORPHED			
@ FOSUN PHARMA	60MG;2.5MG	A088602	001 Apr 11, 1985 Jan CAHN	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL	PYRIDOSTIGMINE BROMIDE			
AB INVATECH PHARMA	60MG	A211181	001 Jul 20, 2018 Jul NEWA	

PYRIMETHAMINE

TABLET;ORAL	DARAPRIM			
+! VYERA PHARMS LLC	25MG	N008578	001	Jan CAHN

QUAZEPAM

TABLET;ORAL	DORAL			
@ GALT PHARMS	7.5MG	N018708	003 Feb 26, 1987 Feb CAHN	
+!	15MG	N018708	001 Dec 27, 1985 Feb CAHN	

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL	QUINAPRIL HYDROCHLORIDE			
@ SUN PHARM INDs LTD	EQ 5MG BASE	A076607	001 Dec 15, 2004 Apr DISC	
@	EQ 10MG BASE	A076607	002 Dec 15, 2004 Apr DISC	
@	EQ 20MG BASE	A076607	003 Dec 15, 2004 Apr DISC	
@	EQ 40MG BASE	A076607	004 Dec 15, 2004 Apr DISC	
@ YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001 Mar 02, 2005 Jan CAHN	
@	EQ 10MG BASE	A076803	002 Mar 02, 2005 Jan CAHN	
@	EQ 20MG BASE	A076803	003 Mar 02, 2005 Jan CAHN	
@	EQ 40MG BASE	A076803	004 Mar 02, 2005 Jan CAHN	

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL	QUINIDINE SULFATE			
@ G AND W LABS INC	300MG	A040045	001 Jun 30, 1994 Jan DISC	

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLE

+ CERECOR INC	5MG	N204736	001	Mar 26, 2013	Feb CAHN
+! MERCK SHARP DOHME	10MG	N204736	002	Mar 26, 2013	Feb CAHN

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

AB ALKEM LABS LTD	20MG	A208644	001	Apr 24, 2018	Apr NEWA
-------------------	------	---------	-----	--------------	----------

RALTEGRAVIR POTASSIUM

TABLET;ORAL
ISENTRESS HD

+! MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May CHRS
----------------------	---------------	---------	-----	--------------	----------

RAMELTEON

TABLET;ORAL
RAMELTEON

AB DR REDDYS LABS SA	8MG	A091693	001	Jul 26, 2013	Mar CAHN
----------------------	-----	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

AB CHARTWELL MOLECULAR	1.25MG	A078745	001	Jun 18, 2008	Jun CAHN
AB	2.5MG	A078745	002	Jun 18, 2008	Jun CAHN
AB	5MG	A078745	003	Jun 18, 2008	Jun CAHN
AB	10MG	A078745	004	Jun 18, 2008	Jun CAHN
@ WATSON LABS	5MG	A076549	003	Oct 24, 2005	Mar DISC
@ YAOPHARMA CO LTD	1.25MG	A077514	001	Jun 18, 2008	Jan CAHN
@	2.5MG	A077514	002	Jun 18, 2008	Jan CAHN
@	5MG	A077514	003	Jun 18, 2008	Jan CAHN
@	10MG	A077514	004	Jun 18, 2008	Jan CAHN

TABLET;ORAL
RAMIPRIL

@ APOTEX INC	1.25MG	A091069	001	Dec 02, 2015	May DISC
@	2.5MG	A091069	002	Dec 02, 2015	May DISC
@	5MG	A091069	003	Dec 02, 2015	May DISC
@	10MG	A091069	004	Dec 02, 2015	May DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL
RANITIDINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD	EQ 150MG BASE	A211058	001	Jul 16, 2018	Jul NEWA
AB	EQ 300MG BASE	A211058	002	Jul 16, 2018	Jul NEWA

SYRUP;ORAL
RANITIDINE HYDROCHLORIDE

AA LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010	May CAHN
AA ! PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Jul CHRS
ZANTAC					
+ @ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988	Jul DISC

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

AB ! AMNEAL PHARMS NY	EQ 300MG BASE	A077824	002	Oct 13, 2006	Jul CHRS
AB VIVIMED GLOBAL	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jul NEWA
AB	EQ 300MG BASE	A210010	002	Aug 01, 2018	Jul NEWA
ZANTAC 150					
+ @ GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Apr DISC
ZANTAC 300					
+ @ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jul DISC

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

@ APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Mar DISC
@	EQ 1MG BASE	A201950	002	Sep 12, 2013	Mar DISC

AB SANDOZ INC	EQ 0.5MG BASE	A201892	001	Jul 27, 2018	Jul NEWA
AB	EQ 1MG BASE	A201892	002	Jul 27, 2018	Jul NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

REMIFENTANIL HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	A206223	001	Jan 16, 2018	Jan NEWA
AP		EQ 2MG BASE/VIAL	A206223	002	Jan 16, 2018	Jan NEWA
AP		EQ 5MG BASE/VIAL	A206223	003	Jan 16, 2018	Jan NEWA
	ULTIVA					
AP	+ MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996	Jan CFTG
AP	+ !	EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996	Jan CFTG
AP		EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996	Jan CFTG

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB	CASI PHARMS INC	0.5MG	A078555	001	Nov 22, 2013	Mar CAHN
AB		1MG	A078555	002	Jan 22, 2014	Mar CAHN
AB		2MG	A078555	003	Jan 22, 2014	Mar CAHN

RIBAVIRIN

CAPSULE; ORAL

RIBAVIRIN

AB	CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Mar CAHN
	TABLET; ORAL COPEGUS @ ROCHE	200MG	N021511	001	Dec 03, 2002	Apr DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE; ORAL

RISEDRONATE SODIUM

AB	IMPAK LABS INC	35MG	A205066	001	Jun 29, 2018	Jun NEWA
>A> AB	ZYDUS PHARMS USA INC	35MG	A203822	001	Sep 11, 2018	Aug NEWA

RISPERIDONEFOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
PERSERIS KIT

+ INDIVIOR INC	90MG	N210655	001	Jul 27, 2018	Jul NEWA
+ !	120MG	N210655	002	Jul 27, 2018	Jul NEWA

SOLUTION; ORAL

RISPERIDONE

AA	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May CAHN
	TABLET; ORAL RISPERIDONE					
AB	CHARTWELL MOLECULAR	0.25MG	A077543	001	May 18, 2011	Mar CAHN
AB		0.5MG	A077543	002	May 18, 2011	Mar CAHN
AB		1MG	A077543	003	May 18, 2011	Mar CAHN
AB		2MG	A077543	004	May 18, 2011	Mar CAHN
AB		3MG	A077543	005	May 18, 2011	Mar CAHN
AB		4MG	A077543	006	May 18, 2011	Mar CAHN
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Jan CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Jan CAHN
AB		1MG	A078707	003	Dec 29, 2008	Jan CAHN
AB		2MG	A078707	004	Dec 29, 2008	Jan CAHN
AB		3MG	A078707	005	Dec 29, 2008	Jan CAHN
AB		4MG	A078707	006	Dec 29, 2008	Jan CAHN

RITONAVIR

CAPSULE; ORAL

NORVIR

+ @ ABBVIE	100MG	N020945	001	Jun 29, 1999	Apr DISC
------------	-------	---------	-----	--------------	----------

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

RIVASTIGMINE

AB	MYLAN TECHNOLOGIES	4.6MG/24HR	A205622	001	Jun 20, 2018	Jun NEWA
AB		9.5MG/24HR	A205622	002	Jun 20, 2018	Jun NEWA
AB		13.3MG/24HR	A205622	003	Jun 20, 2018	Jun NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL							
MAXALT							
+ @ MERCK	EQ 5MG BASE		N020864	001	Jun 29, 1998	Apr	DISC
RIZATRIPTAN BENZOATE			A202244	001	Dec 31, 2012	Mar	DISC
@ APOTEX INC	EQ 5MG BASE		A202244	002	Dec 31, 2012	Mar	DISC
@	EQ 10MG BASE						
TABLET, ORALLY DISINTEGRATING;ORAL							
MAXALT-MLT							
+ @ MERCK	EQ 5MG BASE		N020865	001	Jun 29, 1998	Apr	DISC
RIZATRIPTAN BENZOATE			A202477	001	Jul 01, 2013	Mar	DISC
@ APOTEX INC	EQ 5MG BASE		A202477	002	Jul 01, 2013	Mar	DISC
@	EQ 10MG BASE						

ROCURONIUM BROMIDE

INJECTABLE; INJECTION							
ROCURONIUM BROMIDE							
AP GLAND CHEMS PVT	50MG/5ML (10MG/ML)		A205656	001	Apr 04, 2018	Mar	NEWA
AP	100MG/10ML (10MG/ML)		A205656	002	Apr 04, 2018	Mar	NEWA
AP GLAND PHARMA LTD	50MG/5ML (10MG/ML)		A205656	001	Apr 04, 2018	Apr	CAHN
AP	100MG/10ML (10MG/ML)		A205656	002	Apr 04, 2018	Apr	CAHN

ROFLUMILAST

TABLET;ORAL							
DALIRESP							
+ ASTRAZENECA PHARMS	250MCG		N022522	002	Jan 23, 2018	Jan	NEWA
>D> AB +!	500MCG		N022522	001	Feb 28, 2011	Aug	CTEC
>A> +!	500MCG		N022522	001	Feb 28, 2011	Aug	CTEC
AB +!	500MCG		N022522	001	Feb 28, 2011	Jul	CFTG
ROFLUMILAST							
>D> AB MYLAN PHARMS INC	500MCG		A208257	001	Jul 13, 2018	Aug	DISC
>A> @	500MCG		A208257	001	Jul 13, 2018	Aug	DISC
AB	500MCG		A208257	001	Jul 13, 2018	Jul	NEWA
AB TORRENT PHARMS LTD	500MCG		A208272	001	Aug 06, 2018	Jul	NEWA

ROLAPITANT HYDROCHLORIDE

>A>	EMULSION; INTRAVENOUS						
>A>	VARUBI						
>A> + @ TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)		N208399	001	Oct 25, 2017	Aug	CDFR
>D>	EMULSION; IV (INFUSION)						
>D>	VARUBI						
>D> + @ TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)		N208399	001	Oct 25, 2017	Aug	CDFR
+ @	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)		N208399	001	Oct 25, 2017	Jul	CAHN
+ @ TESARO INC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)		N208399	001	Oct 25, 2017	Jun	DISC
TABLET;ORAL							
VARUBI							
+! TERSERA THERAPS LLC	EQ 90MG BASE		N206500	001	Sep 01, 2015	Jul	CAHN

ROMIDEPSIN

>A>	POWDER; INTRAVENOUS						
>A>	ISTODAX						
>A> +! CELGENE	10MG/VIAL		N022393	001	Nov 05, 2009	Aug	CDFR
>D>	POWDER; IV (INFUSION)						
>D>	ISTODAX						
>D> +! CELGENE	10MG/VIAL		N022393	001	Nov 05, 2009	Aug	CDFR

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL							
ROPINIROLE HYDROCHLORIDE							
@ G AND W LABS INC	EQ 0.25MG BASE		A077460	001	May 05, 2008	Jan	DISC
@	EQ 0.5MG BASE		A077460	002	May 05, 2008	Jan	DISC
@	EQ 1MG BASE		A077460	003	May 05, 2008	Jan	DISC
@	EQ 2MG BASE		A077460	004	May 05, 2008	Jan	DISC
@	EQ 3MG BASE		A077460	005	May 05, 2008	Jan	DISC
@	EQ 4MG BASE		A077460	006	May 05, 2008	Jan	DISC
@	EQ 5MG BASE		A077460	007	May 19, 2008	Jan	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

AP	+	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N 020533	007	Sep 24, 1996	Mar	CTEC
AP	+		500MG/100ML (5MG/ML)	N 020533	009	Jan 04, 2011	May	CTEC
AP	+		1GM/200ML (5MG/ML)	N 020533	010	Jan 04, 2011	May	CTEC
ROPIVACAINE HYDROCHLORIDE								
AP		AKORN	200MG/100ML (2MG/ML)	A 204636	001	Mar 16, 2018	Mar	NEWA
AP			400MG/200ML (2MG/ML)	A 204636	002	Mar 16, 2018	Mar	NEWA
AP		INFORLIFE	200MG/100ML (2MG/ML)	A 206166	001	Jun 11, 2018	May	NEWA
AP			400MG/200ML (2MG/ML)	A 206166	002	Jun 11, 2018	May	NEWA
AP			500MG/100ML (5MG/ML)	A 206166	003	Jun 11, 2018	May	NEWA
AP			1GM/200ML (5MG/ML)	A 206166	004	Jun 11, 2018	May	NEWA
AP		SOMERSET THERAPS LLC	20MG/10ML (2MG/ML)	A 207636	001	Jun 15, 2018	Jun	NEWA
AP			40MG/20ML (2MG/ML)	A 207636	002	Jun 15, 2018	Jun	NEWA
AP			100MG/20ML (5MG/ML)	A 207636	003	Jun 15, 2018	Jun	NEWA
AP			100MG/10ML (10MG/ML)	A 207636	006	Jun 15, 2018	Jun	NEWA
AP			150MG/30ML (5MG/ML)	A 207636	004	Jun 15, 2018	Jun	NEWA
AP			150MG/20ML (7.5MG/ML)	A 207636	005	Jun 15, 2018	Jun	NEWA
AP			200MG/20ML (10MG/ML)	A 207636	007	Jun 15, 2018	Jun	NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+ SB PHARMCO	EQ 2MG BASE	N 021071	002	May 25, 1999	Jul	CTEC
+	EQ 4MG BASE	N 021071	003	May 25, 1999	Jul	CTEC
+ @	EQ 8MG BASE	N 021071	004	May 25, 1999	Jul	DISC
ROSIGLITAZONE MALEATE						
@ TEVA	EQ 2MG BASE	A 076747	001	Jan 25, 2013	Jul	DISC
@	EQ 4MG BASE	A 076747	002	Jan 25, 2013	Jul	DISC
@	EQ 8MG BASE	A 076747	003	Jan 25, 2013	Jul	DISC

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

>A> AB	ALLIED	5MG	A 079168	001	Jul 19, 2016	Aug	CAHN
>A> AB		10MG	A 079168	002	Jul 19, 2016	Aug	CAHN
>A> AB		20MG	A 079168	003	Jul 19, 2016	Aug	CAHN
>A> AB		40MG	A 079168	004	Jul 19, 2016	Aug	CAHN
>D> AB	PAR PHARM INC	5MG	A 079168	001	Jul 19, 2016	Aug	CAHN
>D> AB		10MG	A 079168	002	Jul 19, 2016	Aug	CAHN
>D> AB		20MG	A 079168	003	Jul 19, 2016	Aug	CAHN
>D> AB		40MG	A 079168	004	Jul 19, 2016	Aug	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT	! PERRIGO NEW YORK	2.5%	A 089996	001	Jan 10, 1991	Jul	CHRS
	+ @ CHATTEM	2.5%	N 007936	001			Jul DISC

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ ACI HEALTHCARE LTD EQ 20MG BASE/ML

A 076934 001 Jun 30, 2006 May CAHN

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ CHARTWELL MOLECULAR EQ 25MG BASE

A 077162 001 Feb 06, 2007 Mar CAHN

@ EQ 50MG BASE

A 077162 002 Feb 06, 2007 Mar CAHN

@ EQ 100MG BASE

A 077162 003 Feb 06, 2007 Mar CAHN

@ FOSUN PHARMA EQ 25MG BASE

A 077713 001 Feb 06, 2007 Jan CAHN

@ EQ 50MG BASE

A 077713 002 Feb 06, 2007 Jan CAHN

@ EQ 100MG BASE

A 077713 003 Feb 06, 2007 Jan CAHN

SEVELAMER CARBONATE

TABLET; ORAL

RENVELA

>D> AB	+! GENZYME	800MG	N 022127	001	Oct 19, 2007	Aug	CAHN
>A> AB	+! SANOFI	800MG	N 022127	001	Oct 19, 2007	Aug	CAHN
	SEVELAMER CARBONATE						
AB	SANDOZ INC	800MG	A 200959	001	Mar 20, 2018	Mar	NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A210394	001	May 04, 2018	Apr NEWA
AB	AMNEAL PHARMS NY	EQ 25MG BASE	A202023	001	Jun 27, 2018	Jun NEWA
AB		EQ 50MG BASE	A202023	002	Jun 27, 2018	Jun NEWA
AB		EQ 100MG BASE	A202023	003	Jun 27, 2018	Jun NEWA
	@ APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar DISC
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A203962	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A203962	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A203962	003	Jun 11, 2018	May NEWA
AB	HETERO LABS LTD V	EQ 25MG BASE	A202659	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A202659	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A202659	003	Jun 11, 2018	May NEWA
AB	RUBICON RES PVT LTD	EQ 25MG BASE	A204882	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A204882	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A204882	003	Jun 11, 2018	May NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A091448	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A091448	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A091448	003	Jun 11, 2018	May NEWA

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD AF

@ DR REDDYS LA

1%

N018578 003 Jul 11, 1990 Jun DISC

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+ @ JANSSEN PRODS

EQ 150MG BASE

N205123 001 Nov 22, 2013 May DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

>D>	@ HISUN PHARM	10MG	A206557	001	Nov 13, 2017	Aug CAHN
	@	10MG	A206557	001	Nov 13, 2017	May DISC
>D>	@	20MG	A206557	002	Nov 13, 2017	Aug CAHN
	@	20MG	A206557	002	Nov 13, 2017	May DISC
>D>	@	40MG	A206557	003	Nov 13, 2017	Aug CAHN
	@	40MG	A206557	003	Nov 13, 2017	May DISC
>D>	@	80MG	A206557	004	Nov 13, 2017	Aug CAHN
	@	80MG	A206557	004	Nov 13, 2017	May DISC
>A>	@ HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Aug CAHN
>A>	@	20MG	A206557	002	Nov 13, 2017	Aug CAHN
>A>	@	40MG	A206557	003	Nov 13, 2017	Aug CAHN
>A>	@	80MG	A206557	004	Nov 13, 2017	Aug CAHN
	@ YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan CAHN
	@	10MG	A077766	002	Dec 20, 2006	Jan CAHN
	@	20MG	A077766	003	Dec 20, 2006	Jan CAHN
	@	40MG	A077766	004	Dec 20, 2006	Jan CAHN
	@	80MG	A077766	005	Dec 20, 2006	Jan CAHN

SINECATECHINS

OINTMENT;TOPICAL

VEREGEN

+! FOUGERA PHARMS INC 15%

N021902 001 Oct 31, 2006 Jan CAHN

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

AMMONUL

AP	+! MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	May CDFR
	SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	May CDFR
AP	MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017	May CDFR
AP	NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	May CDFR

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

@ HOSPIRA INC 0.5MEQ/ML
@ 0.5MEQ/MLA202679 001 Mar 07, 2017 Mar DISC
A202981 001 Mar 04, 2016 Mar DISCSODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	450MG/100ML	A208122	001	Jul 23, 2018	Jul NEWA
	SODIUM CHLORIDE 0.9%					
	+ @ MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun CRLD
	+ @	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun CRLD
	+ @	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun CRLD
	+ @	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun CRLD
	+	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Jun CRLD
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+ @ ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Apr DISC
AP	+!	9MG/ML	N019217	001	Jul 13, 1984	Feb CAHN
	+ @ MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun CRLD
	SOLUTION; IRRIGATION					
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT	+! B BRAUN	900MG/100ML	N016733	001		Mar CRLD

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP	SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN
	@ UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013	Jun DISC

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

+ @ MALLINKRODT NUCLEAR 0.8-100mCi
SOLUTION; ORAL
SODIUM IODIDE I-131
+ @ MALLINKRODT NUCLEAR 3.5-150mCi/VIAL

N016517	001		Jun DISC
N016515	001		Jun DISC

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

>D> AP	APICORE US	25MG/ML	A209584	001	Aug 10, 2018	Aug CAHN
AP		25MG/ML	A209584	001	Aug 10, 2018	Jul NEWA
AP	CIPLA LTD	25MG/ML	A210855	001	Jul 16, 2018	Jul NEWA
>A> AP	MEDICURE	25MG/ML	A209584	001	Aug 10, 2018	Aug CAHN
AP	MYLAN LABS LTD	25MG/ML	A210763	001	Apr 17, 2018	Apr NEWA
AP	RENAISSANCE SSA LLC	25MG/ML	A209834	001	Jun 26, 2018	Jun NEWA
>A> AP	SOMERSET THERAPS LLC	25MG/ML	A210882	001	Aug 17, 2018	Aug NEWA
>A>	SOLUTION; INTRAVENOUS					
>A>	NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
>A>	+! EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Aug CDFR
	+!	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018	Jul NEWA
>A>	+!	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Aug CDFR
>D>	SOLUTION; IV (INFUSION)					
>D>	NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
>D>	+! EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Aug CDFR
>D>	+!	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Aug CDFR

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	APNAR PHARMA LP	454GM/BOT	A206815	001	Feb 18, 2016	Mar CAHN
----	-----------------	-----------	---------	-----	--------------	----------

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION; ORAL

LOKELMA

+ ASTRAZENECA PHARMS 5GM/PACKET
+! 10GM/PACKET

N207078	001	May 18, 2018	May NEWA
N207078	002	May 18, 2018	May NEWA

SOMATROPIN

INJECTABLE; INJECTION

BIO-TROPIN

@ FERRING

ZOMACTON

BX	+! FERRING	4.8MG/VIAL	N019774	001	May 25, 1995	Feb CAIN
	+	10MG/VIAL	N019774	002	Jan 04, 2002	Feb CAIN

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN PRESERVATIVE FREE

+ @ PHARMACIA AND UPJOHN 1.5MG/VIAL

NUTROPIN AQ PEN

+ @ GENENTECH 10MG/2ML (5MG/ML)

+ @ VALTROPIN 20MG/2ML (10MG/ML)

@ LG CHEM LTD

5MG/VIAL

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB1	OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	Jul CAHN
AB1		120MG	A075563	002	Nov 07, 2003	Jul CAHN
AB1		160MG	A075563	003	Nov 07, 2003	Jul CAHN
AB1		240MG	A075563	004	Nov 07, 2003	Jul CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB	CASI PHARMS INC	25MG	A086809	001		Mar CAHN
AB	OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Jul CAHN
AB		50MG	A040750	002	Aug 29, 2006	Jul CAHN
AB		100MG	A040750	003	Aug 29, 2006	Jul CAHN
AB	ZYDUS PHARMS USA INC	25MG	A205936	001	Jul 18, 2018	Jul NEWA
AB		50MG	A205936	002	Jul 18, 2018	Jul NEWA
AB		100MG	A205936	003	Jul 18, 2018	Jul NEWA

STANOZOLOL

TABLET; ORAL

WINSTROL

>D>	@ LUNDBECK INC	2MG	N012885	001	May 14, 1984	Aug CRLD
>A>	+ @	2MG	N012885	001	May 14, 1984	Aug CRLD

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	+ B BRAUN	100%	N016734	001		Mar CRLD
----	-----------	------	---------	-----	--	----------

STIRIPENTOL

CAPSULE; ORAL

DIACOMIT

>A>	+ BIOCODEX SA	250MG	N206709	001	Aug 20, 2018	Aug NEWA
>A>	+!	500MG	N206709	002	Aug 20, 2018	Aug NEWA
>A>	FOR SUSPENSION; ORAL					
>A>	DIACOMIT					
>A>	+ BIOCODEX SA	250MG/PACKET	N207223	001	Aug 20, 2018	Aug NEWA
>A>	+!	500MG/PACKET	N207223	002	Aug 20, 2018	Aug NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP	RENAISSANCE SSA LLC	20MG/ML	A210231	001	Jun 04, 2018	May NEWA
AP	ZYDUS PHARMS USA INC	20MG/ML	A209467	001	May 04, 2018	Apr NEWA

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+! ALLERGAN SALES LLC 1GM/10ML

N019183 001 Dec 16, 1993 Jan CAHN

TABLET;ORAL
CARAFATE

AB	+! ALLERGAN SALES LLC	1GM	N 018333	001	Jan CAHN
	SUCRALFATE				
	@ MYLAN IRELAND LTD	1GM	A 074415	001 Jun 08, 1998	Jul DISC

SULFDIAZINE

TABLET;ORAL
SULFDIAZINE

>D>	@ LILLY	500MG	N 004122	002	Aug CRLD
>A>	+ @	500MG	N 004122	002	Aug CRLD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL
BACTRIM

+ @ SUN PHARM INDUSTRIES 200MG/5ML;40MG/5ML
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	LANNETT CO INC	200MG/5ML;40MG/5ML	A 077785	001 Jan 24, 2007	May CAHN
----	----------------	--------------------	----------	------------------	----------

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ FOSUN PHARMA 400MG;80MG
@ 400MG;80MG
@ 800MG;160MG
@ SUN PHARM INDUSTRIES 400MG;80MG
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
@ FOSUN PHARMA 800MG;160MG

A 070889	001 Nov 13, 1986	Jan CAHN
N 018598	003 May 19, 1982	Jan CAHN
A 070890	001 Nov 13, 1986	Jan CAHN
A 071017	002 Aug 25, 1986	Apr CMS1
N 018598	004 May 19, 1982	Jan CAHN

SULINDAC

TABLET;ORAL
SULINDAC

@ FOSUN PHARMA 150MG
@ 200MG

A 072712	001 Aug 30, 1991	Jan CAHN
A 072713	001 Aug 30, 1991	Jan CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMAVEL DOSEPRO

+ @ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N 022239	002 Nov 26, 2013	Mar DISC
+ @	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N 022239	001 Jul 15, 2009	Mar DISC

TABLET;ORAL

SUMATRIPTAN SUCCINATE

@ FOSUN PHARMA EQ 25MG BASE
@ EQ 50MG BASE
@ EQ 100MG BASE

A 076976	001 Aug 10, 2009	Jan CAHN
A 076976	002 Aug 10, 2009	Jan CAHN
A 076976	003 Aug 10, 2009	Jan CAHN

TACROLIMUS

FOR SUSPENSION;ORAL
PROGRAF

+ ASTELLAS	EQ 0.2MG BASE/PACKET	N 210115	001 May 24, 2018	May NEWA
+!	EQ 1MG BASE/PACKET	N 210115	002 May 24, 2018	May NEWA

OINTMENT;TOPICAL

TACROLIMUS

AB	GLENMARK PHARMS LTD	0.1%	A 210393	001 Apr 16, 2018	Apr NEWA
----	---------------------	------	----------	------------------	----------

Tadalafil

TABLET;ORAL
ADCIRCA

>D> AB	+! ELI LILLY CO	20MG	N 022332	001 May 22, 2009	Aug CTEC
>A> AB2	+!	20MG	N 022332	001 May 22, 2009	Aug CTEC
AB	+!	20MG	N 022332	001 May 22, 2009	Jul CFTG

CIALIS

AB	+ LILLY	2.5MG	N 021368	004 Jan 07, 2008	May CFTG
AB	+	5MG	N 021368	001 Nov 21, 2003	May CFTG
AB	+	10MG	N 021368	002 Nov 21, 2003	May CFTG

>D> AB	+!	20MG	N 021368	003 Nov 21, 2003	Aug CTEC
>A> AB1	+!	20MG	N 021368	003 Nov 21, 2003	Aug CTEC
AB	+!	20MG	N 021368	003 Nov 21, 2003	May CFTG

Tadalafil

>D> AB	MYLAN PHARMS INC	20MG	A 200630	001 Aug 03, 2018	Aug CTEC
>A> AB2		20MG	A 200630	001 Aug 03, 2018	Aug CTEC
AB		20MG	A 200630	001 Aug 03, 2018	Jul NEWA
AB	TEVA PHARMS USA	2.5MG	A 090141	001 May 22, 2018	May NEWA

TABLET;ORAL
TADALAFIL

AB	5MG	A090141	002	May 22, 2018	May NEWA
AB	10MG	A090141	003	May 22, 2018	May NEWA
>D> AB	20MG	A090141	004	May 22, 2018	Aug CTEC
>A> AB1	20MG	A090141	004	May 22, 2018	Aug CTEC
AB	20MG	A090141	004	May 22, 2018	May NEWA

>A> TAFENOQUINE SUCCINATE

>A>	TABLET;ORAL					
>A>	ARAKODA					
>A>	+! 60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018	Aug NEWA
	KRINTAFEL					
	+! GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018	Jul NEWA

TALC

AEROSOL;INTRAPLEURAL					
SCLEROSOL					
+! LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997	Mar CPOT

TALIGLUCERASE ALFA

>A>	POWDER; INTRAVENOUS					
>A>	ELELYSO					
>A>	+! PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012	Aug CDFR
>D>	POWDER; IV (INFUSION)					
>D>	ELELYSO					
>D>	+! PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012	Aug CDFR

TAMOXIFEN CITRATE

SOLUTION;ORAL					
SOLTAMOX					
MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Mar CPOT

TAPENTadol HYDROCHLORIDE

SOLUTION;ORAL					
NUCYNTA					
+ @ DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May DISC

TAZAROTENE

CREAM;TOPICAL					
TAZAROTENE					
AB TARO PHARMS	0.1%	A208258	001	Apr 03, 2017	May CAHN

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION					
PULMOLITE					
+ @ JUBILANT DRAXIMAGE	N/A	N017776	001		Feb DISC

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION					
CIS-MDP					
PHARMALUCENCE	N/A	N018124	001		Jan CTEC
MDP-BRACCO					
@ CARDINAL HEALTH 414	N/A	N018107	001		Jan DISC

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION					
DTPA					
+! JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC					
RADIOGENIX SYSTEM					
+ NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Feb NEWA

TECOVIRIMAT

CAPSULE;ORAL					
TPOXX					
+! SIGA TECHNOLOGIES	200MG	N208627	001	Jul 13, 2018	Jul NEWA

TEDIZOLID PHOSPHATE

>A>	POWDER; INTRAVENOUS						
>A>	SIVEXTRO						
>A>	+! CUBIST PHARMS LLC	200MG/VIAL		N 205436	001	Jun 20, 2014	Aug CDFR
>D>	POWDER; IV (INFUSION)						
>D>	SIVEXTRO						
>D>	+! CUBIST PHARMS LLC	200MG/VIAL		N 205436	001	Jun 20, 2014	Aug CDFR

TELAVANCIN HYDROCHLORIDE

>A>	POWDER; INTRAVENOUS						
>A>	VIBATIV						
>A>	+ @ THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL		N 022110	001	Sep 11, 2009	Aug CDFR
>A>	+!	EQ 750MG BASE/VIAL		N 022110	002	Sep 11, 2009	Aug CDFR
>D>	POWDER; IV (INFUSION)						
>D>	VIBATIV						
>D>	+ @ THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL		N 022110	001	Sep 11, 2009	Aug CDFR
>D>	+!	EQ 750MG BASE/VIAL		N 022110	002	Sep 11, 2009	Aug CDFR

TELMISARTAN

TABLET; ORAL							
TELMISARTAN							
@ WATSON LABS	40MG			A 078710	002	Jan 08, 2014	Jul DISC

TEMOZOLOMIDE

CAPSULE; ORAL							
TEMOZOLOMIDE							
AB APOTEX INC	5MG			A 204159	001	Jul 05, 2018	Jun NEWA
AB	20MG			A 204159	002	Jul 05, 2018	Jun NEWA
AB	100MG			A 204159	003	Jul 05, 2018	Jun NEWA
AB	140MG			A 204159	004	Jul 05, 2018	Jun NEWA
AB	180MG			A 204159	005	Jul 05, 2018	Jun NEWA
AB	250MG			A 204159	006	Jul 05, 2018	Jun NEWA
@ MYLAN PHARMS INC	5MG			A 205227	001	Jun 29, 2016	Apr DISC
@	20MG			A 205227	002	Jun 29, 2016	Apr DISC
@	100MG			A 205227	003	Jun 29, 2016	Mar DISC
@	140MG			A 205227	004	Jun 29, 2016	Mar DISC
@	180MG			A 205227	005	Jun 29, 2016	Mar DISC
@	250MG			A 205227	006	Jun 29, 2016	Mar DISC

TEMSIROLIMUS

SOLUTION; INTRAVENOUS							
TEMSIROLIMUS							
AP ACCORD HLTHCARE	25MG/ML (25MG/ML)			A 203153	001	Jul 30, 2018	Jul NEWA
TORISEL							
AP +! PF PRISM CV	25MG/ML (25MG/ML)			N 022088	001	May 30, 2007	Jul CFTG

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL							
TENOFOVIR DISOPROXIL FUMARATE							
AB APOTEX INC	300MG			A 206481	001	Jul 26, 2018	Jul NEWA
AB AUROBINDO PHARMA LTD	150MG			A 090647	001	Jan 26, 2018	Jan NEWA
AB	200MG			A 090647	002	Jan 26, 2018	Jan NEWA
AB	250MG			A 090647	003	Jan 26, 2018	Jan NEWA
AB	300MG			A 090647	004	Jan 26, 2018	Jan NEWA
AB CIPLA LTD	300MG			A 078800	001	Jan 26, 2018	Jan NEWA
AB HETERO LABS LTD III	300MG			A 090636	001	Jan 26, 2018	Jan NEWA
AB LAURUS LABS PVT	300MG			A 209550	001	Feb 26, 2018	Feb NEWA
AB MACLEODS PHARMS LTD	300MG			A 203232	001	Jan 26, 2018	Jan NEWA
AB STRIDES PHARMA	300MG			A 090742	001	Jan 26, 2018	Jan NEWA
AB TEVA PHARMS USA	150MG			A 091612	002	Jan 26, 2018	Jan NEWA
AB	200MG			A 091612	003	Jan 26, 2018	Jan NEWA
AB	250MG			A 091612	004	Jan 26, 2018	Jan NEWA
VIREAD							
AB + GILEAD SCIENCES INC	150MG			N 021356	002	Jan 18, 2012	Jan CFTG
AB +	200MG			N 021356	003	Jan 18, 2012	Jan CFTG
AB +	250MG			N 021356	004	Jan 18, 2012	Jan CFTG

TERCONAZOLE

CREAM;VAGINAL							
TERAZOL 7							
+ @ JANSSEN PHARMS	0.4%			N019579	001	Dec 31, 1987	Feb DISC
TERCONAZOLE							
AB ! TARO	0.4%			A076043	001	Jan 19, 2005	Feb CHRS
SUPPOSITORY;VAGINAL							
TERAZOL 3							
+ @ JANSSEN PHARMS	80MG			N019641	001	May 24, 1988	Feb DISC
TERCONAZOLE							
AB ! PERRIGO NEW YORK	80MG			A077149	001	Mar 17, 2006	Feb CHRS

TERIFLUNOMIDE

TABLET;ORAL							
AUBAGIO							
AB + SANOFI AVENTIS US	7MG			N202992	001	Sep 12, 2012	Jul CFTG
AB +! TERIFLUNOMIDE	14MG			N202992	002	Sep 12, 2012	Jul CFTG
>A> AB TEVA PHARMS USA	7MG			A209700	001	Sep 04, 2018	Aug NEWA
>A> AB 14MG				A209700	002	Sep 04, 2018	Aug NEWA
AB WATSON LABS TEVA	7MG			A209549	001	Jul 27, 2018	Jul NEWA
AB 14MG				A209549	002	Jul 27, 2018	Jul NEWA

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL							
TESTOSTERONE							
AT CIPLA LTD	30MG/1.5ML ACTUATION			A209533	001	Jan 29, 2018	Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION							
TESTOSTERONE CYPIONATE							
AO CIPLA LTD	100MG/ML			A210362	001	Jun 19, 2018	Jun NEWA
AO	200MG/ML			A210362	002	Jun 19, 2018	Jun NEWA

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION							
DELATESTRYL							
+ @ ENDO PHARMS	200MG/ML			N009165	003		Jun DISC
TESTOSTERONE ENANTHATE							
@ MYLAN INSTITUTIONAL	200MG/ML			A040647	001	Oct 05, 2009	Jun DISC
>D> @ NEXUS PHARMS	200MG/ML			A040575	001	Jun 14, 2006	Aug CMFD
>A> AO @	200MG/ML			A040575	001	Jun 14, 2006	Aug CMFD
AO @	200MG/ML			A040575	001	Jun 14, 2006	Jul DISC
AO ! WATSON PHARMS INC	200MG/ML			A040575	001	Jun 14, 2006	Jun CAHN
	200MG/ML			A085598	001		Jun CHRS

TETRABENAZINE

TABLET;ORAL							
TETRABENAZINE							
AB LUPIN LTD	12.5MG			A210544	001	Apr 20, 2018	Apr NEWA
AB	25MG			A210544	002	Apr 20, 2018	Apr NEWA

TETRACAIN HYDROCHLORIDE

SOLUTION;OPHTHALMIC							
TETRACAIN HYDROCHLORIDE							
+! ALCON LABS	0.5%			N208135	001	Feb 29, 2016	Mar CAHN

THEOPHYLLINE

INJECTABLE;INJECTION							
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER							
+! B BRAUN 40MG/100ML				N019826	001	Aug 14, 1992	Jun CTEC
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER							
+! B BRAUN 160MG/100ML				N019826	003	Aug 14, 1992	Jun CTEC
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER							
+! B BRAUN 320MG/100ML				N019826	006	Aug 14, 1992	Jun CTEC
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER							
+ @ HOSPIRA INC 4MG/ML				N019211	007	Dec 14, 1984	Jun DISC
+ @ 40MG/100ML				N019211	001	Dec 14, 1984	Jun DISC
+ @ 160MG/100ML				N019211	003	Dec 14, 1984	Jun DISC
+ @ 320MG/100ML				N019211	006	Jan 20, 1988	Jun DISC

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Jan CTEC
AB		200MG	A087400	004	Feb 21, 1985	Jan CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

@ FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@	15MG	A088132	001	Aug 30, 1983	Jan CAHN
@	25MG	A088133	001	Aug 30, 1983	Jan CAHN
@	50MG	A088134	001	Aug 30, 1983	Jan CAHN
@	100MG	A088135	001	Nov 20, 1984	Jan CAHN
@	150MG	A088136	001	Sep 17, 1986	Jan CAHN
@	200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTEPA

INJECTABLE;INJECTION
THIOTEPA

AP	DR REDDYS LABS LTD	15MG/VIAL	A210337	001	May 04, 2018	Apr NEWA
AP	JIANGSU HENGRUI MED	15MG/VIAL	A209150	001	May 04, 2018	Apr NEWA
AP	! WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Apr CTEC
>A>	POWDER;INTRAVENOUS					
>A>	TEPADINA					
>A>	+! ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Aug CDFR
>A>	+!	100MG/VIAL	N208264	002	Jan 26, 2017	Aug CDFR
>D>	POWDER;IV (INFUSION)					
>D>	TEPADINA					
>D>	+! ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Aug CDFR
>D>	+!	100MG/VIAL	N208264	002	Jan 26, 2017	Aug CDFR

THIOTHIXENE

CAPSULE;ORAL
NAVANE

+ @ PFIZER	1MG	N016584	001		Jan CRLD
+ @	2MG	N016584	002		Jan CRLD
+ @	5MG	N016584	003		Jan CRLD
+ @	10MG	N016584	004		Jan CRLD
+ @	20MG	N016584	005		Jan CRLD

TICAGRELOR

TABLET;ORAL
BRILINTA

>D>	+ ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Aug CFTG
>A> AB	+	60MG	N022433	002	Sep 03, 2015	Aug CFTG
>D>	+!	90MG	N022433	001	Jul 20, 2011	Aug CFTG
>A> AB	+!	90MG	N022433	001	Jul 20, 2011	Aug CFTG
>A>	TICAGRELOR					
>A> AB	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Aug NEWA
>A> AB		90MG	A208390	002	Sep 04, 2018	Aug NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

@ YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan CAHN
@	250MG	A075326	001	Aug 20, 1999	Jan CAHN

TIGECYCLINE

POWDER;INTRAVENOUS
TIGECYCLINE

>A> AP	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jun CDFR
AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Aug NEWA
AP	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Jun CDFR
AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Jun CDFR
	TYGACIL					
AP	+! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Jun CDFR
	POWDER;IV (INFUSION)					
	TIGECYCLINE					
	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jan NEWA

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOPTIC

AT	+	ATON	EQ 0.25% BASE	N018086	001	Jan	CMFD
AT1	+		EQ 0.5% BASE	N018086	002	Jan	CMFD
TABLET;ORAL							
TIMOLOL MALEATE							
@	YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan	CAHN
@		10MG	A072551	001	Apr 13, 1989	Jan	CAHN
@		20MG	A072552	001	Apr 13, 1989	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar	CAHN
AB		EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar	CAHN
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	NEWA
AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN	DR REDDYS LABS INTL	300MG/5ML	A207080	001	Jul 09, 2018	Jun	NEWA
AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Jul	CAHN

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+!	PF PRISM CV	EQ 10MG BASE	N203214	002	May 30, 2018	May	NEWA
----	-------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987	Jan	CAHN
@		250MG	A070289	001	Mar 13, 1986	Jan	CAHN
@		500MG	A070290	001	Mar 13, 1986	Jan	CAHN

TOLBUTAMIDE

TABLET;ORAL

TOLBUTAMIDE

@	YAOPHARMA CO LTD	500MG	A086574	001		Jan	CAHN
---	------------------	-------	---------	-----	--	-----	------

TOLCAPONE

TABLET;ORAL

TOLCAPONE

AB	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Jul	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

@	FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992	Jan	CAHN
TABLET;ORAL							
@	TOLMETIN SODIUM	EQ 200MG BASE	A073588	001	Jul 31, 1992	Jan	CAHN
@		EQ 600MG BASE	A074002	001	Sep 27, 1993	Jan	CAHN

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

@	APOTEX CORP	1MG	A200164	001	Sep 25, 2012	Mar	DISC
@		2MG	A200164	002	Sep 25, 2012	Mar	DISC

TOLVAPTAN

TABLET;ORAL

JYNARQUE

+	OTSUKA PHARM CO LTD	15MG	N204441	001	Apr 23, 2018	Apr	NEWA
+		30MG	N204441	002	Apr 23, 2018	Apr	NEWA
+		45MG	N204441	003	Apr 23, 2018	Apr	NEWA
+		60MG	N204441	004	Apr 23, 2018	Apr	NEWA
+!		90MG	N204441	005	Apr 23, 2018	Apr	NEWA

TOPIRAMATE

CAPSULE;ORAL					
TOPIRAMATE					
@ FOSUN PHARMA	15MG		A079206	001	Oct 14, 2009
@	25MG		A079206	002	Oct 14, 2009

TRABECTEDIN

>A>	POWDER; INTRAVENOUS				
>A>	YONDELIS				
>A>	+! JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015
>D>	POWDER; IV (INFUSION)				
>D>	YONDELIS				
>D>	+! JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRAMADOL HYDROCHLORIDE

TABLET;ORAL					
TRAMADOL HYDROCHLORIDE					
@ FOSUN PHARMA	50MG		A075968	001	Jun 25, 2002

TRANDOLAPRIL

TABLET;ORAL					
MAVIK					
+ @ ABBVIE	1MG		N020528	001	Apr 26, 1996
+ @	2MG		N020528	002	Apr 26, 1996
+ @	4MG		N020528	003	Apr 26, 1996
TRANDOLAPRIL					
AB ! LUPIN	4MG		A077522	003	Jun 12, 2007
@ WATSON LABS	1MG		A077805	001	Jun 12, 2007
@	2MG		A077805	002	Jun 12, 2007
@	4MG		A077805	003	Jun 12, 2007

TRANEXAMIC ACID

INJECTABLE; INJECTION					
TRANEXAMIC ACID					
AP ACIC PHARMS	100MG/ML		A202436	001	Feb 11, 2014

TRANYLCYPROMINE SULFATE

TABLET;ORAL					
TRANYLCYPROMINE SULFATE					
AB KINEDEXE UK	EQ 10MG BASE		A206856	001	Apr 17, 2018

TRAZODONE HYDROCHLORIDE

TABLET;ORAL					
TRAZODONE HYDROCHLORIDE					
@ FOSUN PHARMA	100MG		A072483	001	Apr 30, 1990
AB OXFORD PHARMS	50MG		A072192	001	Feb 02, 1989
AB	100MG		A072193	001	Feb 02, 1989

TREPROSTINIL

SOLUTION; INTRAVENOUS, SUBCUTANEOUS					
REMODULIN					
UNITED THERAP	20MG/20ML (1MG/ML)		N208276	001	Jul 30, 2018
	50MG/20ML (2.5MG/ML)		N208276	002	Jul 30, 2018
	100MG/20ML (5MG/ML)		N208276	003	Jul 30, 2018
	200MG/20ML (10MG/ML)		N208276	004	Jul 30, 2018

TRETINOIN

>A> LOTION;TOPICAL					
>A> ALTRENO					
>A> +! DOW PHARM	0.05%		N209353	001	Aug 23, 2018

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL					
TRIAMCINOLONE ACETONIDE					
AT LANNETT CO INC	0.025%		A040671	001	Jun 09, 2006
AT	0.1%		A040671	002	Jun 09, 2006
AT MACLEODS PHARMS LTD	0.025%		A209535	001	May 18, 2018
AT	0.1%		A209535	002	May 18, 2018
AT	0.5%		A209535	003	May 18, 2018
AT PERRIGO NEW YORK	0.025%		A086413	002	Mar CMS1
AT	0.1%		A086413	003	Mar CMS1

	CREAM;TOPICAL TRIAMCINOLONE ACETONIDE					
AT	TARO PHARM IND'S LTD 0.1%		A040039	001	Nov 26, 1997	May CAHN
	LOTION;TOPICAL TRIAMCINOLONE ACETONIDE					
AT	LANNETT CO INC 0.1%		A040672	002	Dec 13, 2006	May CAHN
	OINTMENT;TOPICAL TRIAMCINOLONE ACETONIDE					
AT	! PERRIGO NEW YORK 0.025%		A087385	002		Jun CMS1
AT	! 0.1%		A087385	003		Jun CMS1
AT	TARO PHARM IND'S LTD 0.1%		A040037	001	Sep 30, 1994	May CAHN
	SPRAY;TOPICAL KENALOG					
AT	+! SUN PHARM IND'S INC 0.147MG/GM		N012104	001		Feb CAHN
	<u>TRIENTINE HYDROCHLORIDE</u>					
	CAPSULE;ORAL SPYRINE					
AB	+! ATON 250MG		N019194	001	Nov 08, 1985	Jan CFTG
	TRIENTINE HYDROCHLORIDE					
AB	WATSON LABS TEVA 250MG		A207567	001	Feb 07, 2018	Jan NEWA
	<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>					
	CONCENTRATE;ORAL TRIFLUOPERAZINE HYDROCHLORIDE					
	@ FOSUN PHARMA EQ 10MG BASE/ML		A085787	001	Apr 15, 1982	Jan CAHN
	<u>TROPICAMIDE</u>					
	SOLUTION/DROPS;OPHTHALMIC TROPICAMIDE					
AT	BAUSCH AND LOMB 0.5%		A040067	001	Jul 27, 1994	Apr CAHN
	<u>UROFOLLITROPIN</u>					
	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS BRAVELLE					
	+ @ FERRING 75 IU/VIAL		N021289	001	May 06, 2002	Jun DISC
	<u>URSODIOL</u>					
	CAPSULE;ORAL URSODIOL					
AB	ABHAI LLC 300MG		A210707	001	May 17, 2018	May NEWA
	TABLET;ORAL URSO 250					
AB	+ ALLERGAN SALES LLC 250MG		N020675	001	Dec 10, 1997	Apr CAHN
AB	+! ALLERGAN SALES LLC 500MG		N020675	002	Jul 21, 2004	Apr CAHN
	<u>VALACYCLOVIR HYDROCHLORIDE</u>					
	TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE					
>D> AB	DR REDDYS LABS LTD EQ 500MG BASE		A079012	001	May 24, 2010	Aug CAHN
>D> AB		EQ 1GM BASE	A079012	002	May 24, 2010	Aug CAHN
>A> AB	TIME-CAP LABS INC EQ 500MG BASE		A079012	001	May 24, 2010	Aug CAHN
>A> AB		EQ 1GM BASE	A079012	002	May 24, 2010	Aug CAHN
	<u>VALBENAZINE TOSYLATE</u>					
	CAPSULE;ORAL INGREZZA					
+!	NEUROCRINE EQ 40MG BASE		N209241	001	Apr 11, 2017	Jun CPOT
+!	EQ 80MG BASE		N209241	002	Oct 04, 2017	Jun CPOT
	<u>VALPROIC ACID</u>					
	SYRUP;ORAL VALPROIC ACID					
AA	LANNETT CO INC 250MG/5ML		A077960	001	Oct 13, 2006	May CAHN

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

+ @ CARMEL BIOSCIENCES	20MG/5ML	N 209139 001 Dec 19, 2017	Jun DISC
+ @	80MG/20ML	N 209139 002 Dec 19, 2017	Jun DISC

TABLET;ORAL

VALSARTAN

AB	SQUARE PHARMS LTD	40MG	A 205347 001 Apr 09, 2018	Mar NEWA
AB		80MG	A 205347 002 Apr 09, 2018	Mar NEWA
AB		160MG	A 205347 003 Apr 09, 2018	Mar NEWA
AB		320MG	A 205347 004 Apr 09, 2018	Mar NEWA
AB	UNICHEM LABS LTD	40MG	A 209261 001 May 04, 2018	Apr NEWA
AB		80MG	A 209261 002 May 04, 2018	Apr NEWA
AB		160MG	A 209261 003 May 04, 2018	Apr NEWA
AB		320MG	A 209261 004 May 04, 2018	Apr NEWA
>D> AB	WATSON LABS INC	40MG	A 090642 001 Jan 05, 2015	Aug DISC
>A>	@	40MG	A 090642 001 Jan 05, 2015	Aug DISC
>D> AB		80MG	A 090642 002 Jan 05, 2015	Aug DISC
>A>	@	80MG	A 090642 002 Jan 05, 2015	Aug DISC
>D> AB		160MG	A 090642 003 Jan 05, 2015	Aug DISC
>A>	@	160MG	A 090642 003 Jan 05, 2015	Aug DISC
>D> AB		320MG	A 090642 004 Jan 05, 2015	Aug DISC
>A>	@	320MG	A 090642 004 Jan 05, 2015	Aug DISC

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@ FRESENIUS KABI USA	EQ 125MG BASE	A 065453 001 Jun 18, 2012	Feb DISC
@	EQ 250MG BASE	A 065453 002 Jun 18, 2012	Feb DISC

FOR SOLUTION;ORAL

FIRVANQ KIT

+! RXMTM THERAPS LLC	EQ 25MG BASE/ML	N 208910 001 Jan 26, 2018	Jan NEWA
+!	EQ 50MG BASE/ML	N 208910 002 Jan 26, 2018	Jan NEWA

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE	EQ 1GM BASE/200ML	N 050671 003 Mar 01, 1999	Apr NEWA
--------------------	-------------------	---------------------------	----------

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+! MYLAN LABS LTD	EQ 250MG BASE/VIAL	N 209481 001 Jul 10, 2018	Jul NEWA
+!	EQ 750MG BASE/VIAL	N 209481 002 Jul 10, 2018	Jul NEWA
+!	EQ 1.25GM BASE/VIAL	N 209481 003 Jul 10, 2018	Jul NEWA
+!	EQ 1.5GM BASE/VIAL	N 209481 004 Jul 10, 2018	Jul NEWA

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+ @ BAYER HLTHCARE	2.5MG	N 021400 003 Aug 19, 2003	Apr DISC
TABLET, ORALLY DISINTEGRATING;ORAL			
STAXYN			

+! BAYER HLTHCARE	10MG	N 200179 001 Jun 17, 2010	Jul CMFD
+ @	10MG	N 200179 001 Jun 17, 2010	Apr DISC

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

+ PF PRISM CV	EQ 0.5MG BASE	N 021928 001 May 10, 2006	Feb CAHN
+!	EQ 1MG BASE	N 021928 002 May 10, 2006	Feb CAHN

VELAGLUCERASE ALFA

INJECTABLE;INTRAVENOUS

VPRI

SHIRE HUMAN GENETIC	400 UNITS/VIAL	N 022575 001 Feb 26, 2010	Jul CDFR
---------------------	----------------	---------------------------	----------

POWDER;INTRAVENOUS

VPRI

@ SHIRE HUMAN GENETIC	200 UNITS/VIAL	N 022575 002 Feb 26, 2010	Jul CDFR
-----------------------	----------------	---------------------------	----------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
EFFEXOR XR

AB	+	WYETH PHARMS	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jul CAHN
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jul CAHN
	@		EQ 100MG BASE	N020699	003	Oct 20, 1997	Jul CAHN
AB	+!		EQ 150MG BASE	N020699	004	Oct 20, 1997	Jul CAHN
		TABLET;ORAL					
		VENLAFAXINE HYDROCHLORIDE					
	@	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
	@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
	@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
	@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
	@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP		AMNEAL PHARMS CO	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Jul NEWA
AP			10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Jul NEWA
AP		EXELA PHARMA SCS LLC	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018	May NEWA
AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987	Jan CPOT
AP		SOMERSET THERAPS LLC	5MG/2ML (2.5MG/ML)	A211015	001	Jun 18, 2018	Jun NEWA
AP			5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Jun NEWA
AP			10MG/4ML (2.5MG/ML)	A211015	002	Jun 18, 2018	Jun NEWA
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Jun NEWA

TABLET;ORAL
ISOPTIN

+ @	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CRLD
+ @		80MG	N018593	001	Mar 08, 1982	Apr CRLD
+ @		120MG	N018593	002	Mar 08, 1982	Apr CRLD

VERAPAMIL HYDROCHLORIDE

@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan CAHN
@		80MG	A071423	001	May 24, 1988	Jan CAHN
@		120MG	A071424	001	May 25, 1988	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL
VERAPAMIL HYDROCHLORIDE

@	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar DISC
@		180MG	A200878	002	Apr 20, 2012	Mar DISC
@		240MG	A200878	003	Apr 20, 2012	Mar DISC

VIGABATRIN

FOR SOLUTION;ORAL
VIGABATRIN

AA		AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb NEWA
AA		TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Apr NEWA
AA		VIGADROME					
AA		AUCTA PHARMS	500MG/PACKET	A210196	001	Jun 21, 2018	Jun NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL
VIIBRYD

+	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan CAHN
+		20MG	N022567	002	Jan 21, 2011	Jan CAHN
+		40MG	N022567	003	Jan 21, 2011	Jan CAHN

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VELBAN

+ @	LILLY	10MG/VIAL	N012665	001		Apr CRLD
-----	-------	-----------	---------	-----	--	----------

VITAMIN A PALMITATE

INJECTABLE;INJECTION

AQUASOL A

+!	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001		Jul CAHN
----	-------------------	-------------------------	---------	-----	--	----------

VORICONAZOLE

INJECTABLE;IV (INFUSION)

VORICONAZOLE

AP	ZYDUS PHARMS USA INC	200MG/VIAL	A208983	001	Jul 16, 2018	Jul NEWA
	TABLET;ORAL					
	VORICONAZOLE					
>D> AB	APP CO PHARMA LLC	50MG	A206762	001	May 24, 2016	Aug CAHN
>D> AB		200MG	A206762	002	May 24, 2016	Aug CAHN
>A> AB	RISING PHARMS	50MG	A206762	001	May 24, 2016	Aug CAHN
>A> AB		200MG	A206762	002	May 24, 2016	Aug CAHN

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

@ YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan CAHN
@	2MG	A040196	002	Sep 30, 1997	Jan CAHN
@	2.5MG	A040196	003	Sep 30, 1997	Jan CAHN
@	3MG	A040196	008	Jul 26, 2000	Jan CAHN
@	4MG	A040196	004	Sep 30, 1997	Jan CAHN
@	5MG	A040196	005	Sep 30, 1997	Jan CAHN
@	6MG	A040196	009	Jul 26, 2000	Jan CAHN
@	7.5MG	A040196	006	Sep 30, 1997	Jan CAHN
@	10MG	A040196	007	Sep 30, 1997	Jan CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

@ MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar DISC
@	EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar DISC
@	EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar DISC
@	EQ 80MG BASE	A202395	004	Oct 10, 2013	Jul DISC

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC

AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Jun NEWA
	ZOLEDRONIC ACID					
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan CAHN

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

@ APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar DISC	
@	5MG	A202078	002	May 14, 2013	Mar DISC	
@ MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Jul DISC	
@	5MG	A203186	002	May 14, 2013	Jul DISC	
AB	ZYDUS PHARMS USA INC	2.5MG	A203019	001	Jul 11, 2018	Jun NEWA
AB		5MG	A203019	002	Jul 11, 2018	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

@ APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar DISC
@	5MG	A202476	002	May 14, 2013	Mar DISC

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

@ SUN PHARM INDs LTD	5MG	A078055	001	Apr 23, 2007	Apr DISC
@	10MG	A078055	002	Apr 23, 2007	Apr DISC

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

+ @ SUNOVION PHARMS INC	50MG	N020789	002	Aug 22, 2003	Jul DISC
	ZONISAMIDE				
@ AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb CAHN
@	50MG	A077645	003	Sep 29, 2006	Feb CAHN
@	100MG	A077645	001	Dec 22, 2005	Feb CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL					
ACEPHEN					
@ G AND W LABS	325MG	N 018060	003	Dec 18, 1986	Jan DISC
@	650MG	N 018060	002		Jan DISC
ACETAMINOPHEN					
+ TARO PHARM IND LTD	120MG	N 018337	003	Sep 12, 1983	May CAHN
+	325MG	N 018337	002		May CAHN
+.!	650MG	N 018337	001		May CAHN
INFANTS' FEVERALL					
+ TARO PHARM IND LTD	80MG	N 018337	004	Aug 26, 1992	May CAHN
TABLET, EXTENDED RELEASE;ORAL					
ACETAMINOPHEN					
HERITAGE PHARMA	650MG	A 207035	001	May 31, 2018	May NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL					
GAVISCON					
+ @ SANOFI AVENTIS US	160MG;40MG	N 018685	002	Dec 09, 1983	May DISC

ASPIRIN

>D>	CAPSULE;ORAL					
	ASPIRIN					
>D>	+! PLX PHARMA	325MG	N 203697	001	Jan 14, 2013	Aug CTNA
>A>	VAZALORE					
>A>	+! PLX PHARMA	325MG	N 203697	001	Jan 14, 2013	Aug CTNA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL					
BUTENAFINE HYDROCHLORIDE					
TARO PHARMS	1%	A 205181	001	Nov 16, 2017	May CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL						
CETIRIZINE HYDROCHLORIDE ALLERGY						
AUROBINDO PHARMA LTD	10MG	A 209107	001	Jul 20, 2018	Jul NEWA	
CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
AUROBINDO PHARMA LTD	10MG	A 209107	002	Jul 20, 2018	Jul NEWA	
TABLET;ORAL						
CETIRIZINE HYDROCHLORIDE ALLERGY						
PLD ACQUISITIONS	5MG	A 077946	001	Dec 27, 2007	Feb CAHN	
	10MG	A 077946	002	Dec 27, 2007	Feb CAHN	
CETIRIZINE HYDROCHLORIDE HIVES						
UNIQUE PHARM LABS	10MG	A 077829	002	Aug 26, 2009	Aug CHRS	
!	10MG	A 077829	002	Aug 26, 2009	Aug CHRS	
>D>	ZYRTEC ALLERGY					
>D>	+ J AND J CONSUMER INC	5MG	N 019835	003	Nov 16, 2007	Aug DISC
>A>	+ @	5MG	N 019835	003	Nov 16, 2007	Aug DISC
>D>	ZYRTEC HIVES RELIEF					
>D>	+ J AND J CONSUMER INC	5MG	N 019835	005	Nov 16, 2007	Aug DISC
>A>	+ @	5MG	N 019835	005	Nov 16, 2007	Aug DISC
>D>	+!	10MG	N 019835	006	Nov 16, 2007	Aug DISC
>A>	+ @	10MG	N 019835	006	Nov 16, 2007	Aug DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
PLD ACQUISITIONS	5MG;120MG	A 077991	001	Mar 05, 2008	Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL						
SOLUPREP						
>A>	+! 3M HEALTH CARE	2%;70%	N 208288	001	Aug 08, 2018	Aug NEWA
SPONGE;TOPICAL						
CHLORAPREP ONE-STEP						
+! BECTON DICKINSON CO	2%;70% (1ML)	N 020832	008	Oct 23, 2008	Feb NEWA	

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

! L PERRIGO CO	1.34MG
@ PLD ACQUISITIONS LLC	1.34MG
	1.34MG
TAVIST-1	
+ @ GLAXOSMITHKLINE CONS	1.34MG

A074512	001	Nov 22, 1995	Jul CHRS
A073458	001	Oct 31, 1993	Jul DISC
A073458	001	Oct 31, 1993	Jan CAHN
N020925	001	Aug 21, 1992	Jul DISC

CLOTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC 1%

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@ BAYER HEALTHCARE LLC 1%,100MG

TABLET;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC 100MG

N018230	002	Dec 26, 1991	Mar DISC
N020389	002	Jun 23, 1994	Feb DISC
N018182	002	Dec 26, 1991	Mar DISC

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

@ AVANTHI INC 6MG;120MG

A078648 001 Feb 27, 2013 Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

PERRIGO R AND D	30MG;600MG
	60MG;1.2GM

A207602	002	Mar 05, 2018	Apr NEWA
A207602	001	Mar 05, 2018	Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

DR REDDYS LABS LTD EQ 20MG BASE

A207673 001 May 15, 2018 Apr NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ @ SANOFI AVENTIS US 30MG/5ML

CHILDREN'S ALLEGRA HIVES

+ @ SANOFI AVENTIS US 30MG/5ML

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

! ACTAVIS MID ATLANTIC 30MG/5ML

@ TARO PHARM 30MG/5ML

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

! ACTAVIS MID ATLANTIC 30MG/5ML

@ TARO PHARM 30MG/5ML

TABLET;ORAL

ALLEGRA HIVES

+ @ SANOFI AVENTIS US 60MG

+ @ 180MG

CHILDREN'S ALLEGRA ALLERGY

+ @ SANOFI AVENTIS US 30MG

CHILDREN'S ALLEGRA HIVES

+ @ SANOFI AVENTIS US 30MG

FEXOFENADINE HYDROCHLORIDE ALLERGY

UNIQUE PHARM LABS 180MG

N201373	001	Jan 24, 2011	Jul DISC
N201373	002	Jan 24, 2011	Jul DISC
A203330	001	Nov 18, 2014	Jul CHRS
A208123	001	Nov 09, 2017	Jul DISC
A203330	002	Nov 18, 2014	Jul CHRS
A208123	002	Nov 09, 2017	Jul DISC

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ @ SANOFI AVENTIS US 30MG

CHILDREN'S ALLEGRA HIVES

+ @ SANOFI AVENTIS US 30MG

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ DR REDDYS LABS LTD 30MG

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ DR REDDYS LABS LTD 30MG

N020872	008	Jan 24, 2011	Jun DISC
N020872	009	Jan 24, 2011	Jun DISC
N020872	005	Jan 24, 2011	Jun DISC
N020872	006	Jan 24, 2011	Jun DISC
A210137	001	Aug 13, 2018	Jul NEWA
N021909	002	Jan 24, 2011	Jul DISC
N021909	003	Jan 24, 2011	Jul DISC
A202978	001	Jan 18, 2013	Jul DISC
A202978	002	Jan 18, 2013	Jul DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

AMNEAL PHARMS	600MG 1.2GM	A207342 001 Jul 11, 2018	Jun NEWA
>A> GUARDIAN DRUG	600MG 1.2GM	A209215 001 Sep 06, 2017	Aug CAHN
>A>		A209215 002 Sep 06, 2017	Aug CAHN
>D>	GUARDIAN PHARMS	A209215 001 Sep 06, 2017	Aug CAHN
>D>		A209215 002 Sep 06, 2017	Aug CAHN
OHM LABS INC	600MG 1.2GM	A209254 001 Jul 16, 2018	Jul NEWA
		A209254 002 Jul 16, 2018	Jul NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753 001 Jun 29, 2018	Jun NEWA
STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469 001 Mar 28, 2018	Mar NEWA
SUSPENSION;ORAL			
IBUPROFEN			
>A> AUROBINDO PHARMA LTD	100MG/5ML	A209179 001 Apr 17, 2018	Apr NEWA
GUARDIAN DRUG	100MG/5ML	A210149 001 Aug 17, 2018	Aug NEWA
TABLET;ORAL			
IBUPROFEN			
>A> AIPING PHARM INC	200MG	A206990 001 Aug 21, 2018	Aug NEWA
DR REDDYS LABS INC	200MG	A076117 001 Nov 20, 2001	Jul CPOT
@ P AND L DEV LLC	200MG	A070733 001 Sep 19, 1986	Jan CAHN
STRIDES PHARMA	200MG	A206989 001 Jun 29, 2018	Jun NEWA
TABLET, CHEWABLE;ORAL			
CHILDREN'S MOTRIN			
+ @ J AND J CONSUMER INC	50MG	N020601 001 Nov 15, 1996	Jul DISC
IBUPROFEN			
@ PERRIGO	50MG	A076359 001 Jan 16, 2004	Jul DISC
!	100MG	A076359 002 Jan 16, 2004	Jul CHRS
JUNIOR STRENGTH MOTRIN			
+ @ J AND J CONSUMER INC	100MG	N020601 003 Nov 15, 1996	Jul DISC

LEVO CETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVO CETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD 5MG

A210375 001 Jan 19, 2018 Jan NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

HAUPT PHARMA 1.5MG

A204044 001 Jul 03, 2018 Jun NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

>A> PERRIGO R AND D	2MG;125MG	A209837 001 Sep 05, 2018	Aug NEWA
---------------------	-----------	--------------------------	----------

LORATADINE

SYRUP;ORAL

LORATADINE

AUROBINDO PHARMA LTD 1MG/ML

A208931 001 Jun 29, 2018 Jun NEWA

TABLET;ORAL

LORATADINE

AUROBINDO PHARMA LTD 10MG

A208314 001 Apr 16, 2018 Apr NEWA

PLD ACQUISITIONS LLC 10MG

A075209 001 Jan 21, 2003 Jan CAHN

TABLET, CHEWABLE;ORAL

LORATADINE

SUN PHARMA GLOBAL 5MG

A210088 001 Apr 16, 2018 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

AUROBINDO PHARMA LTD 10MG

A208477 001 Apr 11, 2018 Mar NEWA

MICONAZOLE NITRATE

CREAM;VAGINAL
 MICONAZOLE NITRATE
 TARO PHARMS 2%
 A074444 001 Jan 13, 1997 May CAHN
 CREAM, SUPPOSITORY;TOPICAL, VAGINAL
 MICONAZOLE 7 COMBINATION PACK
 @ G AND W LABS 2%,100MG
 A076585 001 Mar 26, 2004 Jan DISC

NAPROXEN SODIUM

CAPSULE;ORAL
 NAPROXEN SODIUM
 PURACAP PHARM LLC EQ 200MG BASE
 A208363 001 Mar 15, 2018 Jun NEWA
 TABLET;ORAL
 NAPROXEN SODIUM
 @ PLD ACQUISITIONS LLC EQ 200MG BASE
 A074646 001 Jan 13, 1997 Jan CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
 THRIVE
 >D> GLAXOSMITHKLINE CONS EQ 4MG BASE
 A077656 001 Jun 19, 2007 Aug DISC
 >D> @ EQ 4MG BASE
 A077656 001 Jun 19, 2007 Aug DISC
 >A> EQ 4MG BASE
 A077656 001 Jun 19, 2007 Feb CAHN
 TROCHE/LOZENGE;ORAL
 NICORETTE
 + GLAXOSMITHKLINE CONS EQ 2MG BASE
 N021330 001 Oct 31, 2002 Feb CTNA
 +! EQ 4MG BASE
 N021330 002 Oct 31, 2002 Feb CTNA
 NICOTINE POLACRILEX
 WATSON LABS INC EQ 2MG BASE
 A209206 001 Jun 26, 2018 Jun NEWA
 EQ 4MG BASE
 A209206 002 Jun 26, 2018 Jun NEWA
 WATSON LABS TEVA EQ 2MG BASE
 A209519 001 Jul 02, 2018 Jun NEWA
 EQ 4MG BASE
 A209519 002 Jul 02, 2018 Jun NEWA

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
 OMEPRAZOLE MAGNESIUM
 SPIL EQ 20MG BASE
 A210593 001 Jul 20, 2018 Jul NEWA
 TABLET, DELAYED RELEASE;ORAL
 OMEPRAZOLE MAGNESIUM
 AUROBINDO PHARMA LTD EQ 20MG BASE
 A206877 001 Jun 06, 2018 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
 OMEPRAZOLE AND SODIUM BICARBONATE
 ZYDUS PHARMS USA INC 20MG;1.1GM
 A203345 001 Mar 16, 2018 Mar NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
 POLYETHYLENE GLYCOL 3350
 APNAR PHARMA LP 17GM/SCOOPFUL
 AUROBINDO PHARMA LTD 17GM/SCOOPFUL
 A202071 001 Dec 28, 2012 Mar CAHN
 A209017 001 Apr 09, 2018 Mar NEWA

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
 AFRINOL
 + @ SCHERING PLOUGH 120MG
 N018191 001 Jul DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
 RANITIDINE HYDROCHLORIDE
 >A> GRANULES INDIA LTD EQ 150MG BASE
 A210243 001 Aug 20, 2018 Aug NEWA
 >A> EQ 150MG BASE
 A210243 002 Aug 20, 2018 Aug NEWA
 VIVIMED GLOBAL EQ 75MG BASE
 A209160 001 Mar 05, 2018 Feb NEWA
 EQ 150MG BASE
 A209161 001 Feb 22, 2018 Feb NEWA

TERBINAFINE

GEL;TOPICAL
 LAMISIL AT
 +! GLAXOSMITHKLINE CONS 1%
 N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2018**

NO AUGUST 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	9889144	Mar 17, 2034	DP			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	7459554	Nov 24, 2026	DS		ODE-175	Oct 31, 2024
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028	U-2261			
	9987238*PED	May 13, 2029				
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Feb 10, 2025	DS DP U-1263			
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 001	10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIE</u> N 201292 002	10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIE</u> N 201292 003	10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u> N 020983 001	9861771	Oct 11, 2020	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u> N 021457 001	10022509 10022510	May 18, 2031 May 18, 2031	DP DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u> N 205636 001	10022510	May 18, 2031	DP			
<u>ALCOHOL - ABLYSINOL</u> N 207987 001					ODE-192	Jun 21, 2025
<u>ALCOHOL - ABLYSINOL</u> N 207987 002					ODE-192	Jun 21, 2025
<u>ALLOPURINOL; LESINURAD - DUZALLO</u> N 209203 001	9956205	Dec 28, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u> N 209203 002	9956205	Dec 28, 2031	U-2104			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u> N 208944 001	9867791 9867792 9867793 9877933	Dec 02, 2030 Dec 02, 2030 Dec 02, 2030 Dec 02, 2030	U-2106 U-2106 U-2106 U-2224		I-769	Aug 24, 2020
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u> N 208944 002	9867791 9867792 9867793 9877933	Dec 02, 2030 Dec 02, 2030 Dec 02, 2030 Dec 02, 2030	U-2106 U-2106 U-2106 U-2224		I-769	Aug 24, 2020
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u> N 209410 001	8252331 8574626 RE39069	Mar 13, 2030 Nov 28, 2025 May 29, 2018	DP DP U-20 DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u> N 209410 002	8252331 8574626 RE39069	Mar 13, 2030 Nov 28, 2025 May 29, 2018	DP DP U-20 DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u> N 209410 003	8252331 8574626 RE39069	Mar 13, 2030 Nov 28, 2025 May 29, 2018	DP DP U-20 DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u> N 020965 001					I-766	Mar 09, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u> N 210045 001					NC	May 31, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002					NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003					NC	May 31, 2021
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10028995 9220745 9220745 9572856 9867863	Dec 18, 2034 Dec 18, 2034 Dec 18, 2034 Sep 20, 2030 Dec 16, 2029	U-2338 U-2217 U-2218 U-2221 U-2231		NCE	Dec 21, 2022
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10028995 9220745 9220745 9572856 9867863	Dec 18, 2034 Dec 18, 2034 Dec 18, 2034 Sep 20, 2030 Dec 16, 2029	U-2338 U-2217 U-2218 U-2221 U-2231		NCE	Dec 21, 2022
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507 8802689 9388159 9481663 9884054	Sep 15, 2030 Mar 27, 2027 Mar 27, 2027 Jun 04, 2033 Sep 23, 2033	DS DP U-2237 U-2237 DS DP DS DP U-2237 U-2237		NCE	Feb 14, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 001	7427638 9724330 9724330 9872854 9872854	Feb 16, 2028 Mar 19, 2023 Mar 19, 2023 May 29, 2034 May 29, 2034	DS DP U-1561 U-1595 U-2232 U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	7427638 9724330 9724330 9872854 9872854	Feb 16, 2028 Mar 19, 2023 Mar 19, 2023 May 29, 2034 May 29, 2034	DS DP U-1561 U-1595 U-2232 U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	7427638 9724330 9724330 9872854 9872854	Feb 16, 2028 Mar 19, 2023 Mar 19, 2023 May 29, 2034 May 29, 2034	DS DP U-1561 U-1595 U-2232 U-2233			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	9974742 9974793 9974794	Sep 18, 2035 Sep 18, 2035 Sep 18, 2035	DP DP DP U-2161			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	9941931	Nov 04, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	10016415	Sep 08, 2035	DP		NCE	Oct 05, 2020
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030		U-543		
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENNU</u>						
N 209381 001	10016504	Sep 10, 2033	DP		NP	May 04, 2021
	8999313	Sep 10, 2033	DP			
	9326969	Sep 10, 2033		U-2310		
	9592252	Aug 11, 2032	DP	U-2310		
	9707297	Sep 10, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002				M-158 NPP PED		Mar 12, 2018 Mar 12, 2018 Sep 12, 2018
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9987231	Jan 02, 2033	U-2324			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9987231	Jan 02, 2033	U-2324			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001 >A> 10039718		Oct 04, 2032	DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536 8765764	May 05, 2025 Jan 15, 2023	DS DP U-2314		NCE	May 21, 2023
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592 7112592 8178554 8178554	Feb 24, 2022 Feb 24, 2022 Jul 24, 2021 Jul 24, 2021	DS DP U-2244 DS DP U-282 DS DP U-2245 DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9211259	Feb 28, 2029	U-1796			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9901585	Jun 13, 2023	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616 8420629	Jun 08, 2030 Mar 10, 2029	DS DP U-247		NCE	May 31, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2019	DS DP U-594			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	10022509 10022510	May 18, 2031 May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	10022509 10022510	May 18, 2031 May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	10022509 10022510	May 18, 2031 May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	10022509 10022510	May 18, 2031 May 18, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
N 205580 001	10010533 8609707 8609707 8791270	Jan 28, 2031 Aug 11, 2031 Aug 11, 2031 Jan 12, 2026	DP DP U-1971 DP U-1972 DP U-1971			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
N 205580 001	8791270	Jan 12, 2026	DP U-1972			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
>A>	10052385	Mar 15, 2033	U-1971			
>A>	10052385	Mar 15, 2033	U-1972			
	8791270	Jan 12, 2026	DP U-1790			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9877974	Aug 31, 2030	DP U-1858			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	6642245	Nov 04, 2020	U-257		NCE	Feb 07, 2023
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001					NCE	Jun 27, 2023
					ODE-194	Jun 27, 2025
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
	9687443*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - MIRVASQ</u>						
N 204708 001	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030	U-2222			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001				I-771		Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002				I-771		Apr 06, 2021
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001				NP		Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002				NP		Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9901539	Dec 21, 2032	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9931305	Feb 14, 2022		DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9931305	Feb 14, 2022		DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9931305	Feb 14, 2022		DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9931305	Feb 14, 2022		DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001 >A> 10039757		Jul 18, 2031		U-1480		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002 >A> 10039757		Jul 18, 2031		U-1480		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003 >A> 10039757		Jul 18, 2031		U-1480		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	8426391	Aug 27, 2028		U-1872		
	9861644	Mar 14, 2034	DP			
	9925147	Apr 25, 2028	DP	U-2255		
	9925147	Apr 25, 2028	DP	U-2256		
	9925147	Apr 25, 2028	DP	U-2257		
	9925147	Apr 25, 2028	DP	U-2258		
	9925147	Apr 25, 2028	DP	U-2259		
	9943530	Feb 02, 2027		U-2274		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	8222219	Apr 11, 2025		U-493		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	8222219	Apr 11, 2025		U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	8222219	Apr 11, 2025		U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8222219	Apr 11, 2025		U-493		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	8222219	Apr 11, 2025	U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001 >A> 10039780	6114313	Jul 10, 2035	U-2260			
	6130208	Dec 11, 2018	DP U-1715			
	9925265	Jun 29, 2019	DP U-1715			
		May 13, 2029	U-2260			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7232818	Apr 14, 2025	DS DP			
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIASTE</u>						
N 208694 001	9993471	Mar 15, 2030	U-1680			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001				M-221		Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002				M-221		Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003				M-221		Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP</u>						
N 208288 001				>A> NP		Aug 08, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9603796	Apr 21, 2029	DS DP U-2252	I-770		Mar 02, 2021
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001				>A> NPP		Aug 15, 2021
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	10010537	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	10010537	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	10010537	Oct 10, 2031	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	>A> 10064875	Aug 31, 2030	DP U-1408			
	>A> 10064875	Aug 31, 2030	DP U-1858			
	>A> 10064875	Aug 31, 2030	DP U-193			
	>A> 10064875	Aug 31, 2030	DP U-742			
	>A> 10064875	Aug 31, 2030	DP U-88			
	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	>A> 10039718	Oct 04, 2032	DP			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	>A> 10039718	Oct 04, 2032	DP			
	8148374	Sep 03, 2029	DS DP U-1279			
	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	>A> 10039718	Oct 04, 2032	DP		NC	Jul 17, 2020
	6642245	Nov 04, 2020	U-2352		NCE	Nov 05, 2020
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7470506	Jun 23, 2019	U-2352			
	7700645	Dec 26, 2026	DS DP			
	7803788	Feb 02, 2022	U-2352			
	>A> 8148374	Sep 03, 2029	DS DP U-2353			
	>A> 8148374	Sep 03, 2029	DS DP U-2364			
	>A> 8148374	Sep 03, 2029	DS DP U-2365			
	8518987	Feb 16, 2024	DS DP			
	8597876	Jun 23, 2019	U-2352			
	8754065	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2352			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	9889115	Jun 23, 2019	U-2352			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001 >A> 10039718		Oct 04, 2032	DP			
	9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001 >A> 10039718		Oct 04, 2032	DP			
	9891239	Sep 03, 2029	DP U-257			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>COPANLISIB DIHYDROCHLORIDE - ALIOOPA</u>						
N 209936 001	RE46856	Oct 22, 2029	DS DP U-2124			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001 >A> 8877245		Nov 14, 2023	U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002 >A> 8877245		Nov 14, 2023	U-979			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001 >A> 8980839		Aug 23, 2033	DP U-1483			
>A> 9937225		Aug 23, 2033	DP U-1483			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-2341			
	10028912	Sep 29, 2034	DP U-2342			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9925174	Jun 14, 2023	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406	I-778	Apr 30, 2021	
	7994185	Jan 20, 2030	DS DP U-2031	I-781	May 04, 2021	
	7994185	Jan 20, 2030	DS DP U-2032	ODE-182	Apr 30, 2025	
	7994185	Jan 20, 2030	DS DP U-2296	ODE-183	May 04, 2025	
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	9918973	Dec 13, 2024	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001				ODE-164		Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002				ODE-164		Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003				ODE-164		Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 004				ODE-164		Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 005				ODE-164		Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 006				ODE-164		Nov 09, 2024
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9949986	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2326			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2327			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001				M-222		Feb 06, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u> N 021992 002				M-222		Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u> N 021992 003				M-222		Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u> N 208912 001 >A> 10022502 >A> 10028965 6960346 7560120	Sep 12, 2020 May 23, 2034 Jul 03, 2023 Sep 05, 2022	U-2340 U-2340 DP DP		NP		Feb 09, 2021
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u> N 021038 002 10016396	Jan 04, 2032	DP				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u> N 021038 003 10016396	Jan 04, 2032	DP				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u> N 206628 003 9649296 9717796	Apr 20, 2036 Apr 20, 2036	DP DP				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u> N 206628 004 9649296 9717796	Apr 20, 2036 Apr 20, 2036	DP DP				
<u>DIMETHYL FUMARATE - TECFIDERA</u> N 204063 001 6509376 7320999 7619001 7803840 8399514 8759393	Apr 01, 2019 Oct 20, 2019 Apr 01, 2019 Apr 01, 2019 Feb 07, 2028 Jul 04, 2018	DP U-1384 U-1384 U-1385 U-1384 DP				
<u>DIMETHYL FUMARATE - TECFIDERA</u> N 204063 002 6509376 7320999 7619001 7803840 8399514 8759393	Apr 01, 2019 Oct 20, 2019 Apr 01, 2019 Apr 01, 2019 Feb 07, 2028 Jul 04, 2018	DP U-1384 U-1384 U-1385 U-1384 DP				
<u>DORAVIRINE - PIFELTRO</u> N 210806 001				>A> NCE		Aug 30, 2023
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u> N 210807 001				>A> NCE		Aug 30, 2023
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u> N 022036 001 9861607 9907780	May 18, 2027 Apr 11, 2028	U-620 DP				
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u> N 022036 002 9861607 9907780	May 18, 2027 Apr 11, 2028	U-620 DP				
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u> N 209661 001 9937132	Feb 18, 2033	DP U-1382				
<u>EFAVIRENZ - EFAVIRENZ</u> A 078064 001				PC		Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002				PC		Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003				PC		Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001				PC		Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028	U-1969			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	>A> 6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	>A> 7056927	Sep 10, 2024	DS DP			
	>A> 7176211	Jul 06, 2024	U-2360			
	>A> 7179815	Mar 07, 2021	U-2360			
	>A> 7419983	Jul 06, 2024	DS DP U-2360			
	>A> 7462625	Jan 25, 2021	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	>A> 6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	>A> 7056927	Sep 10, 2024	DS DP			
	>A> 7176211	Jul 06, 2024	U-2360			
	>A> 7179815	Mar 07, 2021	U-2360			
	>A> 7419983	Jul 06, 2024	DS DP U-2360			
	>A> 7462625	Jan 25, 2021	DS DP U-2360			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	DS	U-1571		
	7253185	Apr 29, 2022	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949998	Jun 11, 2034		U-2290		
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	9968553	Nov 06, 2032		U-1723		
	9968553	Nov 06, 2032		U-185		
	9968553	Nov 06, 2032		U-1892		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	>A> 10039745	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP U-2335			
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP U-2335			
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281	I-786	Jul 13, 2021	
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	10004700	Aug 14, 2034	DP U-2325			
	10039728	Aug 14, 2034	U-1828			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001				>A> NCE	Aug 27, 2023	
				>A> GAIN	Aug 27, 2028	
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	RE46965	Jan 08, 2027	DP			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ETHINYLMESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612 001	6716814	Aug 16, 2021	DS DP			
<u>ETHINYLMESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001				>A> NCE		Aug 10, 2023
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	7037917	Dec 13, 2020	DS DP U-256			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8778962	Feb 18, 2022	U-1541	I-773	Apr 10, 2021	
	8778962	Feb 18, 2022	U-2280	ODE-169	Apr 10, 2025	
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8778962	Feb 18, 2022	U-1541	I-773	Apr 10, 2021	
	8778962	Feb 18, 2022	U-2280	ODE-169	Apr 10, 2025	
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8778962	Feb 18, 2022	U-1541	I-773	Apr 10, 2021	
	8778962	Feb 18, 2022	U-2280	ODE-169	Apr 10, 2025	
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6872700	Jan 14, 2020	U-2288	M-224	Apr 02, 2021	
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6872700	Jan 14, 2020	U-2288	M-224		Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10016403	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2019	DP U-1577			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001				I-767		Feb 02, 2021
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS U-1086	NPP		May 11, 2021
	5604229*PED	Aug 18, 2019		PED		Nov 11, 2021
	8324283	Mar 29, 2026	DP			
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027	U-1086			
	9187405*PED	Dec 25, 2027				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 002	5604229	Feb 18, 2019	DS U-1086	NS		May 11, 2021
	5604229*PED	Aug 18, 2019		PED		Nov 11, 2021
	9592208	Mar 30, 2032	DP U-2315			
	9592208*PED	Sep 30, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001					NCE >A> ODE-202	Jul 27, 2023 Jul 27, 2025
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	>A> 9566260 >A> 9629821	Nov 12, 2023 Nov 12, 2023	DP U-2366 DP U-2367		NCE >A> ODE-202	Jul 27, 2023 Jul 27, 2025
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10010632	Nov 28, 2026	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	7915243 7939516 8247395	Sep 08, 2023 Sep 08, 2023 Oct 25, 2022	DP DP DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8534281	Mar 08, 2030	DP		NPP	May 17, 2021
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	7101866 7629335 8113199 8161968 8201556 8534281 8746242 9333310	Aug 03, 2021 Aug 03, 2021 Oct 23, 2027 Feb 05, 2028 Feb 05, 2029 Mar 08, 2030 Oct 11, 2030 Oct 02, 2027	DS DP U-2349 DP DP DP DP DP DP DP		NS	May 17, 2021
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	8534281 9750726	Mar 08, 2030 Nov 29, 2030	DP DP		I-775	Apr 24, 2021
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10022510	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10022510	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP U-2265		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	8426450	May 23, 2032	DS DP		NCE	Apr 19, 2023
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			
	9403772	May 23, 2032	DS U-2301			
	9908907	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS U-2294			
	8163902	Jun 17, 2026	DS U-2294			
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			
	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026	U-2294			
	8951504	Jul 27, 2032	U-2294			
	9266912	Jan 19, 2026	U-2294			
	9283238	Jun 17, 2026	U-2294			
	9737554	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS U-2294			
	8163902	Jun 17, 2026	DS U-2294			
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026	U-2294			
	8951504	Jul 27, 2032	U-2294			
	9266912	Jan 19, 2026	U-2294			
	9283238	Jun 17, 2026	U-2294			
	9737554	Jan 19, 2026	DP			
<u>GADOXETATE DISODIUM - EOVIST</u>						
N 022090 002	6039931	Nov 13, 2021		U-1239		
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001	9375498	Aug 10, 2032	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 001	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 002 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 003 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 004 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 005 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 006 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 007 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 008 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 009 >A> 9241948		Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 010 >A> 9241948		Jul 01, 2033	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001 >A> 10028937		Jun 10, 2030	U-2141		>A> M-230	Aug 06, 2021
>A> 10028937		Jun 10, 2030	U-2362			
>A> 10039754		Jun 10, 2030	U-2141			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001 7358366		Apr 19, 2020	DS		Y	
7358366*PED		Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002 7358366		Apr 19, 2020	DS		Y	
7358366*PED		Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003 7358366		Apr 19, 2020	DS		Y	
7358366*PED		Oct 19, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	>A> 10045958	Sep 22, 2030		U-1816		
	>A> 10045959	Sep 22, 2030		U-1816		
	9962359	Sep 22, 2030		U-1816		
	9999608	Sep 22, 2030		U-1816		
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	9931304	Jun 27, 2021	DP			
	9962338	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	9931304	Jun 27, 2021	DP			
	9962338	Jun 27, 2021	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	9913910	Sep 28, 2024		U-2253		
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
N 210566 001					NDF	May 24, 2021
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP	U-1087	M-220	Feb 15, 2021
	7348361	Nov 06, 2020	DP	U-2250		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10028946	Jul 25, 2033		U-1810		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10028946	Jul 25, 2033		U-1810		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10028946	Jul 25, 2033		U-1810		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10028946	Jul 25, 2033		U-1810		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10028946	Jul 25, 2033		U-1810		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10028946	Jul 25, 2033		U-1810		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u> N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u> N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u> N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u> N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u> N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROCORTISONE BUTYRATE - HYDROCORTISONE BUTYRATE</u> A 209556 001					PC	Aug 11, 2018
<u>HYDROGEN PEROXIDE - ESKATA</u> N 209305 001	9980983	Apr 21, 2035	U-2205			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u> N 019034 001	9248229 9731082	Mar 12, 2034 Apr 23, 2032	DP DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u> N 019034 002	9248229 9731082	Mar 12, 2034 Apr 23, 2032	DP DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u> N 019034 003	9248229 9731082	Mar 12, 2034 Apr 23, 2032	DP DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u> N 019034 004	9248229 9731082	Mar 12, 2034 Apr 23, 2032	DP DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u> N 019034 005	9248229 9731082	Mar 12, 2034 Apr 23, 2032	DP DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u> N 021945 004	8021335 8562564 9180259 9533102 9629959 9789257 9844558 RE44846	Oct 04, 2026 Jan 24, 2026 Jan 24, 2026 Jan 24, 2026 Jan 24, 2026 Feb 11, 2034 May 02, 2036 Aug 10, 2019	DP DP DP DP DP DP U-2236 DP			
<u>HYDROXYUREA - SIKLOS</u> N 208843 001					ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u> N 208843 002					ODE-177	Dec 21, 2024
<u>IBRUTINIB - IMBRUVICA</u> N 205552 001	10004746 10004746 10004746 10004746	Jun 03, 2031 Jun 03, 2031 Jun 03, 2031 Jun 03, 2031	U-1684 U-1946 U-2241 U-2242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10016435	Jun 03, 2031	U-1650			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	89999999	Jun 03, 2031	U-1491			
	89999999	Jun 03, 2031	U-1946			
	89999999	Jun 03, 2031	U-2241			
	89999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	89999999	Jun 03, 2031	U-1491			
	89999999	Jun 03, 2031	U-1946			
	89999999	Jun 03, 2031	U-2241			
	89999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	89999999	Jun 03, 2031	U-1491			
	89999999	Jun 03, 2031	U-1946			
	89999999	Jun 03, 2031	U-2241			
	89999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026	U-1440			
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
	9884094	May 01, 2033	U-2238			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
	9884094	May 01, 2033	U-2238			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Aug 02, 2032	DP			
	9717852	Apr 08, 2033	DP			
	9950039	Dec 10, 2035	U-2277			
	9950039	Dec 10, 2035	U-2278			
	9950039	Dec 10, 2035	U-2279			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9717852	Apr 08, 2033	DP			
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP U-2146			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9943571	Aug 11, 2029	U-1537			
<u>TOBENGUANE I-131 - AZEDRA</u>						
N 209607 001				NP	Jul 30, 2021	
				>A> ODE-204	Jul 30, 2025	
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025	U-2234		ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					>A> ODE-199	Aug 15, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025	U-2234		ODE-188	Mar 17, 2022
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001				>A> ODE-199		Aug 15, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025	U-2234		ODE-188 ODE-189 ODE-190	Mar 17, 2022 Jul 31, 2024 May 17, 2024
				>A> ODE-199		Aug 15, 2025
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	7495103	May 20, 2027	DS DP		ODE-173	Feb 12, 2025
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9974781	Apr 09, 2027	DP U-2318			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9931334	Dec 28, 2026	DP U-2276	M-218		Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9931334	Dec 28, 2026	DP U-2276	M-218		Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	>A> 7495103 >A> 7973038 >A> 8324242 >A> 8410274 >A> 8507534 >A> 8653103 >A> 8741933 >A> 8754224 >A> 8846718 >A> 8993600 >A> 9150552 >A> 9216969 >A> 9670163 >A> 9931334	May 20, 2027 Nov 08, 2026 Aug 05, 2027 Dec 28, 2026 Sep 20, 2030 Dec 04, 2028 Nov 08, 2026 Dec 28, 2026 Dec 04, 2028 Dec 11, 2030 Dec 04, 2028 Nov 08, 2026 Dec 28, 2026 Dec 28, 2026	DS DP U-2374 U-2374 DP DS DP DP U-2374 DS DP U-2375 U-2375 DP U-2375 DP U-2376 U-2376	>A> NCE >A> NP >A> ODE-195		Jul 02, 2020 Aug 07, 2021 Aug 07, 2025
N 211358 002	>A> 7495103 >A> 7973038 >A> 8324242 >A> 8410274 >A> 8507534 >A> 8653103 >A> 8741933 >A> 8754224 >A> 8846718 >A> 8993600 >A> 9150552 >A> 9216969 >A> 9670163 >A> 9931334	May 20, 2027 Nov 08, 2026 Aug 05, 2027 Dec 28, 2026 Sep 20, 2030 Dec 04, 2028 Nov 08, 2026 Dec 28, 2026 Dec 04, 2028 Dec 11, 2030 Dec 04, 2028 Nov 08, 2026 Dec 28, 2026 Dec 28, 2026	DS DP U-2374 U-2374 DP DS DP DP U-2374 DS DP U-2375 U-2375 DP U-2375 DP U-2376 U-2376	>A> NCE >A> NP >A> ODE-195		Jul 02, 2020 Aug 07, 2021 Aug 07, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	9474779	Aug 19, 2033	DS DP U-2350		NCE	Jul 20, 2023
	9850277	Jan 18, 2033	DS DP U-2350	>A>	ODE-203	Jul 20, 2025
	9968595	Mar 13, 2035	DP U-2351			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
<u>LEDIPASVIR; SOFOBUVIR - HARVONI</u>						
N 205834 001	>A> 10039779	Jan 30, 2034	DS DP U-2369			
	>A> 10039779	Jan 30, 2034	DS DP U-2370			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001				>A> I-787	Aug 15, 2021	
				>A> ODE-196	Aug 15, 2025	
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002				>A> I-787	Aug 15, 2021	
				>A> ODE-196	Aug 15, 2025	
<u>LESNURAD - ZURAMPIC</u>						
N 207988 001	9956205	Dec 28, 2031	U-2311			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 001				ODE-165	Nov 08, 2024	
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 002				ODE-165	Nov 08, 2024	
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 001				ODE-165	Nov 08, 2024	
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 002				ODE-165	Nov 08, 2024	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	9868739	Nov 09, 2031	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9914802	Nov 13, 2020	DS DP U-1666			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	10028858	Mar 22, 2034	DP U-2348			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 001				PC		Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 002				PC		Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411 7723390	Mar 14, 2024 Mar 14, 2024	DP DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	9283174 9925264 9931403	May 10, 2031 May 10, 2031 May 10, 2031	DP DP U-2267 DP		NP	Feb 28, 2021
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9890141	Oct 21, 2030	DS			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	10034877	Aug 05, 2029	U-2347			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10022379	Apr 02, 2029	U-2339			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLITPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10022379	Apr 02, 2029	U-2339			
<u>LINAGLITPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10022379	Apr 02, 2029	U-2339			
<u>LINAGLITPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	10022379	Apr 02, 2029	U-2339			
<u>LINAGLITPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9968659	Jan 09, 2037	U-2313			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	>A> 9616180 >A> 9861757	Jan 20, 2026 Jan 20, 2026	DP DP			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	>A> 10039800 >A> 10039800 >A> 10039800 >A> 10039800 >A> 10039800 >A> 10039800 >A> 10039800	Nov 06, 2035 Nov 06, 2035 Nov 06, 2035 Nov 06, 2035 Nov 06, 2035 Nov 06, 2035 Nov 06, 2035	U-1723 U-185 U-1864 U-1991 U-3 U-71 U-8			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10028910 9440029 9855388 9981013	Nov 11, 2030 Jan 30, 2032 Apr 24, 2029 Aug 30, 2030	DP DP DP U-1881 U-2297			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10028910 9440029 9855388 9981013	Nov 11, 2030 Jan 30, 2032 Apr 24, 2029 Aug 30, 2030	DP DP DP U-1881 U-2297			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229 001				NCE		May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10016404 9861622	Mar 07, 2025 Mar 07, 2025	U-1316 U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10016404 9861622	Mar 07, 2025 Mar 07, 2025	U-1316 U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10016404 9861622	Mar 07, 2025 Mar 07, 2025	U-1316 U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10016404 9861622	Mar 07, 2025 Mar 07, 2025	U-1316 U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10016404 9861622	Mar 07, 2025 Mar 07, 2025	U-1316 U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001				>A> M-229		Jul 20, 2021
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001				>A> NP		Aug 22, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001				M-225		Apr 26, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002				M-225		Apr 26, 2021
<u>LULICONAZOLE - LUZU</u>						
N 204153 001				NPP		Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LUSUTROMBOPAG - MULPLETA</u>						
N 210923 001	7601746	Sep 05, 2024	DS DP U-2344		NCE	Jul 31, 2023
	8530668	Jan 21, 2030	DS DP			
	8889722	Jul 29, 2028	DS DP			
	9427402	Sep 29, 2031	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE	Jan 26, 2023
					ODE-166	Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220		ODE-170	Dec 20, 2024
	8192719	Oct 12, 2027	U-2220			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Dec 05, 2025	DS DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	>A> 10040872	Jan 30, 2034	DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	>A> 8927010	Mar 23, 2032	DP		>A> NP	Aug 08, 2021
	>A> 9023389	Mar 23, 2032	DP			
	>A> 9283214	Mar 23, 2032	DP			
	>A> 9498447	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	>A> 8927010	Mar 23, 2032	DP		>A> NP	Aug 08, 2021
	>A> 9023389	Mar 23, 2032	DP			
	>A> 9283214	Mar 23, 2032	DP			
	>A> 9498447	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	>A> 8927010	Mar 23, 2032	DP		>A> NP	Aug 08, 2021
	>A> 9023389	Mar 23, 2032	DP			
	>A> 9283214	Mar 23, 2032	DP			
	>A> 9498447	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	>A> 8927010	Mar 23, 2032	DP		>A> NP	Aug 08, 2021
	>A> 9023389	Mar 23, 2032	DP			
	>A> 9283214	Mar 23, 2032	DP			
	>A> 9498447	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	>A> 8927010	Mar 23, 2032	DP		>A> NP	Aug 08, 2021
	>A> 9023389	Mar 23, 2032	DP			
	>A> 9283214	Mar 23, 2032	DP			
	>A> 9498447	Mar 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	>A> 8927010	Mar 23, 2032	DP		>A> NP	Aug 08, 2021
	>A> 9023389	Mar 23, 2032	DP			
	>A> 9283214	Mar 23, 2032	DP			
	>A> 9498447	Mar 23, 2032	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10006924	Aug 12, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001				>A> NCE	Aug 10, 2023	
				>A> ODE-205		Aug 10, 2025
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001				NCE	Jun 13, 2023	
				ODE-193		Jun 13, 2025
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	10022344	Mar 03, 2026	DP U-1731			
	10022344	Mar 03, 2026	DP U-1732			
	10028925	Mar 03, 2026	DP U-1731			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	10028925	Mar 03, 2026	DP U-1732			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	9931336	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8623826	Nov 18, 2030	U-2293			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836	D-170	Dec 22, 2020	
	7169791*PED	Jan 04, 2024		NPP	Mar 22, 2021	
	8163904	Aug 23, 2028	DS DP	ODE-171	Mar 22, 2025	
	8163904*PED	Feb 23, 2029		ODE-172	Mar 22, 2025	
	8293756	Sep 25, 2027	DP	PED	Jun 22, 2021	
	8293756*PED	Mar 25, 2028		PED	Sep 22, 2021	
	8389537	Jul 18, 2026	DS DP U-1374	PED	Sep 22, 2025	
	8389537*PED	Jan 18, 2027		PED	Sep 22, 2025	
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836	D-170	Dec 22, 2020	
	7169791*PED	Jan 04, 2024		NPP	Mar 22, 2021	
	8163904	Aug 23, 2028	DS DP	ODE-171	Mar 22, 2025	
	8163904*PED	Feb 23, 2029		ODE-172	Mar 22, 2025	
	8293756	Sep 25, 2027	DP	PED	Jun 22, 2021	
	8293756*PED	Mar 25, 2028		PED	Sep 22, 2021	
	8389537	Jul 18, 2026	DS DP U-1374	PED	Sep 22, 2025	
	8389537*PED	Jan 18, 2027		PED	Sep 22, 2025	
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836	NPP	Mar 22, 2021	
	7169791*PED	Jan 04, 2024		ODE-171	Mar 22, 2025	
	8163904	Aug 23, 2028	DS DP	ODE-172	Mar 22, 2025	
	8163904*PED	Feb 23, 2029		PED	Sep 22, 2021	
	8293756	Sep 25, 2027	DP	PED	Sep 22, 2025	
	8293756*PED	Mar 25, 2028		PED	Sep 22, 2025	
	8389537	Jul 18, 2026	DS DP U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS DP U-1374			
	9061029*PED	Oct 07, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	9907756	Jun 07, 2029	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003				M-167		Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	9926559	Jan 09, 2034	U-1943	M-226		May 14, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8143241 >A> 8143241 >A> 8143241 >A> 8143241 >A> 8143241 >A> 8859562 >A> 8859562 >A> 8859562 >A> 8912187 >A> 8912187 >A> 8912187 >A> 8912187	Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Mar 12, 2024 Mar 12, 2024 Mar 12, 2024 Mar 12, 2024	U-2101 U-2102 U-2103 U-2358 U-2359 U-2101 U-2102 U-2358 U-2359 U-2101 U-2102 U-2358 U-2359	I-762 ODE-180 ODE-181		Jan 12, 2021 Aug 17, 2024 Aug 17, 2024
N 208558 002	>A> 8143241 >A> 8143241 >A> 8143241 >A> 8143241 >A> 8143241 >A> 8859562 >A> 8859562 >A> 8859562 >A> 8859562 >A> 8859562 >A> 8859562 >A> 8912187 >A> 8912187 >A> 8912187 >A> 8912187	Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Mar 12, 2024 Mar 12, 2024 Mar 12, 2024 Mar 12, 2024	U-2101 U-2102 U-2103 U-2358 U-2359 U-2101 U-2102 U-2358 U-2359 U-2101 U-2102 U-2358 U-2359	I-762 ODE-180 ODE-181		Jan 12, 2021 Aug 17, 2024 Aug 17, 2024
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795 5948818	May 13, 2019 May 13, 2019	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2020	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235 8946235 9732058 9732058	Aug 08, 2032 Aug 08, 2032 Jul 25, 2032 Jul 25, 2032	DS DP U-1777 DS DP U-2289 DS DP U-1777 DS DP U-2289	I-774 ODE-176		Apr 18, 2021 Apr 18, 2025
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	8946235 8946235 9732058 9732058	Aug 08, 2032 Aug 08, 2032 Jul 25, 2032 Jul 25, 2032	DS DP U-1777 DS DP U-2289 DS DP U-1777 DS DP U-2289	I-774 ODE-176		Apr 18, 2021 Apr 18, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADE</u>						
N 208552 001	8815929	Jan 22, 2024	U-1959			
	9974773	Jun 11, 2035	U-2306			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002				PC		Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001				PC		Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002				PC		Sep 19, 2018
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 001				I-785		Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 002				I-785		Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 003				I-785		Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004				I-785		Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005				I-785		Jun 29, 2021
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	9925212	Oct 08, 2033	U-1766			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	9925212	Oct 08, 2033	U-1766			
<u>PATISIRAN SODIUM - ONPAT</u>						
N 210922 001	>A> 8058069 >A> 8158601 >A> 8168775 >A> 8334373 >A> 8362231 >A> 8372968 >A> 8492359 >A> 8552171 >A> 8642076 >A> 8741866 >A> 8778902 >A> 8802644 >A> 8822668 >A> 8895718 >A> 8895721 >A> 9193753 >A> 9234196 >A> 9364435 >A> 9567582 >A> 9943538 >A> 9943539	Apr 15, 2029 Nov 10, 2030 Oct 20, 2029 May 27, 2025 Mar 30, 2021 Mar 30, 2021 Apr 15, 2029 Mar 30, 2021 Oct 03, 2027 Oct 20, 2029 Mar 30, 2021 Oct 21, 2030 Apr 15, 2029 Mar 30, 2021 Mar 30, 2021 Mar 30, 2021 Oct 20, 2029 Apr 15, 2029 Mar 30, 2021 Mar 30, 2021 Oct 20, 2029 Apr 15, 2029 Mar 30, 2021 Mar 30, 2021 Oct 20, 2029 Apr 15, 2029 Mar 30, 2021 Nov 04, 2023 Nov 04, 2023	DP DP U-2378 DS DP U-2378 DS DP DS DP DS DP DS DP DS DP DS DP U-2378 U-2378 DP U-2378 DP U-2378 DS DP DS DP U-2378 DP U-2378 DS DP DS DP DS DP DS DP DS DP U-2378 DP U-2378 DP U-2378 DS DP DP DS DP	>A> NCE >A> ODE-197	Aug 10, 2023 Aug 10, 2025	
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10028944 6756393 6815458 7115634 7601740 7659285 7732615 7858789 7923564 8110574 8618130 8921393 9296694 9566271 9765053	Jan 15, 2024 Mar 06, 2021 Mar 06, 2021 Oct 06, 2021 Jun 17, 2027 Aug 24, 2026 Jun 03, 2028 Dec 13, 2020 Sep 26, 2025 Dec 13, 2020 Jan 15, 2024 Jan 15, 2024 Mar 06, 2021 Jan 15, 2024 Jul 27, 2022	U-1974 DS DP DS DP U-1843 DS DP DS DP U-1844 DS DP DS DP DS DP DS DP U-1845 U-1846 DS DP U-1974 U-1974			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10028944 6756393 6815458 7115634 7601740 7659285 7732615 7858789 7923564 8110574 8618130 8921393 9296694 9566271 9765053	Jan 15, 2024 Mar 06, 2021 Mar 06, 2021 Oct 06, 2021 Jun 17, 2027 Aug 24, 2026 Jun 03, 2028 Dec 13, 2020 Sep 26, 2025 Dec 13, 2020 Jan 15, 2024 Jan 15, 2024 Mar 06, 2021 Jan 15, 2024 Jul 27, 2022	DS DP DS DP U-1843 DS DP DS DP U-1844 DS DP DS DP DS DP DS DP DS DP U-1845 U-1846 DS DP U-1974 U-1974	NCE	Apr 29, 2021	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8383150	Sep 22, 2026	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001	8383596	Jun 02, 2031	DS U-2328			
	8822424	Nov 21, 2028	DP			
	9266919	Nov 21, 2028	U-2328			
	9688711	Nov 21, 2028	DS U-2328			
				NCE		Jun 25, 2023
				GAIN		Jun 25, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	10011637 9610321 9610321 9919024 9919024 9925231	Jun 05, 2034 Sep 15, 2031 Sep 15, 2031 Sep 15, 2031 Sep 15, 2031 Sep 15, 2031	DS U-1999 U-2230 U-1999 U-2230 DP		I-764	Jan 24, 2021
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	>A> 8198262 >A> 8198262 >A> 8673939 >A> 8673939 >A> 8735428 >A> 8735428 9993467	Jun 17, 2025 Jun 17, 2025 May 15, 2023 May 15, 2023 May 15, 2023 May 15, 2023 May 19, 2030	U-1360 U-2254 U-1360 U-2254 U-1360 U-2254 DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	>A> 8198262 >A> 8198262 >A> 8673939 >A> 8673939 >A> 8735428 >A> 8735428 9993467	Jun 17, 2025 Jun 17, 2025 May 15, 2023 May 15, 2023 May 15, 2023 May 15, 2023 May 19, 2030	U-1360 U-2254 U-1360 U-2254 U-1360 U-2254 DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	>A> 8198262 >A> 8198262 >A> 8673939 >A> 8673939 >A> 8735428 >A> 8735428 9993467	Jun 17, 2025 Jun 17, 2025 May 15, 2023 May 15, 2023 May 15, 2023 May 15, 2023 May 19, 2030	U-1360 U-2254 U-1360 U-2254 U-1360 U-2254 DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	>A> 8198262 >A> 8198262 >A> 8673939 >A> 8673939 >A> 8735428 >A> 8735428 9993467	Jun 17, 2025 Jun 17, 2025 May 15, 2023 May 15, 2023 May 15, 2023 May 15, 2023 May 19, 2030	U-1360 U-2254 U-1360 U-2254 U-1360 U-2254 DP			
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
A 211067 001				>A> CGT		Feb 25, 2019
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
A 211067 002				>A> CGT		Mar 06, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 001				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 002				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 003				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 004				NPP		May 03, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u> N 021446 005				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 006				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 007				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u> N 021446 008				NPP		May 03, 2021
<u>PREGABALIN - LYRICA</u> N 022488 001				NPP		May 03, 2021
<u>PREGABALIN - LYRICA CR</u> N 209501 001 >A> 10022447 >A> 10022447		Nov 02, 2026 Nov 02, 2026	U-2136 U-2137			
<u>PREGABALIN - LYRICA CR</u> N 209501 002 >A> 10022447 >A> 10022447		Nov 02, 2026 Nov 02, 2026	U-2136 U-2137			
<u>PREGABALIN - LYRICA CR</u> N 209501 003 >A> 10022447 >A> 10022447		Nov 02, 2026 Nov 02, 2026	U-2136 U-2137			
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u> N 203971 001 6635234		Nov 17, 2022	U-2271			
<u>REGORAFENIB - STIVARGA</u> N 203085 001 9957232		Jul 09, 2032	DS			
<u>RIBOCICLIB SUCCINATE - KISQALI</u> N 209092 001 8962630 8962630 8962630 9416136 9416136 9416136 9868739 9868739 9868739		Dec 09, 2029 Dec 09, 2029 Dec 09, 2029 Aug 20, 2029 Aug 20, 2029 Aug 20, 2029 Nov 09, 2031 Nov 09, 2031 Nov 09, 2031	U-1981 U-2355 U-2356 U-1981 U-2355 U-2356 U-1981 U-2355 U-2356	I-783 I-784		Jul 18, 2021 Jul 18, 2021
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u> N 202022 001				M-223		Feb 01, 2021
<u>RIOCIGUAT - ADEMPAS</u> N 204819 001 7173037		Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u> N 204819 002 7173037		Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u> N 204819 003 7173037		Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u> N 204819 004 7173037		Dec 04, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	7173037	Dec 04, 2026	DS DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	>A> 10058554	Sep 26, 2026	U-2363			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	>A> 10058554	Sep 26, 2026	U-2363			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
<u>RITONAVIR - RITONAVIR</u>						
A 202573 001					PC	Sep 16, 2018
<u>RITONAVIR - NORVIR</u>						
N 209512 001					ODE-184	Jun 07, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					D-171	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012	I-772	Apr 06, 2021	
	7351701	Jul 23, 2024	U-2101	ODE-168	Apr 06, 2025	
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	7351701	Jul 23, 2024	U-2012	I-772	Apr 06, 2021	
	7351701	Jul 23, 2024	U-2101	ODE-168	Apr 06, 2025	
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003	7351701	Jul 23, 2024	U-2012	I-772	Apr 06, 2021	
	7351701	Jul 23, 2024	U-2101	ODE-168	Apr 06, 2025	
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
SIMEPREVIR SODIUM - OLYSIO						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKEELMA						
N 207078 001	6332985	Mar 29, 2019	U-2312	NCE	May 18, 2023	
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS	U-2312		
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKEELMA						
N 207078 002	6332985	Mar 29, 2019	U-2312	NCE	May 18, 2023	
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS	U-2312		
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKEELMA</u>						
N 207078 002	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS	U-2312		
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	>A> 9616180	Jan 20, 2026	DP			
	>A> 9861757	Jan 20, 2026	DP			
<u>SOYBEAN OIL - LIPOSYN III 30%</u>						
N 020181 001	9717852	Apr 08, 2033	DP			
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001				>A> NCE	Aug 20, 2023	
				>A> ODE-198	Aug 20, 2025	
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002				>A> NCE	Aug 20, 2023	
				>A> ODE-198	Aug 20, 2025	
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001				>A> NCE	Aug 20, 2023	
				>A> ODE-198	Aug 20, 2025	
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002				>A> NCE	Aug 20, 2023	
				>A> ODE-198	Aug 20, 2025	
<u>TADALAFIL - CIALIS</u>						
N 021368 001	6821975	Nov 19, 2020	DS DP U-1184	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-533	Y	PED	Aug 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y		
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-1184	Y		
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 002	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	6821975	Nov 19, 2020	DS DP	Y		
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001				>A> NCE	Jul 20, 2023	
				>A> NP	Aug 08, 2021	
<u>TAFENOQUINE SUCCINATE - KRINTAFEL</u>						
N 210795 001				NCE	Jul 20, 2023	
				>A> ODE-201	Jul 20, 2025	
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	9999593	May 28, 2029	DP			
<u>TALC - STERITALC</u>						
N 205555 001				ODE-191	May 01, 2024	
<u>TALC - STERITALC</u>						
N 205555 002				ODE-191	May 01, 2024	
<u>TALC - STERITALC</u>						
N 205555 003				ODE-191	May 01, 2024	
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9855241	Jan 25, 2033	U-2149			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016	Y		
	7582621*PED	Nov 26, 2027				
	9549938	Feb 16, 2026	U-1951			
	9549938*PED	Aug 16, 2026				
	9566289	Feb 16, 2026	DP			
	9566289*PED	Aug 16, 2026				
	9566290	Feb 16, 2026	U-1970			
	9566290*PED	Aug 16, 2026				
	9572823	Feb 16, 2026	U-1970			
	9572823*PED	Aug 16, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	7737168	May 03, 2027	U-2346		NCE	Jul 13, 2023
	8039504	Jul 23, 2027	DP	>A>	ODE-200	Jul 13, 2025
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024		U-2346		
	9339466	Mar 23, 2031	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9968655	Nov 01, 2025	U-2308			
	9968656	Nov 01, 2025	U-2308			
	9968658	Nov 01, 2025	U-1320			
	9974835	Nov 01, 2025	U-1320			
	9974837	Nov 01, 2025	U-1320			
	9981014	Nov 01, 2025	U-1320			
	9981016	Nov 01, 2025	U-1320			
	9987334	Nov 01, 2025	U-1320			
	9987335	Nov 01, 2025	U-1320			
	9993528	Nov 01, 2025	U-1320			
<u>TIGECYCLINE - TIGECYCLINE</u>						
N 211158 001	>A> 9855355	Apr 07, 2033	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	7696178	Sep 22, 2022	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	7842699	Dec 08, 2020	U-2322		I-780	May 30, 2021
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	6956041	Dec 08, 2020	DP		I-780	May 30, 2021
	6965027	Mar 25, 2023	DS			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	7842699	Dec 08, 2020		U-2322		
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	9937181	Mar 14, 2034	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	8501730	Sep 01, 2026	DS			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001	8895557 8895557*PED	Jan 07, 2028 Jul 07, 2028	DP		NCE ODE-100 PED PED	Oct 23, 2020 Oct 23, 2022 Apr 23, 2021 Apr 23, 2023
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423 8835443 8835443 8835443 8835443 8835443 8835443	May 29, 2027 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025	DS DP U-1581 U-1582 U-2020 U-2037 U-2302 U-2305		I-778 I-781 ODE-182 ODE-183	Apr 30, 2021 May 04, 2021 Apr 30, 2025 May 04, 2025
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423 8835443 8835443 8835443 8835443 8835443 8835443	May 29, 2027 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025	DS DP U-1581 U-1582 U-2020 U-2037 U-2302 U-2305		I-778 I-781 ODE-182 ODE-183	Apr 30, 2021 May 04, 2021 Apr 30, 2025 May 04, 2025
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423 8835443 8835443 8835443 8835443 8835443 8835443	May 29, 2027 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025 Jun 10, 2025	DS DP U-1581 U-1582 U-2020 U-2037 U-2302 U-2305		I-778 I-781 ODE-182 ODE-183	Apr 30, 2021 May 04, 2021 Apr 30, 2025 May 04, 2025
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8497393	Dec 15, 2028	DS		Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8497393	Dec 15, 2028	DS		Y	
<u>TRETINOIN - ALTRENO</u>						
N 209353 001				>A> NDF		Aug 23, 2021
<u>TRYPAN BLUE - VISIONBLUE</u>						
N 021670 001	6367480 6720314	Oct 26, 2019 May 07, 2019	U-2321 U-2321			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	8534281	Mar 08, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8534281	Mar 08, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2019	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2019	DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022		U-1490		
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022		U-1490		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9937223	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-782 M-228 ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-782 M-228 ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-782 M-228 ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7713999	May 30, 2024	DS DP U-2291			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm